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"Yet, you may detest a thing, though it is good for you. And you might 
love a thing, though it is evil for you, for God knows and you do not 
know."
The Holy Koran 
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SUMMARY
The Wemicke-Korsakoff syndrome (WKS) is a severe neuropsychiatric 
disorder most commonly seen as a result of malnutrition associated with chronic 
alcohol abuse. In its acute form (Wernicke’s encephalopathy, WE) it is characterised 
by ophthalmoparesis, nystagmus, ataxia and an apathetic confiisional state. In those 
that survive this initial phase, over 70% will be left with a specific form of memory 
impairment with a varying degree of severity. In those most severely affected (-50% 
Korsakoff s psychosis, KP), the impairment will be such that they are incapable of 
independent living and many will require long-term institutional care.
In Scotland there is good evidence of an increase, over the past two 
decades, in the number of people suffering from alcohol-related brain damage, of 
which KP is the major form (Smith & McColl, 1992). As a result the absolute 
number of patients in long term psychiatric care and suffering from alcoholic KP has 
grown. They form a small but significant proportion of beds in the refractory wards 
of mental hospitals. One general argument that has fuelled interest in the possibility 
of genetic factors in alcoholic KP is the fact that only a small percentage of those 
who chronically abuse alcohol and become malnourished ever develop the 
characteristic neuropathology.
In 1930 Wagner and Weir reported on the association of the WKS with 
thiamine depletion. Thiamine exists in three forms, thiamine monophosphate, 
triphosphate and pyrophosphate(TPP): the last making up 80-90% of total thiamine 
in cells. TPP is a cofactor for many enzymes of carbohydrate metabolism including 
pyruvate dehydrogenases, a-ketoglutarate dehydrogenase and transketolase (TK). 
Several studies have implicated TK in the pathogenesis of the WKS.
The aim of this study was to investigate the role of TK in the WKS 
using quantitative and qualitative methods of analysis in patient and control groups.
Blood from 30 hospitalized patients with the WKS and 25 normal
1
controls was analysed for erythrocyte transketolase (ETK) activity and stimulated 
erythrocyte transketolase (ETKs) activity by the addition of TPP using an end point 
assay. By employing a modified TK assay (Smeets et al., 1971; Bayoumi & 
Rosalki, 1976), mean ETK activity in 10 normal controls was found to be 0.418 ± 
0.193 IU/mg protein which was not significantly different (p>0.1) from the 20 
patients (mean ETK activity 0.406 ± 0.155 IU/mg protein). The same was true for 
the ETKs activity in which normal controls had a mean of 0.738 ± 0.208 IU/mg 
protein and patients 0.680 ± 0.190 IU/mg protein. This difference was not 
statistically significant (p>0.1).
A report (Kaczmarek & Nixon, 1983) suggesting the existence of 
several species of TK was investigated by polyacrylamide gel electrophoresis 
(PAGE). TK activity was detected on PAG by specific TK enzyme stain. All 
normal controls and patient samples were run on PAG and then stained both 
specifically and generally (Coomassie-Brilliant Blue (CBB) R-250 and silver stain). 
They yielded two ETK bands which varied in intensity and were cathodal to 
haemoglobin. Although qualitative analysis strongly suggested ETK to be 
heterogeneous, it did not provide means of investigating WKS by biochemical 
analysis.
Because the analysis of ETK (quantitatively and qualitatively) showed 
no apparent differences between the two groups, it was further investigated following 
the purification of the enzyme. PAGE crosslinked with DHEBA, a form of 
crosslinker which allows gels to be solubilized under alkaline conditions, provided 
means of isolating pure fractions of TK from red blood cells of normal controls and 
patients. These extracted fractions were subjected to analysis using high performance 
liquid chromatography (HPLC), isoelectric focusing (IEF) and endpoint assay. 
Despite confirmation of TK heterogeneity (with respect to ionic strength, isoelectric 
point (pi) and ETK activity), no differences in electrophoretic profile between 
patients and controls were revealed. In all samples two distinct bands of varying 
intensity appeared at pi 7.35 and 6.55 on IEF gels.
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Further studies on native TK were carried out after purification from 
white blood cells which had been collected as buffy coats from normal individuals 
(Mocali & Paoletti, 1989). Enzyme recovery declined as the steps of purification 
progressed, therefore another purification method was developed from the method of 
Takeuchi et. al.(1986) (where enzyme recovery was not sufficient for amino acid 
analysis). The fractions isolated by this method were subjected to fast protein liquid 
chromatography (FPLC) on Mono Q column which yielded two peaks containing TK 
activity. The fractions were also loaded on an SDS-PAGE where the protein band 
had a molecular weight (MW) of 68kD (kiloDaltons). These results suggested that 
TK exists in at least two forms varying in ionic strength as revealed by the 
chromatographic profile from FPLC. Amino acid analysis and amino acid sequencing 
of TK was carried out on enzyme purified by DHEBA-PAGE. The extracted fraction 
was loaded on SDS-PAGE and then transblotted on to an Immobilon-P transfer 
membrane. The membrane was then stained with CBB R-250 to detect presence of 
protein, namely TK Two distinct bands appeared with estimated MW of 51 and 
35kD, similar to the MW estimated from purified ETK by Warnock and Prudhomme 
(1982).
Amino acid analysis of the 5IkD band showed the presence of 16 
amino acid residues with molar ratios(%): D=11.95, E=7.43, S=11.85, G=6.62, 
H=3.90, R=2.00, T=5.20, A=9.29, P=7.18, Y=3.32, V=7.12, M=0.73, 1=4.45, 
L=9.58, F=3.99, K=5.39. As for the 35kD band, amino acid analysis revealed 15 
residues with molar ratio(%): D=7.39, E=6.62, S=6.31, G=8.85, H=5.24, R=2.27, 
T=6.06, A= 13.56, P=5.75, Y=2.17, V=11.60, M=0.73, L=13.90, F=4.98, K=4.58. 
The molar ratios(%) of amino acids of each protein band were compared statistically 
using non-parametric Kendall and Wilcoxon signed rank tests. Both statistical 
analyses showed the two protein bands to be positively correlated with significantly 
similar distribution of amino acids. Therefore statistical analysis strongly suggests 
that the two protein bands represent similar proteins. An amino acid sequence of 15 
residues (V-L-L-P-A-E-E-T-N-V-K-T-A-L-G) was obtained for the 35kD peptide 
but sequencing was not possible for the 51kD peptide due to N-terminal blockage. 
The amino acid sequence for the smaller peptide was compared with other sequences 
in the Gen Bank Database for existing homologies. This verified that the sequence
3
obtained was unique.
The work performed on the analysis of TK verifies the existence of at 
least two forms of the enzyme. They have different MW and pi values. No evidence 
was obtained to illustrate a difference in TK activity or its banding pattern between 
control and patient samples.
The amino acid sequence, described in this study, may be used as a 
template for oligonucleotide synthesis and then to clone the gene for the 35kD 
peptide or by cloning from a cDNA library generated using monoclonal antibodies. 
This would allow the role of TK in the aetiology of WKS to be investigated at the 
gene level.
4
CHAPTER 1: INTRODUCTION
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1.1 WERNICKE-KORSAKOFF SYNDROME
1.1.1 General Background
The Wemicke-Korsakoff syndrome is a severe neuropsychiatric 
disorder which most commonly results from chronic alcohol abuse and malnutrition. 
The syndrome has a variable mode of onset but most typically presents with an acute 
phase (Wernicke’s encephalopathy) that can evolve suddenly (hours to days) and may 
merge into the chronic phase (Korsakoff s psychosis) in some individuals. In a small 
number of cases, the chronic phase occurs without a previous history of Wernicke’s 
encephalopathy.
Wernicke’s encephalopathy (WE) is characterised by ophthalmoparesis, 
nystagmus, ataxia and an apathetic confiisional state. This can result in recovery, 
death or a chronic Korsakoffs Psychosis (KP) of variable severity. KP is 
characterized by memory and learning impairment, anterograde and retrograde 
amnesia, sometimes coupled with confabulation. Historically, these two syndromes 
were described separately and many decades followed before the common pathology 
was recognized. It was the classic study of this condition (Victor et al., 1971) that 
coined the widely used term "Wemicke-Korsakoff syndrome" (WKS). Some 
controversy on whether KP can result independently from WE, or whether other 
coexisting pathology is essential, still continues (Freund, 1973; Freund, 1983; 
Lishman, 1990).
A current synonym for KP is alcohol amnestic disorders. However, 
non-alcoholic cases have been described (Hartman et al., 1987; Beatty et al., 1989; 
Becker et al., 1990; Parkin et al., 1991) and this synonym may therefore be 
misleading. The role of alcohol neurotoxicity in the aetiology of the syndrome is an 
issue of current contention (Freund, 1983; Harper, 1989; Lishman, 1990) and the 
most commonly held view is that the sole causative factor is thiamine deficiency 
(TD) (Victor et al., 1971; 1989). It is held by the proponents of this latter view that 
the early administration of thiamine completely reverses the syndrome and prevents 
a permanent KP stage. The severity of KP ranges from the mild learning difficulties
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that do not impair normal memory but are detectable on psychological tests, through 
to severe memory impairment and apathetic states requiring constant nursing 
supervision.
The age of onset of the condition is variable but most often occurs in 
the fifth and sixth decades of life. The study of WKS by Victor and associates 
(1989) showed women tended to develop the condition a decade or two earlier than 
men and men outnumbered women. However, women were over-represented if the 
relative incidence of alcoholism in men as compared to women was considered.
The prevalence of WKS probably varies throughout the world, 
although the literature on epidemiology is sparse. Patients with KP often become 
long term residents in mental hospitals or alternative institutions. A survey of 
patients at the Boston State Hospital in 1954 showed that 6.4% of all patients had KP 
(Victor & Laureno, 1978). In Scotland data extracted from two surveys of longstay 
mental hospital patients (McCredie et al., 1983; 1990) revealed that patients with 
Korsakoff s psychosis or alcohol dementia formed a significant proportion of this 
population. Of those who had been in hospital between 1 and 6 years and were 
under 65 years at point of admission, 11.6% (66 out of 571) had this form of alcohol 
brain damage. Of those over 6 years in hospital and under 65 years at point of 
admission, 4.6% (121 out of 2606 individuals) had been diagnosed with this 
condition. (Smith & McColl, 1992). In addition, there is evidence of an 
accumulation of such cases in Scottish mental hospitals over the past two decades 
(Table 1.1). These patients are forming an increasing proportion of the long-stay 
mental hospital population (Smith & McColl, 1992). Given the disabling nature of 
this condition coupled with a near normal life expectancy these patients represent a 
substantial cost to the National Health Service.
Victor et al. (1989) regard alcoholic dementia as indistinguishable from 
alcoholic KP, both being attributed to TD and its resultant neurotoxicity. Others 
consider that the two entities are a spectrum of disease occurring from the interplay 
of alcohol neurotoxicity and thiamine depletion that results in cortical and sub- 
cortical brain pathology. The greater the former pathology, the more likely is the
7
Table 1.1: Accumulation of alcoholic Korsakoffs psychosis (291.1)* and
alcoholic dementia (291.2)* in Scottish mental hospitals (1970-1990). 
(Reproduced from Smith & McColl, 1992).
YEAR 291.1 291.2 TOTAL
1970 33 - 33
1975 116 - 116
1980 148 10 158
1985 162 35 197
1990 189 58 247
* The Diagnostic and Statistical Manual of Mental Disorders (DSMIII) and the 9th edition of the International 
Classification of Diseases (ICD-9) classifies Korsakoff Psychosis as 291.1 and alcoholic dementia as 291.2 
(Freund, 1983).
classification as a case of alcoholic dementia; the greater the latter, the more likely 
is classification as a case of alcoholic KP (Lishman, 1990).
The possibility of accurate cross-national comparison of the prevalence 
of the condition is limited due to a dearth of literature. Yellowlees (1986) reported 
that WKS was rare in the U.S.A. and U.K. while being very prevalent in Australia. 
However, many individuals with WKS do not show clinical symptoms and therefore 
are not diagnosed until post-mortem. For example, Harper (1983) found that of 131 
cases of alcoholic WKS diagnosed at autopsy, only 26 had been suspected during life. 
Post mortem prevalence figures include 2.5% in Oslo, 2.2% in Cleveland and 1.7% 
in New York, U.S.A (Victor et al., 1989) but these may be under or overestimates 
as not all the deaths result in autopsies.
1.1.2 Historical Background
I
In 1881 Wernicke described three patients with similar symptoms of 
nystagmus, ophthalmoparesis, apathy and ataxia who subsequently died. Two of the 
patients were male alcoholics and the third was a 20 year old female who swallowed 
sulphuric acid that had led to uncontrollable vomiting. Wernicke concluded 
following postmortem studies of the brains that there were pathological changes in 
these cases representing an acute inflammatory disease of the oculo-motor nuclei 
("polioencephalititis hemorrhagica superioris11) leading to death (Victor et al., 1989).
In 1887 Korsakoff gave the first detailed account of the now 
eponymous amnestic disorder with a description of symptoms and pathology affecting 
both the central and peripheral parts of the nervous system. The description of the 
syndrome made by Korsakoff was given in a series of reports from 1887-1891. The 
first report was based on 20 alcoholic and non-alcoholic patients presenting with 
multiple neuritis for which he suggested the name "psychosis polyneuritica". With 
further studies, Korsakoff changed the name of this amnestic disorder to 
"Cerebropathia psychica toxaemica" after concluding that the disorder was a result 
of a toxin affecting the spinal cord and the brain. In 1897 Jolly suggested that KP 
should replace "Cerebropathia Psychica toxaemica". The clinical relationship between
9
WE and KP was not established until 1904 by Bonhoeffer et al.. In 1928 Gamper 
concluded that both disorders shared a characteristic neuropathology with similar 
anatomic distribution.
1.1.3 Pathology and Treatment
WKS is a focal syndrome with a characteristic histopathology affecting 
specific brain regions. The pathological changes in the WE are in the cortex, the 
cerebellum and in the midbrain and hypothalamus. Pathological changes in the brain 
cortex in KP were first reported in 1931 (Thomson et al., 1987). Such changes 
involve cerebral damage which exists over a wide range in the brain affecting the 
grey matter, third and fourth ventricles and Sylvian aqueduct involving the thalamus 
(Victor, 1971), hypothalamus, midbrain, floor of the fourth ventricle and the 
mammillary bodies with presence of cell necrosis (Hore, 1980). The brain ventricles 
tend to be larger in alcoholics with poor memory KP than normals making those 
alcoholics susceptible to cortical changes and possibly neuronal loss due to alcohol 
neurotoxicity (Lishman, 1990). However, the sequence of events leading to severe 
neurological dysfunction and irreversible histopathological changes of certain 
selective vulnerable parts of the brain remains unknown (Thomson et al., 1980).
Chronic alcohol abuse leads to nutritional deficiencies and, in some, 
organic brain damage. Thus chronic alcoholics can show neurologic disorders as a 
result of malnutrition. In addition, all clinical and pathological evidence presented 
by Neville et al. (1968) and Ron (1977) conclude that the major aetiological factor 
in most neurological disorders associated with chronic alcohol abuse is malnutrition 
(Thomson et al., 1980). The depletion of vitamins which are essential to cerebral 
function (thiamine, nicotinic acid, pyridoxine and vitamin B12) can result in 
neurologic damage.
The first report indicating the association of TD with WKS was made 
by Wagner and Weir (Victor et al., 1989). In 1978 Thomson concluded that vitamin 
deficiency may be a common cause of brain damage in alcoholics (Thomson et al., 
1980). Long-term thiamine defeciency due to hyperemesis of pregnancy, chronic
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gastrointestinal disease, malnutrition secondary to metastatic cancer and anorexia 
nervosa may all lead to the development of the WKS. Jollife and associates in 1941 
followed by Phillips and associates in 1952 showed that TD causes the acute 
reversible phase of WE with or without the presence of alcohol (Freund, 1983). 
However, no evidence was available to show that TD causes KP rather than chronic 
alcohol abuse alone (Freund, 1973).
Damage from malnutrition and direct ethanol toxicity are not mutually 
exclusive in KP; they may contribute or interact to various degrees in causing mental 
impairment. In addition, available morphological evidence in some patients with KP 
support the possibility that diencephalic and mesencephalic lesions are induced by TD 
(Freund, 1973). Lishman drew the following hypothesis on the cause-effect in the 
WKS. Increased susceptibility to alcohol neurotoxicity can lead to cerebral 
shrinkage, cognitive impairment tending to recede with abstinence. However, 
increased susceptibility to TD results in a mild and transient WKS. Finally, increased 
susceptibility to both alcohol neurotoxicity and thiamine depletion develops into the 
chronic resistant KP (Lishman, 1990).
Recovery and the reversal of symptoms in WE patients after treatment 
with thiamine was demonstrated by Phillips et al. in 1952 and Gould in 1954 
(Thomson et al., 1980, Hunt, 1983). In a study of 245 patients, with WKS followed 
up for 10 years the ocular abnormalities were reversed hours after thiamine 
supplementation in 60% of patients whereas the horizontal nystagmus remained. 
There was an improvement of the confusional state in 15% of patients with a 
complete recovery after a week or two. Less than 20% of all cases showed a 
significant degree of recovery. Large doses (50mg) of thiamine were administered, 
yet as little as 2-3mg would modify the ocular signs. (Victor, 1971). However, KP 
does not respond to thiamine treatment, possibly, due to an accumulation of structural 
pathology over the years. This would also contribute to the gradual development of 
the syndrome. (Lishman, 1990).
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1.2 THIAMINE: VITAMIN B1
1.2.1 Definition and Characteristics
Thiamine is an organic molecule of molecular weight 337.28kD and 
is required as an essential dietary factor for physiological function. Foods rich in 
thiamine include whole grain cereals, pork and legumes followed by other meats, 
fish, green vegetables, fruits and milk. Poor sources include polished rice, sugar, 
alcohol, fat and other refined foods.
There are three common forms of thiamin esters, thiamine 
monophosphate (TMP), thiamine triphosphate (TTP) and thiamine pyrophosphate 
(TPP) also widely known as thiamine diphosphate (TDP). Approximately 30mg of 
thiamine is stored in the body as 80% TPP, 10% TTP and 10% TMP and free 
thiamine. Almost half of the body store of thiamine is found in the skeletal muscle 
while the rest is distributed amongst the heart, liver, kidneys, nervous tissues 
including the brain which contains mostly TTP (Gibson, 1990). The normal human 
erythrocyte contains 50-150ng of TPP per 1ml packed cells (Sauberlich, 1984).
Thiamine is absorbed in the small intestine by an active transport 
process. The energy required for thiamine uptake at low (physiological) 
concentration is provided from the hydrolysis of ATP by Na+K+ ATPase system. As 
for higher (pharmacological) concentration absorption is carried out by a non 
saturable passive diffusion process.
1.2.2 Biochemical Function of Thiamine
The biochemical significance of TMP and TTP is obscure, however it 
has been suggested by Pincus in 1969 that TTP is essential in the central nervous 
system (Victor et al., 1989). TPP is the active coenzyme form of thiamine. 
Therefore ingested thiamine must be phosphorylated in order to become active and 
functional.
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This mechanism is carried out in all cells by adenosine triphosphate (ATP) which acts 
as a phosphate donor.
In 1953, Horecker demonstrated the role of TPP as a cofactor for a 
range of enzymes involved in carbohydrate and amino acid metabolism (Butterworth, 
1989). TPP is the prosthetic group requiring magnesium (Mg44) in two general types 
of reactions. The first reaction is the oxidative decarboxylation of a-keto acids 
catalyzed by the dehydrogenase complexes including pyruvate dehydrogenases (PDH) 
and a-ketoglutarate dehydrogenase. In the second reaction, transketolase (TK) 
catalyzes the formation of a-ketols (ketoses). The multienzymatic dehydrogenase 
complexes, affecting decarboxylative conversion of a-keto acids to acetyl 
cholinesterase derivatives, are utilized in Kreb’s cycle in the mitochondria. 
Transketolase requires TPP for carbohydrate metabolism in the hexose 
monophosphate shunt (pentose phosphate pathway), an alternative pathway for the 
oxidation of glucose, and is essential in the synthesis of ribose for nucleotide 
formation (McConachie and Haskew, 1988). The interrelationship of these TPP 
dependant enzymes is illustrated in Figure 1.1.
1.2.3 Thiamine Deficiency
The central role of thiamine is in carbohydrate metabolism. Hence, 
there will be a greater demand for it when the main source of energy is carbohydrate. 
(Figure 1.2). This applies to chronic alcohol abusers, as their only source of energy 
is alcohol which metabolizes entirely as a carbohydrate. The National Research 
Council (NRC) recommends a daily allowance of lmg of thiamine and slightly more 
for pregnant and elder individuals. This amount is utilized daily by the healthy well 
nutritioned adult. Therefore it is inadequate for the treatment of thiamine deficient 
individuals who would require lOOmg of thiamine. In order to completely saturate 
all their body tissues 50mg of thiamine is administered parenterally and 50mg orally 
(Victor et al., 1989).
There are several mechanisms which give rise to a TD state. These 
include inadequate intake of thiamine and decreased intestinal absorption as a result
GLUCOSE
I
Glucose-6-Phosphate
PENTOSES
NADPH
i
Hexose
Monophosphate
Shunt
Transketolase o
Embden Meyerhof 
Pathway
LACTATE < - PYRUVATE-
CHOLINE
ACETYLCHOLINE
©
ACETYL-CoA
♦
FATTY ACIDS
AMINO ACIDS
Pyruvate
Dehydrogenase complex
ATP
Kreb’s
Cycle
a  Ketoglutarate 
Dehydrogenase
♦
AMINO ACIDS
©
©
Figure 1.1: Enzyme activities impaired in thiamine deficiency. The enzymes
effected are transketolase (1), pyruvate dehydrogenases (2), a- 
ketoglutrate dehydrogenase (3), and the synthesis of acetylcholine (4) 
(Schenker et al., 1980).
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of chronic alcohol abuse (Thomson, 1980; Butterworth, 1989). Other effects of 
chronic alcohol abuse leading to TD, include reduction in phosphorylation of 
thiamine in the brain (Butterworth, 1989), increased metabolic demands (‘empty’ 
calories) (Figure 1.2), ethanol inhibition of Na+K+ ATPase system (Rosalki, 1984), 
and reduced storage capacity. Other mechanisms involve intake of food preparations 
which contain anti-thiamine factors, increased excretion of thiamine in the urine 
(Gradual et al., 1985) and finally presence of diarrhoea or infection. The latter will 
cause Mg'* deficiency which would impair the turnover of thiamine (Traviesa, 1974; 
Victor et al., 1989). The time required to produce a TD state is variable and may 
develop rapidly in a matter of hours, or may take weeks (Thomson et al.,1980; Victor 
et al., 1989). TD causes biochemical lesions in the brain as a secondary effect of 
chronic alcohol abuse (WKS) or as a direct effect.
1.23.1 Effect of Thiamine Deficiency on the Brain
Thiamine plays an important role in the overall function of the nervous 
system (Thomson et al., 1980; Rosalki, 1989). The brain becomes particularly 
vulnerable to TD as a result of the overall margin between the thiamine flux across 
the blood-brain barrier and the turnover rate of thiamine (Thomson et al., 1987). It 
is also known that diets lacking in thiamine result in alteration of brain metabolism. 
However, it is unknown at which point neurochemical transmission is affected, should 
the nerve-cell metabolism become susceptible, and at what level irreversible damage 
occurs (Thomson et al., 1980). Moreover, malfunction of blood-brain barrier (may 
be a result of direct ethanol toxicity) and failure of thymidine incorporation into brain 
DNA (reversible with thiamine treatment) have been illustrated (Thomson et al., 
1980; Rosalki, 1984).
In the 1960’s, Dreyfus and coworkers studied the enzymes affected by 
thiamine depletion in the nervous system. The mechanism of TD encephalopathy had 
been suggested by Parker and colleagues to be an impairment of PDH activity which 
results in a decline of cerebral ATP synthesis and acetyl-CoA production from 
pyruvate (Figure 1.1). However, Dreyfus and Hauser (1965) demonstrated that PDH 
was less susceptible to thiamine depletion and concluded that the "biochemical
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lesion” incurred by TD was a failure in TK activity (Figure 1.2). McCandless and 
Schenker (1968) demonstrated a greater decline of tissue TK activity as compared 
with PDH activity during induced TD. They also demonstrated that, in addition to 
the reversal of several neurologic signs following thiamine treatment, PDH activity 
returned to normal whereas TK activity increased slightly. Gibson et al., (1988) 
confirmed low TK activity (30-32% of normal) despite thiamine supplementation 
while a-KGDH and glucose oxidation returned to normal. Several other studies have 
been performed to investigate the effect of induced TD on PDH, a-KGDH and IX  
in peripheral and central nervous system of mammals (rats, monkeys) and other 
species (pigeons) (Gibson et al., 1988; Rindi, 1989; and Witt, 1985). Other works 
on a-KGDH and PDH in brains of rats and other animals were reviewed in 1989 by 
Victor and associates.
1.2.3.2 Beri Beri
Beri beri is the classical syndrome of TD. It has a high prevalence in 
the Orient where the main source of food is polished rice. Due to improvement in 
nutritional status the incidence of beri beri has declined but sporadic cases have been 
reported (Kuriyama et al., 1980). The major clinical manifestation of beri beri are 
of cardiac and neuropathetic origin.
The apoenzymes PDH, a-KGDH and TK have been studied in beri 
beri patients. The levels of PDH and a-KGDH have been found to be elevated 
whereas TK activity was reduced (Victor et al., 1989). Direct assessment of thiamine 
status has been widely applied for diagnosis of beri beri followed by analysis of TK 
activity (Kuriyama et al., 1980).
1.2.4 Assessment of Thiamine Status
Several biochemical parameters can be used to measure levels of 
thiamine (Sauberlich, 1967; Victor et al., 1971). However, direct measurements of 
thiamine levels in serum, erythrocytes, whole blood and urine have not proved 
satisfactory due to the limitation of the methodology, and the fact that the decrease
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in blood thiamine levels during deficiency is not great (Sauberlich, 1984). Also, 
daily fluctuations in thiamine levels in normal individuals may mimic the low levels 
associated with TD (Kuriyama et al., 1980).
Biochemical tests based on levels of TPP, that is measuring coenzyme 
activation of erythrocyte enzymes rather than thiamine, may reflect more accurately 
the status of the individual. One such test used measures the ratio of lactic acid to 
pyruvic acid in blood after administering glucose. These metabolites would be 
elevated in TD (Victor et al., 1989). A more recent and widely used biochemical test 
is measuring erythrocyte transketolase (ETK) activity before and after addition of 
TPP in vitro (Rosalki, 1984).
13. TRANSKETOLASE (E.C. 2.2.1.1)
13.1 Definition and Function
TK (E.C. 2.2.1.1.) is a conjugated enzyme consisting of a protein 
moiety, the apoenzyme, and a prosthetic group, the coenzyme, joined by a metal ion, 
the cofactor. The prosthetic group serves as an intermediate carrier of specific 
functional group. In 1976, Conn and Stumpf reported that TK is made up of two 
identical subunits utilizing both TPP as its prosthetic group and Mg** as its cofactor. 
In the presence of these two factors, the transketolase holoenzyme is formed and 
activated. Horecker and Smymiotis (1953) and Baker et al. (1953) demonstrated the 
requirement for TPP. The native enzyme TK had been shown to contain Mg** in its 
molecular structure (Victor et al., 1989). The positive cooperative interaction 
between TPP binding sites and Mg** was demonstrated by Kochetov et al (1975). 
Moreover, Egon and Sable suggested the function of Mg** to be related to the 
modification of the enzyme structure in the complex formation with TPP (Jung et al.,
1988).
TK is a cytoplasmic enzyme creating, like transaldolase (TA), a 
reversible link between the hexose monophosphate shunt and glycolysis (Figure 1.3). 
The reactions catalyzed by these enzymes yield the formation of two hexoses and one
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triose from three pentoses (Reactions 1, 2 and 3 in Figure 1.3). That is, TK catalyzes 
the transfer of a 2-carbon unit, activated aldehyde group, from a 5-carbon sugar 
ketose (ketol donor) to an aldose (aldehyde acceptor). The specific reaction catalyzed 
by TK is illustrated in Figure 1.4. In addition, TK participates in recycling ribose-5- 
phosphate into glucose-5-phosphate for glycolysis.
13.2 Brain Transketolase and Thiamine Deficiency Related 
Disorders
The work by Peters and colleagues on thiamine deficient brain tissue, 
in the 1930’s, demonstrated the basis for the organic brain disorder to be a failure of 
some thiamine dependent metabolic process. The discovery of TK in the hexose 
monophosphate shunt (1950’s) provided the basis of the biochemical lesion in the 
central nervous system of TD. It was also illustrated that TK was significantly 
reduced at the early stages of TD (Pratt et al., 1985). The findings of Dreyfus and 
Hauser in 1965 have also confirmed that the the failure in the TK system might be 
responsible for initiating clinical and pathological changes. Their work has also 
indicated that TK activity varies from one part of the nervous system to another. It 
was lowest in the cerebral cortex, highest in the spinal cord and greater in heavily 
myelinated structures than in neuronal masses. This may be related to the 
disproportion of effected myelin structures comprising both nerve cells and 
myelinated fibres (e.g. mammillary bodies). (Victor et al., 1989)
Despite severe reduction of TK activity in the brain, McCandless and 
coworkers in 1981 and 1982 reported the hexose monophosphate shunt to be 
unaffected in induced TD (Victor et al., 1989). Giguere and Butterworth (1987) also 
found a 25% reduction of TK in the lateral vestibular nucleus and surrounding pons 
prior to onset of neurological symptoms in chronically thiamine-deprived rats. This 
had persisted in the brain stem and cerebral regions despite treatment of thiamine. 
Adding TPP in vitro did not normalize TK activity suggesting loss of the apoenzyme 
(Giguere & Butterworth, 1987; Gibson et al., 1989; Butterworth, 1989; Thomson et 
al., 1980). Finally, Mukherjee et al. (1987) found that ribose-5-phosphate (R-5-P), 
produced from reversed reaction of TK (Figure 1.3), was essential in maintaining
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Figure 1.3: Metabolic pathway of hexose monophosphate shunt. Products required
for reductive biosynthesis (NADPH) and nucleotide synthesis (ribose- 
5-phosphate) are illustrated. The flow of glucose-6-phoshate depends 
on the need of:
a) ribose-5-phosphate > NADPH then the flow of reactions 1,2,
& 3 are reversed by transketolase and transaldolase.
b) ribose-5-phosphate = NADPH then flow as illustrated above
c) ribose-5-phosphate < NADPH then
i) Recycling of ribose-5-phosphate into glucose-6- 
phosphate in the oxidative branch
ii) Proceeding of glyceraldehyde-3-phosphate and fructose- 
6-phosphate to glycolysis.
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21
cerebral gluthione (GSH) in the reduced state, thus a decline of NADPH will result 
in low GSH impairing the function of the cerebral metabolic pathway.
1.3.3 Clinical Application of Transketolase Assay
In 1958 it was discovered that TK activity could be monitored in red 
blood cells (RBC) and an abnormal activity may be restored by the addition of TPP, 
the TK activation test (Brin et al., 1960). This abnormality also reflects similar 
changes in the brain (Pratt et al., 1985). It was the work of Brin and associates that 
demonstrated the presence of TK in RBC, and that it was the only thiamine 
dependent enzyme in RBC. They were also the first to develop a method for the 
estimation of TK in red cell hemolysates (Brin et al., 1960). Two years later, 
Dreyfus and Moniz developed a simple and reproducible method for direct assay of 
TK activity from microgram quantities of tissues and microlitre amounts of whole 
blood using a calorimetric method. Their findings suggested that TK activity varies 
with levels of coenzyme present. The addition of TPP into the assay would increase 
enzyme activity and is related to the degree of the saturation of enzyme with 
cofactor. This is termed the "TPP effect" (TPPE) and is expressed as a percentage 
of the basal activity. TPPE was found to reflect the amount of apoenzyme not 
saturated with thiamine.
13.3.1 Measurement of Erythrocyte Transketolase Activity
The method of Dreyfus and Moniz (1962) requires two haemolyzed 
blood samples, both incubated with excess R-5-P substrate reagent and one with 
excess TPP. ETK activity is determined by the formation of sedoheptulose-7- 
phosphate (S-7-P) measured spectrophotometrically, and expressed in //g/ml 
haemolysates. The difference in enzymatic activity with and without the addition of 
TPP in vitro is expressed as percentage of TPP.
Despite the modification (Wamock et al., 1975; Takeuchi et al., 1984)
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of the previous method (Dreyfus & Moniz, 1962) extreme care and caution were 
required to produce reliable results (Rosalki, 1984). Therefore, an enzymatic method 
for determining ETK activity has been employed widely in the last twenty years or 
so which provides more consistent and reproducible results. The method employed 
is based on the coupled reaction formed by linking TK reaction to a dehydrogenation 
step that can be monitored by following the change in absorbance at 340nm 
spectrophotometrically (section 2.1.4.1). This was first described and applied by 
Smeets et al. (1971) (on 10 samples) who reported mean ETK activity to be 0.368 
IU/gHb at a haemoglobin (Hb) concentration in hemolysate of 45-50g/l. That is, one 
unit of TK activity was defined as the amount of enzyme that catalysed the formation 
of 1/miol of NAD per minute.
To summarize, the principle of the ETK activity test is based on four 
main criteria. The first criterion is that the basal activity of TK in erythrocytes 
(ETK) represents the endogenous enzyme (holotransketolase, HoloTK) activity 
depending on amount of coenzyme already present in erythrocyte. The second 
criterion is that the determined stimulated TK (ETKs) activity by the addition of 
excess TPP in vitro represents the maximum potential enzyme activity. Both ETK 
and ETKs activity can be expressed as per gram of Hb, per number of RBC’s or in 
terms of erythrocyte volume (mL). The third criterion compares the values ETK and 
ETKs activity to indicate the degree of enzyme unsaturated with coenzyme. The 
final criterion regards the expression of data in terms of activity coefficient or the 
elevation of TPPE, expressed as a percentage. It must also be noted that the ratio of 
ETKs to ETK is used due to the elevation of ETK activity in inter-subject variation, 
and on the assumption that the apotransketolase (ApoTK) levels are not affected by 
TD.
133.2 Index for Thiamine Deficiency and Other Disorders
In 1958 Brin et al. demonstrated the activity of TK to be markedly 
depressed in the erythrocytes of TD rats and in humans with WE The use of ETK 
activation by TPP as an indirect measure of thiamine content was applied since it was 
inversely related to thiamine concentration in erythrocytes. It was also concluded that
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in TD, in vitro ETK activity falls whereas TPPE rises (Sauberlich, 1967). Following 
this, several workers began applying the ETK activity and TPPE test for thiamine 
assessment in population studies, in disorders relating to malnutrition, and in the 
diagnosis of WKS.
Population studies assessing nutritional status by ETK activity and 
TPPE tests have been carried out using colorimetric methods (Vuilleumier et al., 
1983; Londsdale, 1988; Fidanza et al., 1989; Hill & Truswell, 1990) or enzymatic 
methods (Duffy et al., 1981). Duffy et al. (1981) measured ETK, ETKs activity and 
TPPE on 1920 Melanesians from Torres Strait Islands and found 21% had elevated 
TPPE (>15%) while 2.2% had a high TPPE (>20%). It was concluded that 10-20% 
of the Australian population had a daily thiamine intake below the recommended 
amount. In 1983 Vuilleumier et al. performed ETKA activation test on 150 blood 
donors in Switzerland and found that 6.7% had a moderate risk for TD. Lonsdale 
(1988) studied the ETK, ETKs activity and TPPE in 1011 patients from 1983 to 1986 
attending a private practice specializing in nutritional correction. It was found that 
24% of patients were thiamine deficient (elevated TPPE) while 28% had either/both 
abnormal ETK activity and TPPE, suggesting an abnormality of ApoTK or other 
factors. Lonsdale concluded that there is a widespread health problem in the U.S. 
relating to modem nutrition (Lonsdale, 1988). Hill and Truswell (1990) evaluated 
ETK activity and TPPE in 107 homeless men from two hostels and a clinic in 
Sydney, Australia to assess nutritional status. Their findings showed 36% of those 
men had elevated TPPE (21% had marginal and 15% had severe deficiency) and 
concluded that the nutritional status results not only from dietary effects but also 
from environment, ill-health and genetic factors. All these studies indicate the 
reliability of ETK activity and TPPE for thiamine assessment and its relation to 
nutritional status. (Duffy et al., 1981; Vuilleumrer et al., 1983; Lonsdale, 1988; 
Fidanza et al., 1989; Hill & Truswell, 1990). Finally TPPE has been shown to be 
independent of age and sex (Duffy et al., 1981; Jeyasingham, 1987; Lonsdale et al.,
1988).
The TK activation test has been employed in the assessment of several 
other disorders. In 1977 Kjosen & Seim studied ETK activity and TPPE in patients
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with diabetes mellitus, anemia, polyneuritis and malnourishment secondary to 
vascular disease of brain. Their findings showed ETK activity to be reduced in 
patients with diabetes mellitus and polyneuritis while elevated in those with 
pernicious anaemia. ETK activity in the malnourished alcoholic group, control 
alcoholic group and a normal control group did not vary significantly nor did TPPE 
between all groups regarding TPPE. This would suggest a variation in ApoTK levels 
that results from disease and not malnutrition (Kjosen & Seim, 1977). However, 
ETK activity and TPPE assessed in bed beri patients showed a decline in ETK 
activity with elevated TPPE as a result of TD (Kuriyama et al., 1980; Kawai, 1980). 
Gibson et al. (1988) studied ETK activity in Alzheimer’s disease and found a 
reduction of ETK activity to 45% in the brain and peripheral tissues with other 
abnormalities in RBC and fibroblasts. These studies suggest that ETK activity and 
TPPE should be applied independently with regard to the aetiology of the disorder 
(Sauberlich, 1984).
ETK activity and TPPE in chronic alcohol abusers have been studied 
in Order to establish alcohol neurotoxicity, thiamine deprivation and the development 
of WKS. Fennelly et al. (1967) evaluated ETK activity in malnourished (TD) 
alcoholics (n=17) with liver cirrhosis and signs of neuropathy and found that 10 
patients had reduced levels of ETK activity. It was also found that ETK activity in 
TD1 patients without liver disease was increased significantly after in vitro addition 
of TPP in RBC hemolysates whilst having a negligible effect on those with liver 
cirrhosis. Similar results were observed after oral administration of thiamine which 
did not improve peripheral neuropathy nor ETK activity in patients with severe liver 
cirrhosis. This suggests that the abnormality of ETK activity was unrelated to the 
blood thiamine level (Fennelly et al., 1967). Melgaard and associates (1989) also 
reported no differences in ETK activity between a group of alcoholics and a normal 
group which suggests no relation between alcoholic neuropathy and nutritional 
deficiency. Thiamine status in alcoholic patients (n=20) before and after 
intramuscular thiamine hydrochloride supplementation (200mg) was studied by the 
TK activation test. It was found that ETK and ETKs activity in alcoholic patients 
were significantly different from normal controls (McLaren et al., 1981; Gradual et 
al., 1985) and that the treatment had no significant effect on ETK and ETKs activity
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but TPPE was significantly decreased. Kerr and associates also studied the effect of 
oral treatment with thiamine on ETK activity in alcoholic WKS patients (n=16), and 
normal controls (n=ll) maintained for several months and then stopped abruptly. 
These findings showed a rapid decline (completing in 4 weeks) of ETK activity in 
WKS while there was a gradual decline of ETK activity in normal controls. This 
difference between the response of the two groups to thiamine withdrawal supports 
the hypothesis that at least some WKS patients possess an abnormality in TK (Kerr 
et al., 1986). Finally, there was one report describing an abnormality of TK in a 
WKS patient due to magnesium deficiency which was improved by treatment with 
intramuscular MgS04 suggesting importance of Mg** ion as a cofactor (Traviesa, 
1974). All these studies (Fennelly et al., 1967; McLaren et al., 1981; Gradual et al., 
1985; Kerr et al., 1986) strongly suggest that abnormality in ETK activity reflects 
abnormality in TK and that of TPPE reflects abnormality in thiamine status only. 
Morevoer, both chronic abuse and TD can result in WKS (Sauberlich, 1967; Victor 
et al., 1971) as a result of an abnormality in TK (Sauberlich, 1989; Victor et al.,
1989).
13.4 Biochemical Analysis of Purified Holotranskelotase
Human tissue TK, unlike yeast and some mammalian species, has not 
been fully characterized with respect to its catalytic and chemical properties due to 
a lack of homogeneous enzyme preparation (Jung et al., 1988). Most of the known 
properties on TK were derived from studies on purified TK from spinach in 1971, 
yeast in 1961, pig liver in 1960 and from rat liver in 1953 (Paoletti, 1983; Himmo 
et al., 1988). The purification of rat liver TK allowed the determination of its 
molecular weight (MW) 139kD (made up of two subunits of 69kD) with multiple 
forms having pi values from 7-8 as detected by isolectric focusing (IEF). (Paoletti, 
1983; Paoletti Aldinucci, 1986). The isolation of TK from the rabbit liver was 
reported to have a MW of 162kD near to that of Baker’s yeast (158-159kD) (Masri 
et al., 1987).
Several reports have attempted the isolation of IX  from human
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erythrocytes and other tissues, in a purified homogenous form, to characterise its 
properties. Purification techniques involved mostly ion exchange chromatography 
(Wamock & Prudhomme, 1982; Greenwood et al., 1984; Takeuchi et al., 1986; Jung 
et al., 1988; Sheu et al., 1988), gel filtration (Pratt et al., 1985; Mocali & Paoletti,
1989), affinity chromatography (Himmo et al., 1988; Mocali & Paoletti, 1989) and/or 
application of sophisticated techniques such as fast protein liquid chromatography 
(FPLC) (Takeuchi et al., 1986; Jung et al., 1988).
Preparations of pure homogenous human TK showed that it existed in 
more than one form differing in MW (Wamock & Prudhomme, 1982; Pratt et al., 
1985, Sheu et al., 1988), ionic strength (Greenwood et al., 1984; Takeuchi et al., 
1986; Mocali & Paoletti, 1989), and TPP binding affinity (Wamock & Prudhomme, 
1982; Greenwood et al., 1984; Pratt et al., 1985; Jung et al., 1988). Such 
| preparations also provide a mean of estimating Km values for substrates utilized by 
TK (3.0-4.0 x lO"4 M for R-5-P and 1.5-2.0 x 10-4 M for X-5-P) with an optimum pH 
of 7.6-8.0 (Wamock & Prudhomme, 1982; Takeuchi et al., 1986; Himmo et al., 1988) 
at temperature 40-50°C (Takeuchi et al., 1986; Himmo et al., 1988). Purified TK 
was shown to be inhibited by phosphate ions (0.01M) (Prudhomme & Warnock, 
1982; Himmo et al., 1988). This was not confirmed by Takeuchi and associates 
(1986) who reported a maximum velocity for TK (4.2 X 102 mol/min/mol of enzyme) 
and that 1 mol TK subunit contained 0.9 mol TPP. It was also found that HoloTK 
was more heat stable than ApoTK (Takeuchi et al., 1984; Sheu et al., 1988) and 
could be stored below 0°C for several weeks without loss of activity (Wamock & 
Prudhomme, 1982; Takeuchi et al., 1986; Sheu et al., 1988; Mocali & Paoletti, 1989). 
Finally, the homogenous preparations of TK allowed the analysis of the amino acid 
composition (Takeuchi et al., 1986) and generation of polyclonal antibodies in order 
to characterize catalytic activity of TK by immunoaffinity and physical properties of 
TK by immunochemical staining of western blots (Takeuchi et al., 1986; Jung et al., 
1988; Sheu et al., 1988; Mocali & Paoletti et al., 1989).
Partial purification of ETK by ion-exchange chromotography eluted in 
two peaks which were well separated from hemoglobin (Kaczmarek & Nixon, 1983; 
Greenwood et al., 1984) and differed in the proportion of ApoTK present. The later
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eluted peak of ETK activity required the addition of TPP in order to express activity 
(Greenwood et al., 1984). Similarly, gel filtration also yielded two peaks of ETK 
activity differing in binding affinity and MW. The low affinity enzyme (which 
requires TPP for activation) was shown to be half the MW of the high affinity 
enzyme (which is firmly bound to TPP) as determined by its position on the 
chromatograph (Pratt et al., 1985; Thomson et al., 1987). Other work has shown 
heterogeneity of TK with respect to its MW with 50-60, 26-30 and 33kD (Wamock 
& Prudhomme, 1982).
The detection of multiple forms of TK, differing in pi values, by DEF 
analysis of partially purified human ETK was first reported by Kaczmarek and Nixon 
(1983). This finding indicated the presence of 8 individual species of ETK (detected 
by TK specific activity stain) with pi values ranging from 6.6-9.2 and the presence 
of six different patterns of these species in 25 healthy individuals having common 
isoenzymes at pi 7.5, 7.8 and 8.1. Kaufmann et al. (1987) confirmed the presence of 
at least two ETK bands with pi 7.3 and 8.6 in all 63 healthy individuals by the same 
method. A somewhat similar analysis was reported by Paoletti et al. (1989) who 
applied IEF techniques and western blotting for separation of TK from fresh human 
leukocytes. Their findings also confirmed the presence of at least two TK variants 
differing in pi (range 7.4-8.4) and specific activity. The rare variant (1.5% of 217 
healthy individuals) had 20-25% less activity from the standard as detected by 
immunostaining (Paoletti et al., 1989).
The above reports and others, on the purification and partial 
purification of TK have shown TK to be heterogenous in ionic strength, pi values 
(Kaczmarek & Nixon, 1983; Greenwood et al., 1984; Paoletti et al., 1989), MW 
(Wamock & Prudhomme, 1982; Kaczmarek & Nixon, 1983; Pratt et al., 1985; 
Thomson et al., 1987; Sheu et al., 1988) binding affinity and activation by TPP 
(Greenwood et al., 1984; Pratt et al., 1985; Thomson et al., 1987; Jeyasingham & 
Pratt, 1988).
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1.4 Studies of Human Erythrocyte Transketolase in
Wernicke-Korsakoff Syndrome
Several reports have described variation in TPPE values and its 
elevation (Smeets et al., 1971; Bayoumi & Rosalki, 1976; Duffy et al., 1981; Kjosen 
et al., 1977; Sauberlich, 1984; Lonsdale, 1988) in TD and related disorders with 
particular emphasis to WKS (Victor et al., 1971; Sauberlich, 1984). In a particular 
study, Bayoumi and Rosalki (1976) investigated the TK activation test and concluded 
that abnormal ETK activity and TPPE are directly related to clinical evidence of TD 
based on their study of normal and alcoholic subjects. Of 47 alcoholic and 
malnourished inpatients, 13 had abnormal ETK activity (one geriatric patient, 8 
alcoholics with WKS and 4 alcoholics with no clinical TD) while those patients with 
no clinical evidence of TD had normal ETK activity. This report and others 
suggested the finding of TK variation results from the dissociation of part of the 
enzyme into its ApoTK (Jeyasingham et al., 1987) or from an abnormality in the 
binding affinity of ApoTK to coenzyme (Kjosen, 1977; Gradual et al., 1985; Kerr et 
al., 1986; Takeuchi et al., 1988) and that the abnormality is most prominent in WKS 
(Blass & Gibson, 1977; Greenwood et al., 1984; Pratt et al., 1985; Kerr et al., 1986; 
and Jeyasingham et al., 1987).
The classical WKS which occurs in a small number of patients, most 
commonly as a secondary effect of chronic alcohol abuse may be caused by thiamine 
depletion superimposed on a genetic abnormality of TK. This was first postulated 
by Blass and Gibson in 1977 who examined TK in cultured cells from four patients 
with WKS. They found a significant difference (p<0.001) between the apparent Km 
values for TPP in fibroblast TK of patients and normal controls. This abnormality 
of TK in fibroblasts continued through several passages in culture medium containing 
excess thiamine and no alcohol. Blass and Gibson (1977) thus concluded that the 
biochemical abnormality in TK from WKS fibroblasts appear to be genetic and may 
be a result of an apoenzyme mutation, rather than a consequence of disease (Olson 
& Doisy, 1979).
There are several clinical and epidemeolgical observations supporting
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a genetic aetiology of WKS: (i) there is only a small minority of alcoholics, both TD 
and non TD, and other chronically malnourished persons who develop WKS (Victor 
et al., 1971; Blass & Gibson, 1979), (ii) it occurs more frequently in Europeans than 
non-Europeans on a similar thiamine diet whereas Asians develop "wet” cardiac beri 
beri (Sauberlich, 1967), (iii) the variation and overlap of ETK activity among and 
between normal populations (Sauberlich, 1967), (iv) the existence of patients in 
whom the addition of TPP in vitro and large thiamine doses in vivo does not restore 
normal ETK activity nor reverse symptoms (Sauberlich, 1967). These, and the fact 
it is rare, provide evidence of a genetic predisposition (Blass & Gibson, 1979).
Further evidence of a genetic abnormality of TK in WKS comes from 
a report of a pair of monozygotic twins, one of whom suffered from WKS (verified 
at autopsy) and one unaffected. Both twins had low basal ETK activity, similar to 
that described by Blass and Gibson in 1977 (Leigh et al., 1981). Mukherjee and 
associates (1986) studied ETK activity from fibroblasts of a diabetic patient who 
developed WE after treatment with tolzamide, and 3 diabetic kindred with no history 
of WE. It was found that the Km value for TPP of the patient and one diabetic sib 
were similar to the values estimated in WKS. Mukherjee and associates had also 
reported a TK abnormality in familial chronic alcoholic males, in their non alcoholic 
sons and in 3 generations of a non-alcoholic Amish family. These findings indicated 
that TK abnormality may exist in a non-alcoholic population and that it may be 
present in male and female sibs (Mukherjee et al., 1987). In 1988 Lonsdale 
described a TPPE abnormality in an 8 year old girl who was suffering from recurrent 
infection, similar to her mother and father suggesting an unknown familial 
component. Finally, the work performed by Nixon and associates strongly suggested 
genetic variation of TK. By applying IEF techniques on ETK in 42 patients with 
WKS and 36 normal controls, a specific isozyme pattern, (characterized by pi values 
ranging 6.6-9.2) was detected in 39 patients with WKS but in only 8 normal controls 
(Nixon et al., 1989).
Recent studies have implied that the abnormality of TK in WKS may 
be a result of environmental factors and not genetic. It has been reported that a 
severe alcoholic state is the immediate cause of damage to TK which produces an
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abnormal variant more readily in thiamine deficient individuals (Pratt et al., 1985). 
This variant may be structural (e.g. smaller molecule), catalytic (low binding affinity 
to TPP) or a combination of both and is present in high proportions in patients with 
WKS (Greenwood et al., 1984; Pratt et al., 1985; Jeyasingham et al., 1987; Thomson 
et al., 1987; Nixon, 1983; Nixon et al., 1984). It had also been reported that the 
decline in ETK and ETKs activity may result from loss of both apoenzyme and 
coenzyme. This can lead to a decreased synthesis, or increased destruction of 
apoenzyme, to a greater degree in malnourished alcoholics and in those with WKS 
(Kerr et al., 1986; Takeuchi et al., 1988). The formation of a damaged or degraded 
TK variant in WKS, with respect to its binding affinity with TPP, may cause 
impaired brain metabolism that can result in brain tissue damage (Pratt et al., 1985; 
Thomson et al., 1987; Jeyasingham et al., 1987).
Pratt, Jeyasingham and associates (1985-1988) provided a tentative 
explanation on how brain damage occurs in TD and why only certain individuals 
were susceptible to the more severe form of WKS. Their conclusions were supported 
by Lishman (1990) who also suggested that TK variants could have arisen from 
damage to the TK system (Lishman, 1990), although a real genetic component may 
be present (Pratt et al., 1985). Chronic alcohol abuse may cause damage to TK 
which is accelerated in a thiamine deficient state and could lead to an impairment of 
TK activity (Pratt et al., 1985; Lishman, 1990). Thus, high energy phosphate will be 
reduced below the normal level and is compensated for by increasing the rate of brain 
glucose utilization. This will lead to excessive production and accumulation of 
lactate in the brain cells due to a limitation of substrate transport across the blood- 
brain barrier, and results in brain damage associated with WKS (Pratt et al., 1985). 
It has also been suggested that ageing effects and liver status may also contribute to 
abnormality in ETK activity and brain damage in WKS (Fennelly, 1967; Thomson 
et al., 1987).
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1.5 AIMS OF THE STUDY
The aim of this study is to examine the role of TK in the aetiology of
WKS by application of multiple methods of TK analysis.
Three complimentary approaches are used:
1. Quantitative investigation of TK by evaluation of existing (published) 
methods of TK assay and development and application of an optimised 
method to measure endogenous TK activity before and after activation 
with cofactor in erythrocytes from patients with WKS and normal 
controls.
2. Qualitative investigation of endogenous ETK and partially purified 
ETK using a variety of protein separation methods to search for 
evidence of structural variations in WKS patients.
3. Characterisation of TK by preparation of a purified enzyme suitable 
for analysis by amino acid composition and amino acid sequencing.
CHAPTER 2: MATERIALS & METHODS
2.1 ANALYSIS OF ERYTHROCYTE TRANSKETOLASE 
IN CRUDE SAMPLE
2.1.1 Sample Collection and Storage
Control blood samples (30ml) were obtained by venepuncture from a 
total of 25 students and members of staff at the Duncan Guthrie Institute of Medical 
Genetics and collected in 3 x 10ml lithium heparin tubes. Blood was also collected 
from 30 patients with WKS by Dr. Ian Smith. The age of each subject and date of 
collection was noted (Table 2.1). The median age for normal controls was 27 years 
and for the patients 65 years.
The samples were centrifuged at 2000 RPM for 10 minutes in an MSE 
MULTEX centrifuge. The plasma and buffy coat were discarded by careful 
aspirations using a pasture pipette. To the packed red blood cells, an equal volume 
of 0.9% saline was added and mixed. The tubes were spun down as beforehand. 
The saline (upper layer) was aspirated and discarded. This step was repeated until 
a clear upper layer was obtained (three washes were adequate). The upper layer was 
discarded and an equal volume of buffered citrate glycerol (2 parts glycerol, 3 parts 
citrate solution containing 0.6% K2HP04 and 0.47% KH2P04, pH 7.4) was added and 
mixed thoroughly. This acts as a cryo-protective agent and prevents red cell 
hemolysis on freezing. The packed red blood cells (RBC) were stored in plastic 
tubes (3.5ml) at -20°C.
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Table 2.1 List of red blood cell samples collected from patients with Wernicke- 
Korsakoff syndrome. Samples were stored at -20°C in buffered citrate 
glycerol.
Collection & 
Storage Date
Sample Sex Age
11/1988 100194 M 70
11/1988 100195 M 64
11/1988 100196 M 63
11/1988 100197 M 78
11/1988 100198 M 64
18/9/1989 100100 F 65
3/1990 100101 M 66
3/1990 100102 M 79
3/1990 100103 M 64
3/1990 100104 M 65
3/1990 100105 M 61
3/1990 100106 F
3/1990 100107 F
3/1990 100108 M 62
3/1990 100109 M 72
3/1991 100110 M 69
3/1990 100111 M 71
3/1990 100112 M 62
16/5/1990 100113 M 64
16/5/1990 100114 M 68
16/5/1990 100115 M 60
16/5/1990 100116 F 66
28/5/1990 100117 F 65
28/5/1990 100118 M 78
28/5/1990 100119 M 72
28/5/1990 100120 M 71
30/5/1990 100121 M 70
30/5/1990 100122 M 69
24/7/1991 100134 M 57
24/7/1991 100135 F 57
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2.1.2 Haemoglobin Estimation
Since Hb concentration is proportional to the quantity of red cells in 
the haemoysate, red cell enzyme activity may be expressed as a ratio of the Hb 
concentration. This is measured by the addition of ferricyanide-cyanide reagent 
(Drabkin’s solution) to the haemolysate which converts Hb to cyanmethemoglobin. 
The optical density at 540 nm is proportional to the concentration of 
cyanmethemoglobin.
30/d of haemolysate was added to 1ml of Drabkin’s solution 
(Appendix II. 1) in a 1.5ml eppendorf and mixed. The reaction tubes were left at 
room temperature for 5 minutes to allow the complete conversion of Hb to 
cyanmethoglobin. The optical density of the sample was read spectrophotometically 
against a reagent blank at 540nm. The Hb concentration was calculated by using the 
following formula:
(2.1)
c _ d x O D X M O x M x W *  
540 HI CN 
^ _ vol. of Haem. (0.03ml) + vol. of reagent (1 mt) 
vol. of haemoly; (0.03ml)
C = Hb concentration (gm/dL)
d = dilution factor = 34.3
HiCN = millimolar extinction coefficient of cyanmethemoglobin at
540nm = 11.0 
M = molecular weight of Hb (16,520).
All estimations were performed in duplicate and Hb concentration is expressed as 
grams/dL.
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2.1.3 Protein Assay
Red cell enzyme activity may also be expressed as a ratio of total 
protein concentration. In order to estimate the protein concentration of a given 
solution, a dye-binding assay was used (Bradford, 1976). This method is based on 
the fact that when protein binds to a dye, (Commassie Brilliant Blue, CBB, G-250), 
the absorbance maximum shifts from 465nm to 595nm. A protein standard is used 
to allow the estimation of the unknown sample. Albumin is widely used since the 
extinction coefficient of the albumin-dye complex is constant over a 10-fold 
concentration range (Spector, 1978). A commercially available protein assay kit 
(BioRad) was used. The protein standard used was bovine serum albumin (BSA).
A microassay procedure was employed to avoid the use of excessive 
volumes of sample. Several dilutions of protein standard (BSA) were prepared 
containing 5-25 mg/ml. Into 1.5ml eppendorf, 20/d at protein standard or protein 
sample (previously diluted with water) was added to 1ml of a 1:5 dilution of dye 
reagent (Phosphoric acid). The solutions were mixed gently to avoid excessive 
foaming and left at room temperature for a least 10 minutes up to one hour. The 
solution was then transferred to a plastic cuvette and read against a "blank" at 595nm 
in PYE UNICAM PU8800 spectrophotometer. The absorbances at 595nm of the 
protein standard were plotted against standard concentration. The concentration of 
protein in the unknown sample were read from the standard curve. All samples were 
assayed in duplicate.
2.1.4 Quantitative Analysis of Erythrocyte Transketolase
The concentration of an enzyme in a haemolysate is proportional to its 
activity which can be estimated using a suitable reaction system. By adjusting the 
assay conditions, such as pH, temperature and concentration of substrates and 
intermediates of the reaction system, the enzyme analyzed is made the true rate- 
limiting step. The rate of reaction, which is proportional to the enzyme activity, is 
measured in terms of the quantities of products formed per unit of time. If those
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quantities do not have light-absorption maxima and therefore present difficulties in 
measuring optical density, then the reaction is coupled to another enzymatic reaction 
which gives an easily measured optical change. This system is known as a coupled 
reaction. The rate of the product accumulation is directly proportional to the change 
in absorbance measured by a spectrophotometer. This change in optical density is 
linear with time under optimum conditions. It may be measured by following the 
rate of reaction over a period of time recorded continuously with a pen and chart 
plotter (Kinetic Assay). An alternative approach is an endpoint assay which reads 
the initial optical density of the reaction (t0) and once again after a given period of 
time (tj), thus measuring the change in optical density over a given period (tj-to). To 
establish if the enzyme activity is altered within a patient group, it is essential to 
first determine a normal range of enzyme activity. This range can be defined by 
performing statistical analysis of results obtained from normal individuals.
2.1.4.1 Erythrocyte Transketolase Assay
Transketolase activity was assayed based on a method described by 
Smeets et al. (1971), modified by Bayoumi and Rosalki (1976), using the following 
coupled reaction:
TK
1. Ribose-5-phosphate + Xylulose-5-phosphate ** Sedoheptulose-7-phosphate +
Glyceraldehyde-3-phosphate
TPI
2. Glyceraldehyde-3-phosphate ** Dihyroxyacetone-phosphate
GDH
3. Dihydroxyacetone phosphate + NADH Glycerol-3-phosphate + NAD
In the presence of excess triosephosphate isomerase (TPI), glycerol-3- 
phosphate dehydrogenase (GDH) and NADH, glycerol-3-phosphate is rapidly 
converted to dihydroxyacetone phosphate by TPI in reaction (2) which is 
subsequently reduced to glycerol-3-phosphate and NAD. For each molecule of
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dihyroxyacetone-phosphate converted from glycerol-3-phosphate formed in reaction 
(1) and reduced, one molecule of NADH is oxidized to NAD. This results in a 
decrease in absorbance at 340nm which is followed spectrophotometrically (340nm 
absorption maximum for NADH). Since TK activity is to be measured, it is made 
the rate-limiting component by the appropriate adjustment of the reaction system. All 
reagents and concentrations used are listed in Appendix II.2a.
Sample Preparation:
Red cell samples stored at -20°C in buffered citrate glycerol were 
retrieved and thawed at room temperature. To 1ml of packed RBC, 1.5ml of 1% 
Triton X-100 was added and vortex mixed. To precipitate the cell debris, the 
samples were spun at 12800 RPM for 10 minutes. The Hb concentration was 
estimated as described in section 2.1.2, and adjusted by further dilution with Triton 
(if necessary), to approximately 40 gm/dl. Two aliquots for each haemolysate were 
prepared (i) 75% haemolysate, and 25% TPP solution for assay with cofactor (ETKs 
activity), and (ii) 75% haemolysate, 25% Tris-HCl, for assay without cofactor (ETK 
activity). These along with the reaction reagents, were preincubated at 37°C for 15 
minutes in a covered water bath.
Assay Protocol:
The reaction reagents were freshly prepared. To the substrate buffer 
(R-5-P), 0.4% GDH/TPI solution and 2% NADH solution were added. The total 
volume was divided into two bottles; 20% of TPP solution was added to one portion 
and 20% Tris-HCl pH 7.6 to the other. Each sample was assayed with and without 
cofactors, in duplicate.
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Each reaction tube contained 1.27ml of substrate reagents and 30/d of 
haemolysate to provide an intial optical density (OD) reading (to) and final OD 
reading (tx). Four tubes were set up for each haemolysate as follows:
Aliquot 1 2 3 4
Substrate Reagent 1.27ml - 1.27ml -
Blank Reagent - 1.27ml - 1.27ml
Haemolysate with 
TPP
0.03ml 0.03ml - -
Haemolysate - - 0.03ml 0.03ml
All aliquots were preincubated at 37°C as before for 15 minutes (t0) and for a further 
45 minutes (tx). The tubes were then removed from water bath and placed on ice to 
stop any further reaction. 1ml of reaction mixture was placed in a quartz curvette 
and read against a reagent blank at 340nm.
Calculation of TK activity:
The change in optical density ( a  OD) was determined from the 
difference between OD at tx and OD at t^ and AOD/min was determined by dividing 
aOD by the difference in incubation time between (t0) and (tx). ETK and ETKs 
activity is calculated from the following formula.
(2.2)
. . AOQfmin. x  Vmx  100
ETK activity = —  ---------- --------
1 Hb (gm/dL) x E x  VH
where Ve = final volume in eppendorf (ml)
Hb = haemoglobin concentration (gm/dL)
E = millimolar Extinction of NAD = 6.22
VH = volume of haemolysate (ml)
ETK activity is expressed in International Units per gm of Hb. (IU/gmHb).
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To calculate TPPE the following formula was used:
(2.3)
TPPE = 100 - f 57X5 activity x 10()) 
{ ETK activity )
This value is expressed as % activation and any value exceeding 25% is considered 
abnormal (Sauberlich, 1967).
2.1.4.2 Optimizing the Assay
The assay was further modified by varying conditions such as 
incubation times, addition of MgCl2 etc, as suggested by Tate and Nixon (1987) and 
Heinrich et al. (1972) respectively to obtain complete activation of TK with cofactor 
and to reduce Hb interference. All reagents, sample and reaction mixtures were 
prepared as described in section 2.1.4.1 unless otherwise specified. The modifications 
and variations carried out are listed in Table 2.2.
2.1.43 Application of Transketolase Endpoint Assay for the Analysis of
Patients and Control Samples
From the modification of the endpoint assay, optimum conditions were 
derived and applied to the analysis of normal control and patient samples. The 
reagents used and their concentrations are listed in Appendix IL2b.
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Table 2.2 List of modifications and their specification performed to optimize the 
endpoint assay.
Modification Stage in Assay Purpose Other Specification
Boiling Haemolysate Prior to Adding TPP i Hb Interference 2 min, 5 min.
Addition 10% TCA W n -
Addition 20% NaOH H ff -
Heating Reaction Mix Prior to Measuring OD t ETK Activation 60°C, 80°C
Use Shaker Water 
bath
Incubation of Reaction 
Mix
t Binding of TPP 
to TK
-
Addition of l.OmM 
DTT
Prior to incubating 
Haemolysate
t  ETK Activation -
Reducing Hb 
concentration
Prior to Adding TPP i Hb Interference From 40gms to 
20gms/dl
Addition of 1.2mM 
MgCl2
Prior to Incubating 
Reaction Mix
t TPP Binding + 
ETK Activation
-
Addition of 7.0mM 
X-5-P
tt t  Complete 
Reaction with 
Substrate
-
Varying Incubation 
Times
t i - t . Best Constant Rate 
of Reaction
10,30,45,60,90,120
mins.
t  increase
4 decrease
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Sample Preparation:
The samples were retrieved as before (2.1.4.1) and thawed out at room 
temperature. The concentration of haemolysate to be used was adjusted to give a 
final protein concentration of approximately 20mg/ml. Protein estimation was 
determined by using Bio-Rad protein assay (Section 2.1.3). After final dilution of 
haemolysate with 1% Triton, the samples were spun at 12800 RPM for 10 minutes. 
The haemolysates and reagents were preincubated for 15 minutes at 37°C in a 
covered water bath.
Assay Protocol:
The reagents (Appendix 11.3) were preincubated at 37°C for 10 
minutes. For each sample, four aliquots were prepared in a 1.5ml eppendorf 
containing:
Aliquot 1 2 3 4
Substrate Buffer 920/d 920/d 920/d 920/d
GDH/IPI 5/d 5/d 5/d 5/d
NADH 20/d 20/d 20/d 20/d
TPP 40/d - 40/d -
MgCl2 5/d 5/d 5/d 5/d
Tris-HCL (pH 7.75) - 40/d - 40/d
Haemolysate 20/d 20/d 20/d 20/d
This gives a total of 1.1ml in each eppendorf. Two sets of reaction 
mixture were prepared for each sample in addition to a reagent blank. One set was 
incubated for 30 minutes (to) and the other for 60 minutes (tj). The reaction mixture 
(lml) was then placed in a quartz curvette and read against a reagent blank at 340nm. 
All samples were assayed in duplicate.
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Calculation of TK activity:
ETK and ETKs activity were calculated using formula 2.2 with the 
following slight modification in formula:
(2.4)
AOEjfmin x  1000 x  V9
ETK activity =
NAD x V H
ETK and ETKs activity are expressed in IU/L haemolysate. To obtain ETK activity
in IU/mg protein, the following formula was applied:
(2.5)
ETK activity (lUlmg protein) =
'  C
I
' where Pc = protein concentration mg/L.
2.1.4.4 Statistical Analysis
To perform statistical analysis on ETK and ETKs activity in patients 
with WKS and normal controls, the mean and standard deviation were calculated. 
Significant differences between the mean ETK and ETKs activity was calculated 
using the parametric student’s t-test in the following formulae:
(2-6)
MEAN
n
Standard deviation = \ n
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x = ETK or ETKs activity of each sample 
n = number of sample 
x = mean
0 = standard deviation 
t = student’s t-test
2.1.5 Qualitative Analysis of Erythrocyte Transketolase
Electrophoresis achieves high resolution of protein mixtures, hence 
allowing characterization of proteins in terms of microheterogeneity, degradation and 
subunit structure. It functions as a transportation system of ions or charged 
molecules through a stable solution contained in a viscous medium (supporting 
matrix) under an electrical field. The macromolecules (mixture of proteins) migrate 
in the supporting matrix according to their size, shape and ion charge. Thus the rate 
of migration enables the distinction and measurement of the proteins separated. The 
mobility of proteins is influenced by choice of buffer, pH and pore size of the 
support gel matrix. The matrices minimize the diffusion of sample components 
which may occur in free solution, and reduce any convection resulting from heat 
generation during electrophoresis. The separation of proteins is obtained in gels by 
free passage of small molecules and impeded passage of larger molecules, therefore 
producing a molecular sieving effect. There are different types of supporting gel 
matrix such as polyacrylamide, agarose, cellulose acetate and starch which differ in 
structure and filtration properties. The choice of matrix to be used is related to the 
type of separation required.
2.1.5.1 Starch Gel Electrophoresis
The separation of protein mixture using this method is achieved not
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only on net ionic charge but also on differences in molecular size. In an electrical 
field, the anions would migrate towards the positive electrode (Anode) and the 
cations migrate toward the negative electrode (Cathode). The strength of the electric 
field and the size of the net charge on an enzyme molecule influence the speed of 
migration. The pH of the buffer solution determines migration speed (based on the 
ionic strength) and the voltage setting, on the power supply, determines strength of 
the electrical field (through the electrodes). The method of starch gel electrophoresis 
was developed by Smithies, 1959. All reagents and buffers used are listed in 
Appendix H.3.
Red cells stored at -20°C in Glycerol Citrate were retrieved, thawed 
and diluted with 1% Triton as described in section 2.1.4.1. and 20Qul of haemolysate 
containing 0.3mM TPP was prepared. The samples were preincubated at 37°C for 
15 minutes prior to loading onto gel. The hydrolysed starch gel solution (0.5L) was 
poured immediately into gel mould plates (15 x 22cm), avoiding formation of air 
bubbles, to give a 6mm depth. The gel was left at room temperature to set for 10-20 
minutes and then transferred to the cold room (to solidify) for at least six hours. The 
upper glass plate was lifted up slowly with a spatula so not to break the gel. A wide 
strip of gel (2cm) was cut out and removed. Along 6cm, the gel was sliced and slid 
backward to provide a gap between the two portions of the gels. Sample inserts (1 
x 0.5cm 3mm filter paper) were loaded with 10-20/zl of sample. The inserts were 
blotted and inserted vertically between the two gels. The cut sections of gel was slid 
back together and the 2cm end strip replaced. Any remaining gaps were filled with 
liquid paraffin. Electrophoresis was performed on an LKB Multiphor overnight 
(approx. 19 hours) at 0.34 kV and constant current of 2mA with cooling (4°C using 
LKB Multitemp).
2.1.5.2 Cellogel Electrophoresis
Cellogel is a form of cellulose acetate which is available commercially. 
It is supplied in 2.5cm or 15cm wide x 20cm long strips contained in 30% (w/v) 
methanol packs. The gel is of porous structure and the separation of protein mixture 
is based on the difference in charge and size. Electrophoresis using this method is
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quick and requires small volumes of sample (as little as 5/d). The reagents and 
buffers used are given in Appendix n.3.
The cellogel strip (15 x 20cm) was soaked in gel buffer for 30 
minutes. Six samples were applied to the dull side of the strip using a special 
applicator that was loaded from drops of haemolysate (prepared as for starch gel 
electrophoresis). Two applications were made on a predetermined line (three quarters 
of the way up) on the Cellogel taking care to avoid smears. The cellogel strip was 
placed on the racks in the electrophoresis tank, so as the end nearest the sample line 
was toward the cathode buffer. The electrode wicks were soaked in appropriate 
buffers and placed on either end of the cellogel to act as electrode bridge. 
Electrophoresis was performed at 4°C for 30-90 minutes under constant current of 
0.2-0.3mA.
2.1.53 Polyacrylamide Gel Electrophoresis
Polyacrylamide Gel Electrophoresis (PAGE) is a useful technique for 
separating specific protein fractions. The gel pore-size can be accurately controlled 
by varying the acrylamide and bis-crosslinker concentration, hence contributing a 
molecular sieving effect. PAG is stable over a wide range of pH, temperature and 
ionic strength and is chemically inert in polymerized form. It is prepared by 
polymerising the monomeric form of acrylamide together with methylene 
bisacrylamide which provides a rigid inert cross-linked gel matrix. Tetramethyl- 
ethylendiamine (TEMED) and ammonium persulphate are required as catalysts to 
initiate the polymerisation of the gel. The ratio of bis-acrylamide to acrylamide 
determines the density, elasticity, mechanical strength and pore size of the gel. By 
varying concentration of the acryclamide bis-acrylamide solution, (3%-25%) 
manageable gels can be obtained. An alternative crosslinker is DHEBA (N jN ^ lA  
dihydroxyethylene) bis-acrylamide) which possesses both a periodate-sensitive 1,2 
diol structure and two amido methyl bonds that are cleavable under alkaline 
conditions. By using DHEBA as crosslinker, the gel structure can be solubilized after 
electrophoresis, and seperated protein bands can be isolated. All reagents and buffers 
are listed in Appendix II.4.
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Preparation of gel:
For a 1.5mm thick gel (16 x 16cm), 36ml of gel solution was required 
consisting of two parts acrylamide-DHEBA solution, one part TEMED, four parts 
ammonium persulphate, and one part Tris-glycine buffer pH 8.2. The gel solution 
was poured into a vertical gel mould apparatus. The gel comb (10 x 1.5mm sample 
wells) was then inserted in the space between the two plates. Gel polymerisation 
required a minimum of one hour at room temperature but best results were obtained 
by leaving gels overnight. After assembly of the electrophoresis apparatus (BioRad 
Protean II Cell), the gel comb was removed and 2L of 1 in 10 dilution of Tris- 
glycine buffer pH 8.2 was poured into the tank and the upper chamber.
: Sample Preparation and Application:
i[
One volume of packed RBC in glycerol citrate at -20°C was added to 
two volumes of 1% Triton. The haemolysates were centrifuged at 12800 RPM for 
ten minutes and divided into two aliquots, each containing 97/d haemolysate and 3/d 
of 3mM TPP. The samples were then incubated for one hour at 37°C. Two volumes 
of sample were the mixed with one volume glycerol, to prevent any smearing of Hb 
and facilitate free migration of proteins during electrophoresis. 20/d of sample 
glycerol solution was loaded into the sample wells. Bromophenol blue (BPB) was 
used as a tracking dye to indicate the migration velocity. The running conditions for 
the electrophoresis were 0.5kV constant voltage with 300mA current and running 
time of approximately one hour for 16 x 16cm gel and 90 minutes for 20 x 20cm 
with cooling (4°C).
2.1.6 Staining
Two staining methods were used: specific enzyme staining and a 
general protein staining. The former is used for detection of enzyme activity in situ, 
and for direct demonstration of individual components of an enzyme (isoenzymes) 
in the electrophoretic matrix. The latter was used to estimate protein quantity by 
band intensity and monitoring protein purification. Commassie-Brilliant Blue R-250
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(CBB R-250) and Silver Staining were used to stain proteins.
2.1.6.1 Specific Transketolase Stain
This technique detects specific proteins on the basis of enzymatic 
activity, thus requires the presence of specific substrates and cofactors. The 
technique used is an electron-transfer dye staining method which requires the 
coenzymes NAD or NADP and transfer dyes. Suitable dyes are tetrazolium salts 
(methyl thiazolyl tetrazolium, MIT; nitroblue tetrazolium, NBT) which are reduced 
at the end of the reaction sequence to yield an insoluble dark-purple formazan at the 
site of activity. This reaction is catalysed by the presence of phenazine 
methosulphate (PMS). It can be applied to detect enzymes which lead to the 
production of NADH and NADPH as well as other enzymes that can be coupled by 
intermediate reactions to reduce NAD and NADP to NADH and NADPH. The stain 
is light sensitive hence incubation must be carried out in the dark. Visualization of 
electrophoretic profiles can be achieved by three techniques. Firstly, the gel can be 
immersed directly into the staining solution containing all required reagents; secondly, 
by immersing a Whatman 3mm filter paper in the staining solution and placing it on 
gel to visualize enzyme activity in situ. Thirdly, the reagents are immobilized in an 
agrose gel which is used as an overlay which reduces the rate of diffusion of soluble 
reaction products. A specific enzyme staining method for TK was modified from that 
described by Kaczmarek and Nixon (1983). Figure 2.1 illustrates the Transketolase 
staining reactions. A coupled enzyme reaction was used to incorporate an 
intermediate coenzyme (NAD). The reagents used are listed in Appendix H.5.
(i) Staining Starch Gels
A 3mm Whatman filter paper was cut to the same size as that part of 
the gel containing Hb band and immersed in the freshly prepared stain (stable for 2-3 
hours). The filter paper is laid on the cut surface of the starch gel. The gel was 
placed in a LEEC incubator at 37°C for two hours. The filter paper was replaced by 
a fresh one at least once. The filter paper was then removed and bands were 
visualized.
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Figure 2.1: Diagrammatic representation of the specific transketolase (TK) stain.
In this reaction the substrates (xylulose-5-phosphate and ribose-5- 
phosphate) are added in the stain with MgCl2 so TK catalyzes the first 
reaction where two products are formed. Glycerolaldehyde, one of the 
products, enters a secon reaction (as a substrate with arsenate) which 
glycerol-3-phophate dehydrogenase (GDH) catalyzes to form 3- 
phosphate-glycerol. This reaction is linked to a transfer dye reaction 
that utilizes methyl thiazolyl tetrazolium (MTT) as a substrate and is 
catalyzed by phenazine methasulphate (PMS) which requires an 
electron. This is provided from the reduction of coenzyme NAD to 
NADH. The product formed at the site of activity is the fluorescent 
NADH in the form of formazon.
(Chemicals inside the squares are the required reagents).
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Gil Staining Cellogels
As with starch gels, a 3mm filter paper was cut to the size of the 
cellogel and immersed in the freshly prepared stain. The soaked filter paper was laid 
on top of the cellogel and incubated at 37°C (LEEC incubator) for 45 minutes. The 
filter paper was then removed, cellogel placed on a water moistened filter paper to 
avoid drying of cellogel and bands were visualised.
(iiO Staining of Polyacrylamide Gels
The preparation of the stain varies from that described earlier. The 
concentration of PMS was reduced to minimize heavy background staining. Since 
the filter paper had a tendency to adhere to the PAGE gel and tear when lifted, an 
agrose gel overlay was developed as an alternative. Once the electrophoretic run was 
completed, the gel was removed from the glass plates. The section of gel to be 
stained was cut and a mould built around it with plasticine. The agarose is added to 
40ml Tris-HCl pH 7.6 and brought to boil on a hot plate. The agarose solution was 
cooled gradually to about 60°C at which time, the staining components were added. 
It was necessary to avoid solidification of agrose gel prior to addition of reagents. 
The staining solution was poured on top of the gel and allowed to cool and set in the 
dark prior to incubation at 37°C (LEEC incubator) for one hour. The agarose was 
then removed from the surface and bands of enzyme activity were visualized.
To confirm that the bands stained were TK activity, a control 
experiment was performed. One half of the gel was stained as described and the 
other stain depleted from the substrate.
2.1.6.2 General Protein Stain
{i} Coomassie Brilliant Blue R-250
Coomassie Brilliant Blue (CBB) R-250 is a non-poly sulphated 
triphenylamine dye which forms electrostatic bonds with ammonium groups and non-
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covalent bonds with non-polar regions in the protein. This type of staining is stable, 
uniform and ideal for densitometry. It has an adequate sensitivity to detect as little 
as O.lmg of protein.
Staining was carried out in a solution containing 0.1% (w/v) CBB R- 
250 in 45% distilled water, 45% methanol and 10% acetic acid. Staining time varies 
and depends on the thickness of the gel and polyacrylamide concentration. Usually, 
for a 16 x 16cm, 1.5mm thick gel, one hour was sufficient. However, it was 
sometimes necessary to stain the gel for a longer period (overnight) to obtain higher 
resolution of bands. The gel was then placed in destain solution and the time 
required for destaining also varied according to the thickness and polyacrylamide 
concentration of the gel. It can take as long as 24 hours to destain, with several 
changes of destain solution (45% (w/v) methanol, 10% (w/v) acetic acid) to reduce 
heavy background staining.
fill Silver Staining
The type of silver staining used was derived from the method of 
Merril, et. al. (1981). It is highly sensitive, 10-50 fold more than CBB R-250 and 
can detect up to 0.1ng/mm2. Therefore it is ideal for detection of trace impurities 
during protein purification. It may be applied on most forms of PAGE gels and IEF 
gels. This method, however, is time consuming and expensive.
The protocol was based on that described by the manufacturer (BioRad 
silver stain kit). Staining time depends on the thickness of the gel and volume 
depends on the size of the gel and is carried out at room temperature.
The method was a modified to improve the quality of staining 
(Appendix II.7) by gentle agitation at each staining step. Therefore, the size of the 
glass container for staining gels should be of appropriate size to allow free movement 
of the gel while having sufficient volume to cover the gel during shaking. Gels 
stained with CBB R-250 prior to a silver stain did not require first fixing step but 
must be destained completely. These gels gave best resolution of bands.
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2.2 PURIFICATION OF ERYTHROCYTE TRANS­
KETOLASE BY ELECTROPHORETIC TECHNIQUES
Purification was undertaken in order to characterise the protein in 
terms of its activity, structure and function. Upon planning a purification strategy, 
the following points must be considered; the amount of purified protein required, the 
importance of maintaining its activity, and the degree of purity. The amount of 
protein recovered after the purification will depend on the amount of starting material 
and yield. As protein tends to be lost in each purification step, the amount of starting 
material should be maximized and the number of purification steps minimized.
Purity is defined in terms of the percentage of the total protein which 
has the desired characteristics. It is essential to have some information on the 
chemical and physical properties of an enzyme in order to design a suitable 
purification method. In the purification of a protein, its catalytic activity may be 
used to monitor the effects of each stage in the process. Purification of TK was 
attempted using three different methods for preparative and analytical purposes.
2.2.1 Polyacrylamide Gel Electrophoresis
Transketolase was purified from red blood cells by PAGE. This 
method was developed from the technique used to isolate a CF protein by Jamieson 
(1983). Gels (16 x 16cm) were prepared using the BioRad vertical electrophoresis 
apparatus (Protean II cell) as described in section 2.1.5.3 with a DHEBA cross-linker 
in place of the methylene bis-acrylamide. Sample wells were formed using a 10mm 
wide comb.
2.2.1.1 Sample Preparation and Application
RBC from normal controls and patients were retrieved from RBC 
storage at -20°C in buffered citrate glycerol. The samples were prepared by adding 
300/d of 1% Triton to 200/d of packed RBC and 100/d Glycerol, and vortex mixed.
20/d of tracking dye (bromo phenyl blue) was loaded into one well and 20/d of
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sample into the remaining wells on each gel. Each sample was run in triplicate. 
Electrophoresis was performed under a constant voltage of 0.5Kv with 300mA 
current at 4°C for 90 minutes.
2.2.1.2 Excision of Transketolase Bands
The region of gel, from the anode end up to 10mm cathodic to the Hb 
band, was cut and discarded. The remainder of the gel was cut into three portions 
each containing 3 wells into which the same sample had been loaded. These portions 
were further sliced, from the cathodic end, to 4.5-5 cm wide and 2 cm long. This 
region of the gel contained TK activity as detected from PAGE using gel specific 
enzyme stain (Figure 2.2). A 1 x 2cm gel strip was sliced, from the track loaded 
with BPB, and used as the blank control. The three portions were each sliced in 
halves to yield six strips of 2 x 2.5cm.
2.2.13 Solubilization of gels
Each strip, incorporating sample, was placed in a universal tube 
containing 20ml of 0.01M Tris/HCl pH 10.0. The universal tubes were left overnight 
at room temperature, to dissolve the gel strips. On the following day, if the gel(s) 
was not dissolved, the tube(s) was placed in a 37°C water bath until it dissolved 
completely. The pH of each gel solution was measured and to those below pH 8.5, 
1M Tris/HCl pH 10 was added to bring pH above 8.5.
2.2.1.4 Dialysis and Lyophilisation
Dialysis tubing (2-18/32) was prepared by soaking it in distilled water 
overnight. The solutions were then dialyzed for 24 hours, changing dialysis buffer 
twice, against 0.001M Tris-HCl pH 10.0 at 4°C. All solutions comprising one sample 
were combined and placed in a 250ml conical flask and freeze-dried (Edwards 
Freeze-dryer Modulyo) overnight. The freeze-dried samples were weighed and stored 
at -20°C in bijou tubes.
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2.2.2 Analysis of Purified Erythrocyte Transketolase
2.2.2.1 Quantitative Analysis
Protein estimation was performed as described in section 2.1.3 using 
BioRad protein assay kit. The extracted freeze-dried fractions were reconstituted in 
2ml distilled water. 400/d of aliquots were assayed by adding 400/d dH20  and 200/d 
Biorad protein assay reagent.
The isolated protein fractions were assayed for TK activity using the 
assay as described in section 2.1.4.3 with minor modifications. For each sample, four 
aliquots were prepared in a 1.5ml eppendorf containing:
Aliquots 1 2 3 4
Substrate solution without
MgCl/TPP
(in 0.1M Tris-HCl)
700/d 700/d • -
Substrate solution + 
MgCl/TPP
- - 700/d 700/d
Sample 500/d - 500/d -
0.1M Tris HC1 - 500/d - 500/d
This gave a total of 1.2ml in each eppendorf. The reaction mixtures 
were preincubated at 37°C for two hours. 500/d aliquots were removed and the 
initial optical density (to) measured at 340nm. The remaining reaction mixture was 
left incubating at 37°C in a water bath overnight. The final optical density (tx) was 
measured at 340nm. A blank, using a protein free fraction, was subtracted from final 
change in optical density (tx - to). ETK and ETKs activity were determined by 
applying formula 2.4 and 2.5.
2.2.2.2 Qualitative Analysis
Electrophoretic profiles of the isolated fractions were analyzed by 
PAGE and IEF. Protein detection was performed initially by specific TK stain (to
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confirm that the protein bands represented TK activity) and finally by silver staining 
using BioRad silver stain kit. The reagent concentrations and all buffers used in the 
following sections are given in Appendix 11.10.
(i) Polyacrylamide Gel Electrophoresis
Polyacrylamide gels were prepared as described previously in section
2.1.5.3 a (16 x 16 cm 1.5mm thick). Sample wells were made using a 10 well gel 
comb. Into each well, 100/d of reconstituted fraction from each sample was loaded 
with 20/d of BPB track dye. Electrophoresis was performed at 4°C for 60 minutes 
under a constant 0.4KV and 350mA current. The gel was initially stained once with 
TK enzyme stain to detect TK activity, as described in section 2.I.6.I. The gel was 
also stained with BioRad silver stain kit (section 2.1.6.3) for a 16 x 16 cm gel of 
1.5cm thickness.
liil Isoelectric Focusing
IEF is an electrophoretic technique for the separation of a mixture of 
proteins with regard to net charge. It involves the separation of proteins in a 
continuous pH gradient that increases from the anode (acidic) to the cathode (basic). 
The migration of proteins continues as long as they retain a negative or a positive 
charge. Once the net charge on the molecule becomes zero, migration ceases. This 
point in the pH gradient is the Isoelectric point (pi) of the protein. IEF allows the 
detection of electrical charge variants of an enzyme. This technique is best 
performed using slab gels run on a horizontal flat-bed apparatus, with an efficient 
cooling platten to cope with the heating effect caused by the high electrical field 
strengths.
PREPARATION OF IEF GELS
The gel solution was prepared by adding 10ml of 29.1% acrylamide, 
10ml of 0.9% bis-acrylaride, 7ml of 87% Glycerol and 1.5ml ampholine (Pharmacia, 
pH 3.5-10) to 31.5ml distilled water. The solution was degassed for 10 minutes, and
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1.5ml of 1% ammonium persulphate and 50/d of TEMED were added. With a 60ml 
syringe, the gel solution was loaded carefully in the gel mould (avoiding formation 
of air bubbles). The gel was left at room temperature for one hour to polymerise and 
then placed at 4°C for at least one hour before use.
LOADING AND RUNNING SAMPLE
The gel plate was placed on the cooling platten of the Multiphor 
apparatus (LKB) and one double layer of 15 x 0.5cm electrode wick (1cm wide 3mm 
Whatman filter paper) was soaked in phosphoric acid and placed on the anode end 
while another wick was soaked with sodium hydroxide and placed on the cathode 
end. 40/d of reconstituted sample was applied to a double layer sample applicator 
(3mm filter paper) placed 1cm below the cathode wick 1.5cm apart 20/d of pi 
markers (Pharmacia, pi 3.5-10) were applied on two applicators. The gel was 
focused for 30 minutes under a constant power of 30W, limited voltage 2kV and a 
starting current of 75mA at 4°C. After 30 minutes, power was cut off and a further 
25/d of each sample was applied. The power supply (LKB2103) was reconnected 
and electrophoresis continued under the same conditions for a further 30 minutes. 
The previous step was repeated so that the total volume of sample applied was 100/d 
and electrofocusing was carried out for 90 minutes in total.
PROTEIN DETECTION OF IEF GELS
The gel was initially stained once with TK enzyme stain. The staining 
solution (100ml) was prepared by mixing all the staining reagents (section 2.1.6.1) 
in 0.1M Tris-HCl pH 7.6 in a dark container. The IEF gel was placed in the freshly 
prepared stain solution in a stainless steel tray and covered. The tray was incubated 
in a 37°C oven for approximately two hours. This method was applied to verify that 
any bands detected represented TK activity. IEF gels were also stained with BioRad 
silver stain kit in order to establish exact pi of the TK bands and to ensure no 
contaminating proteins were present. The IEF gel was fixed with 500ml of 12% 
TCA (trichlorocetic acid), 3.5% SAA (sulphosalicylic acid), 30% methanol, 54.5% 
dH20  (Fix I) for one hour to precipitate the proteins and wash away the ampholines
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prior to staining. This solution was decanted, and 500ml of 12% TCA, 30% 
Methanol, 48% dH20  (Fix II) was added into the tray and left for one hour. The 
solution was decanted and a fresh fixing solution (Fix II) was added for a further 
hour. The gel was then placed in 400ml of 10% ethanol, 5% Acetic Acid for 30 
minutes to start the silver staining. Subsequent steps performed were similar to those 
described in section 2.1.6.3.
(iifi SDS-Polyacrvlamide Gel Electrophoresis
This technique allows the separation of a protein mixture with regard
| to its molecular weight only. An effective solubilizing agent such as sodium dodcyl
I sulphate (SDS) is employed to mask the intrinsic charge of a polypeptide chain so
i that the net charge is constant. Therefore electrophoresis can only be performed in
I
a molecular sieving matrix (PAGE). Effective separation of a protein mixture, of a
[
j given range of molecular weight, is determined by the concentration of the
I
polyacrylamide gel. That is, for proteins of MW 20-350kD, a 5% Polyacrylamide
s
I gel would be ideal whereas for a protein with a MW15-200kD a 10% polyacrylamide
gel would be used.
The discontinuous buffer system devised by Lammeli (1970) and based 
on the system of Omstein (1964) and Davies (1964) with the addition of 0.1% (w/v) 
SDS has been applied. This improves the resolution of protein since the buffer ion 
concentrations differ between the gel and electrode solutions. It also allows the 
concentration of a sample prior to its separation. Hence, a stacking gel of low ionic 
strength with large pores (ie. lower polyacrylamide concentration) is laid on top of 
the resolving gel. The sample is applied on the stack gel and upon application of an 
electrical field, proteins will migrate rapidly through the stack gel and concentrate 
into a narrow sharp zone. The ions from the discontinuous buffer migrates behind 
the protein and causes it to unstack once the protein enters the resolving gel, where 
the pH gradient increases and the pore size decreases. In the resolving gel, the 
protein will separate according to its molecular radius (approximate MW). All SDS- 
proteins have a net negative charge at pH 7.2, and migrate toward the anode (lower 
electrode).
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In order to achieve the complete binding of SDS (1.4g SDS to lg of 
protein) the polypeptide chain configuration must be unfolded and its disulphide 
bonds reduced. It is therefore important to pretreat the sample prior to loading on 
gel by boiling the sample in a solution containing SDS and a reducing agent (p- 
Mercaptoethanol, Dithiothreitol).
GEL MOULD PREPARATION
The resolving gel was prepared by mixing 6ml of Polyacrylamide 
solution with 3.3ml of gel buffer (Appendix n.9b), 1ml Glycerol and 3.7ml dHzO and 
degassing the solution for approximately fifteen minutes. To that, 225/d of 10% 
ammonium persulphate and 22.5/d TEMED was added and mixed gently. The 
resolving gel was poured up to a height of about 13cm, and overlayed with 
isobutanol and left to polymerize for several hours in the BioRad Protean II gel 
mould apparatus. The isobutanol was poured off and the top of the gel was rinsed 
several times with the dH20  and finally with the gel buffer. The stack gel was 
prepared by mixing the following: 700/d polyacrylamide buffer, 2ml gel buffer, 40/d 
of 10% ammonium persulphate and 7.5/d TEMED (total stacking gel solution »9ml) 
and poured on top of the resolving gel. The gel comb (10 well, 1.5mm thick) was 
inserted at an angle into the stack gel and the gel was left overnight to polymerise.
LOADING AND RUNNING OF SAMPLE
To an eppendorfjone part reconstituted TK sample (fractions isolated 
by PAGE) and one part sample buffer (Appendix II.9a) were added. The aliquots 
were mixed, boiled for 2-3 minutes and spun at 12800 RPM for 10 minutes. The 
MW protein marker (Sigma, 20-215kD) were reconstituted with 1 to 1 dilution of 
sample buffer, and heated as described above.
The sample wells were rinsed firstly with dH20  and last with cathode 
buffer. The gel was assembled in the Protean II Cell apparatus. In the upper 
chamber 500/d of cathode buffer was added and 2L of anode buffer was added to the 
lower chamber. About 150/d of sample was added to the well and 50/d of protein
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marker was added to a different well. The gel was run for approximately 2 hours at 
4°C with constant 0.35kV and current of 200mA.
In the denaturing conditions applied in this method, TK activity would 
be lost, so the specific enzyme stain was not used. The gel was immersed in 500ml 
of 0.1% CBB R-250 (in 45% methanol, 10% acetic acid) for several hours to 
visualize the bands. Destaining was carried out overnight with several changes of 
destain solution (45% methanol, 10% acetic acid). To obtain a better resolution, the 
gel was then silver stained starting at the second fixation step (section 2.1.6.3) using 
BioRad silver stain kit.
2.2.23 High Performance Liquid Chromatography (HPLC)
HPLC is an analytical technique for separating a mixture of 
macromolecules into single compounds by passing them through a separation matrix 
under high pressure. Subsequently, qualitative and quantitative analysis can be 
performed on collected fractions. HPLC is a form of liquid-solid chromatography 
and is referred to as "High Performance" due to the level of high sensitivity and 
resolution that it can achieve.
There are many advantages for the use of HPLC. These include the 
achievement of better resolution than any other form of chromatography and 
reproducibility is improved. The automation and quantification provides control over 
the operating conditions such as column temperature, inlet pressure, flow rate and 
separation time. In addition, it is fast and versatile and the column may be used 
many times without the need of regeneration (Hamilton & Sewell, 1982). 
Compounds can be separated on the basis of polarity, MW, thermal instability, ionic 
strength, organic strength and any combination of these factors.
The operation of HPLC undergoes two main competing phases, the 
solid stationary phase and the liquid mobile phase which is forced through, under 
high pressure. The sample, mixture of components to be separated, is injected and 
carried through by the mobile phase (solvent, eluting agent) to the stationary phase
61
(column) where it is retained, and where separation of components occurs. The 
component of interest is eluted with the solute and passes through the detector and 
out into the fraction tube.
The basic apparatus of HPLC consists mainly of a solvent reservoir 
(mobile phase), and sample injector, high pressure pumping system, a column 
(stationary phase) and a sensitive detector (Figure 2.3). A programmable controller 
and a recorder are other useful but non-essential components. The controller is 
capable of delivering accurate solvent flow (O.lml/min - lOml/min), provide a 
gradient elution, produce non-pulsatile flow and store useful programmes. The 
chromatographic profile is deliniated on a chart recorder. The HPLC system used 
consists of: LKB 2210 Recorder (2-Channel), LKB 2158 Uvicord SD, LKB 2152 
HPLC Controller, LKB 2150 HPLC Pump, and LKB 2133-500 DEAE-5PW Column 
(8.0 x 7.5 mm ID x cm)
The mode of separation performed on the extracted TK by ion- 
exchange chromatography in order to establish presence of ETK variants. In this 
type of separation, the exchange of ions (opposite charges) takes place in the column 
by binding a molecule with a strong negative or positive site on the matrix. 
Therefore, this separation depends on the strength of the interaction between the 
solute’s ions and the exchange site. There are two types of ion-exchange 
chromatography, anion-exchange and cation-exchange. In the former, the components 
pH would be lower than that of the column thus gains a positive charge, while in the 
latter the opposite holds true. Depending on the ionic strength of the component, a 
weak or strong ion exchanger is applied to prevent very strong or very weak retention 
respectively. A short and broad column is ideal for this mode of separation and a 
gradient elution is required.
The column must be first equilibrated with filtered and degassed with 
solvent A (20mM Tris-HCl pH 7.5). Prior to injecting the sample, 50/d of solvent 
A was injected into the DEAE-5PW column and a gradient run (Table 2.3a) was 
applied for 10 minutes to detect any background trace (recorded on the chart). The 
column was allowed to re-equilibrate for 5 minutes, and 100/d of sample was
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SAMPLE 
Mixture of 
components)
MOBILE PHASE
STATIONARY
PHASE
SOLVENT
RESERVOIR-------- 1
 J
 J
CONTROLLER
RECORDER DETECTOR
PUMP
-  Inlet - Outlet Cables
FRACTION
COLLECTOR
Figure 2.3: Instrumentation and operation of high performance liquid
chromatography. The sample is injected to the column and the
components seperated and eluted with the solvent which is forced
through the pump. The solute is monitered by the detector and forced 
through to the fraction collector, while the elution profile recorded on 
a chart All operations are controlled by the controller.
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a
Table 2.3 Gradient elution programmes used for the separation of transketolase 
by ion-exchange chromatography with high performance liquid 
chromotography. Solvent A contained 20Qa Tris-HCl pH 7.5 and 
Solvent B contained 1M NaCl in solvent A. These programmes were 
stored in the LKB2152 controller.
Table 2.3a Gradient elution programme 1 applied for a 10 minute washing of the 
column before and after sample injection.
Time (min) Flow Rate 
(ml/min)
% Solvent A % Solvent B
0 .8 100 0
1 .8 100 0
4 .8 65 35
6 1.0 0 100
8 1.0 0 100
10 1.0 100 0
Table 2.3b Gradient elution programme 2 applied for the seperation of 
transketolase in 40 minutes.
Time (min) Flow Rate 
(ml/min)
% Solvent A % Solvent B
0 .8 100 0
5 .8 100 0
25 .8 65 35
30 1.0 0 100
35 1.0 0 100
40 1.0 100 0
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injected. The gradient elution programme (Table 2.3b) was initiated from the
controller and the solute was monitored at 280nm wavelength with a sensitivity
setting of 0.002 absorbance units (Au). The chart recorder speed was set at 
5mm/minute and the gradient run was set for forty minutes.
23  PURIFICATION OF TRANSKETOLASE FROM
WHITE BLOOD CELLS
In 1989, Mocali and Paoletti developed a new technique to purify TK 
from white blood cells (WBC). The purification was performed in five steps; sample 
preparation, desalting and gel Alteration, DEAE-cellulose adsorption, ammonium 
sulphate fractionation and finally affinity adsorption on CM-cellulose. Modifications 
of this method included sample preparation, the column dimension for gel Alteration, 
and the omission of afinity adsorption step using CM-cellulose.
23.1 Quantitative Analysis of Transketolase Fractions
(Fractions collected at each step were assayed for protein and TK
activity).
Protein estimation was performed using Bradford’s method (1976), a 
modification of the method described in section 2.1.3. BrieAy, the reagent was 
prepared by dissolving lOOmg of CBB G-250 in 50ml of 95% Ethanol. To this 
100ml of 85% phosphoric acid was added and then diluted to one litre with dHjO 
water. The solution was stored in a dark bottle at room temperature. The protein 
assay was performed by adding 20/d of sample into a test tube. To it, 1ml of 
Bradford’s reagent was added and mixed gently. The tube was left at room 
temperature for at least 10 minutes up to a maximum of 60 minutes. Absorbance 
was measured at 595nm. BSA (0-200mg/ml) was used as protein standard.
TK activity was determined using a kinetic assay (Appendix 11.10).
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Two aliquots were prepared for each fraction to be assayed containing the following 
reaction mixture:
Alliquot 1 2
0.1M Tris-HCL pH 7.6 - 920/d
0.1M Tris-HCl pH 7.6 
containing substrates
920/d -
GDHyTPI 5/d 5/d
NADH 20/d 20/d
TPP 40/d 40/d
MgCl2 5/d 5/d
The reaction mixture was placed in a quartz curvette (1cm light path) 
at 37°C, monitored at 340nm with band width of 0.2 AU and recorded at chart speed 
setting of 0.5mm/min for 5 minutes on a Guildford 2600 spectrometer. Then 20/d 
of sample was added and mixed. The reaction was monitored on the chart at the 
same settings for 10 minutes. TK activity was calculated from the following formula: 
(2.7)
. . AOCjfmin x  1000 x V,
TK activity^ — - --------------------
E x V e
where:
AOD/min = calculated from the chart (AOD/min for TK activity - AOD/min 
for TK activity without substrates)
Vf = Total volume in cuvette (1.01ml)
E = Millimolar Extinction of NAD = 6.22 
Vc = sample volume (20/d)
Total TK activity was expressed in IU/L and specific TK activity was 
expressed in IU/mg of protein.
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23.2 Sample Preparation
WBC were extracted from a pool of 400ml of buffy coats obtained 
from several healthy donors from the Regional Blood Transfusion Service at Law 
Hospital. Four extractions were carried out, and once the required amount was 
obtained, all the WBC extracted and stored at -20°C were pooled prior to cell lysis.
23.2.1 Preparation of Human Leukocytes from Buffy Coats
About 10ml of buffy coat was placed in a 50ml conical tube. To it
40ml of dextran solution (1.2g/100ml isotonic solution) was added, mixed well and 
left at room temperature for approximately one hour. The supernatant was carefully 
removed into a 20ml Sterilin universal tube and centrifuged at 3700 RPM for 15 
minutes. The supernatant was discarded and the pellets were suspended in 2ml saline 
and spun at 2000 RPM for 5 minutes. The supernatant was discarded and if the 
pellet was contaminated with RBC 1.5ml of ice-cold water was added, resuspended 
and mixed thoroughly with a pasteur pipette to lyse the RBC. The mixture was left 
for 90 seconds at room temperature and 0.5ml of ice-cold 3.6% NaCl was added and 
mixed by inverting the tube. The tubes were spun at 2000 RPM in MSE centrifuge 
for 60 seconds. The supernatant was discarded and the pellet was transferred to a 
1.5ml eppendorf. If RBC were still present, the lysis step was repeated. The final 
pellet was weighed and stored in 0.5ml saline at -20°C until all extractions were 
complete and ready for use.
23.2.2 Lysis of White Blood Cells
The pellets were retrieved, thawed and pooled together. The total dry 
weight of white blood cells (3.0g) was resuspended in 30ml of 0.01M Tris-HCl pH 
7.8 and kept on ice. The cells were disrupted by six cycles of 5 second sonication 
at 70W with 60 second intervals. The sonicate was left on ice for 20 minutes then 
spun at 16000 x g in a high speed Beckman centrifuge for 20 minutes at 4°C. A 
clear supernatant (30ml) was collected and assayed for protein and TK activity.
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23.3 Gel Filtration and Desalting
The chromatographic separation, by gel filteration and desalting, is 
based on the molecular size of a compound. In this mode an isocratic elution of 
varying buffer conditions is used. The efficiency of the resolution depends on the 
column packing particle’s pore size, distribution, density, porosity, and flow rate and 
on the viscosity of the elution buffer. A thin and long column is ideal for this type 
of separation. The column must be calibrated prior to use.
For a 4 x 30cm Amicon column, 200ml of packing media (Sephadex 
G-25 coarse, Pharmacia) was used. The sephadex was swollen by dissolving lOOg 
of G-25 in 1L of dHzO and left overnight at room temperature. The thick slurry was 
poured slowly in the column against a glass rod while stirring occasionally to prevent 
formation of air bubbles. The column was then equilibrated with 400ml of 0.01M 
Tris-HCl pH 7.8 at a flow rate 225ml/hr controlled by a peristaltic pump (Pharmacia 
P-l). The column was calibrated by loading a mixture of 4mg of dextran blue and 
2mg of DNPH in 1ml of 0.01M Tris-HCl pH 7.8. The mixture was eluted with 1L 
of 0.01M Tris-HCl pH 7.6 at a flow rate of 225ml/hr. Fractions were collected every 
three minutes with LKB2112 Redirac fraction collector.
The crude extract (30ml) was loaded onto the column at a flow rate 
of 3.7ml/min and the components were eluted with 600ml of 0.01M Tris-HCl pH 7.8. 
Fractions were collected every 3 minutes. Protein estimation in column effluents was 
obtained by measuring absorbance in alternate fractions at 280nm. Fractions 
containing high protein concentrations were assayed for TK activity, pooled (66ml) 
and stored at 4°C.
23.4 DEAE-Cellulose Adsorption
DEAE-cellulose was prepared by dissolving 50g of DE-52 in 500ml 
of 50mM Tris-HCl pH 7.8, centrifuged for 10 minutes, and the supernatant then 
decanted. The cellulose was equilibrated with lOmM Tris-HCl pH 7.8 for 20 minutes
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while shaking occasionally. It was centrifuged for 10 minutes and the supernatant 
was decanted. The wash was repeated and the DEAE-cellulose was stored at 4°C.
TK activity in void fractions (66ml) was mixed with 4.5g wet DEAE- 
cellulose by gentle stirring for 15 minutes. A supernatant was collected under a mild 
vaccum and was assayed for TK activity and protein concentration.
23.5 Ammonium Sulphate Fractionation (45-90%)
To 71ml protein solution 19.738g of ammonium sulphate was added 
slowly and gradually while stirring on ice for 15 minutes to obtain a 45% saturation. 
The solution was spun down at 16000 x g for 20 minutes at 10°C and the supernatant 
collected was assayed for TK activity and protein concentration. To a final 
supernatant (80ml) 26.07g of ammonium sulphate was added while stirring on ice to 
yield a 90% final saturation. The fraction was centrifuged at 16000 x g at 10°C for 
one hour. The supernatant was collected and the precipitate (45-90% ammonium 
sulphate) was dissolved in 3ml 0.01M Tris-HCl pH 7.8. The supernatant and 
suspended pellet were assayed for TK activity and protein concentration and then 
stored at 4°C.
2.4 PURIFICATION OF ERYTHROCYTE TRANS­
K E T O L A S E  BY C H R O M A T O G R A P H I C  
TECHNIQUES
The following method used was modified from that of Takeuchi et. al. 
(1986). The complete isolation of TK was achieved in three steps: sample 
preparation, ion-exchange chromatography on DEAE-sepharose, and fast protein 
liquid chromatography (FPLC). Fractions were collected at the end of each step and 
assayed for TK activity at 340nm using the Kinetic assay, for 10 minutes at 37°C 
with and without the substrates described in section 2.3.1. Total protein estimation, 
from pooled fractions from each step, was determined by a modification of 
Bradford’s method described previously in section 2.3.1.
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2.4.1 Sample Preparation
Blood (60ml) was collected from a normal volunteer and placed in 6 
heparin tubes, each containing 10ml. Packed, washed red cells were prepared as 
described in section 2.1.1, and the cells from all six tubes were pooled in 500ml 
conical flask giving a total volume of 36ml. The packed RBC were shock frozen 
with liquid nitrogen (-196°C) for at least five minutes and thawed in a 37°C water 
bath. Three freeze/thaw cycles were carried out and 36ml of deionized water was 
added and mixed. The final solution was dialyzed (dialysis tubing 2-18132) against 
4L of 0.01M Tris-HCl pH 8.3 for 36 hours at 4°C with a single change of dialysis 
buffer after 24 hours. The dialyzed heamolysate was spun at 17,000 x g for one hour 
at 4°C. From that, 200/d was taken and diluted with 800/d 0.1M Tris-HCl pH 7.6 
to assay for TK activity and protein concentration.
2.4.2 Ion Exchange Chromatography on DEAE-Sephorose
The 500ml preswollen DEAE-Sepharose Fast Row (Pharmacia) was 
poured into an Amicon column (10 x 10cm) at 4°C. The column was equilibrated 
with several volumes of Buffer A (0.01M Tris-HCL pH 8.3) until the pH of the 
elutant was 8.3.
The hemolysate (70ml) was loaded on the column at a flow rate 
90ml/hr. The column was washed with 500ml Buffer A. Fractions were collected 
at 12 minute intervals in a 20ml test tube. A linear gradient of equal volumes (2L 
in total) of Buffer A and Buffer B (1M NaCl in Buffer A) was eluted at a flow rate 
of 1.5ml/min. Absorbance of alternate fractions was measured at 280nm to give a 
rough estimate of protein concentration. TK activity was assayed in every four 
fractions and conductivity was measured in every fifth fraction.
Subsequently fractions containing TK activity were pooled into one 
fraction. Two fractions of pooled TK activity (A & B) were collected and assayed 
for protein concentration. The two fractions (A & B) were diaylised (Medical
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International Dialysis Tubing, 1-8/32) against 0.01M Tris-HCl pH 8.3 for 36 hours 
with a single change of dialysis buffer after 18 hours. The dialyzed fractions were 
assayed for TK activity and protein concentration.
2.43 Fast Protein Liquid Chromatography
FPLC is a specific modular HPLC system supplied by pharmacia-LKB. 
Separation of a protein mixture can be achieved in a short time with high resolution. 
It has the same characteristics as HPLC and is used widely for the purification and 
analysis of proteins. FPLC® Pharmacia-LKB comprises a liquid chromatography 
controller (LCC-500), a FPLC Pump (R-500), a single path monitor control unit 
(UK1), a chart recorder, a fraction collector (FRAC-100), and a 100ml sample 
superloop. The mode of separation applied on the FPLC in the third step of 
purification was ion-exchange chromatography on Mono Q column.
The FPLC system was washed with Buffer A and Buffer B prior to 
connecting the Mono Q column. The column was equilibrated with Buffer A for 5 
minutes, then 10 minutes with Buffer C (0.2M NaCl in Buffer A) and finally 15 
minutes with Buffer A at a flow rate l.Oml/min. The sample superloop was also 
washed with Buffer A prior to use. The chart recorder was set at 0.5cm/min, 
absorbance band width was set at 0.5 Au and the UV monitor was set at 280nm. A 
baseline for background absorbance was recorded on the chart prior to loading 
sample.
Fraction A (50ml) was injected in the superloop at a flow rate 
0.5ml/min. The sample was then eluted in the column with Buffer A at a flow rate 
lml/min. No fractions were collected at this point. The gradient elution (0-100% 
Buffer C) programme (Table 2.4) was initiated and 1.3ml fractions were collected. 
The absorbance at 280nm was monitored in each fraction and recorded on the chart 
The column was washed as described previously with Buffer A and C prior to 
loading Fraction B. Fraction B (63ml) was injected in the superloop and onto the 
column at a flow rate 0.75ml/min and eluated in the same way as Fraction A. 
Fractions containing high protein absorbance (peaks on the chart) were assayed for
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Table 2.4: Gradient elution programme used for the separation of transketolase
by fast protein liquid chromatography. This programme was used to 
elute dialyzied fractions A and B from ion exchange chromatography 
on DEAE-Sepharose. Buffer A contained 0.01M Tris-HCl pH 8.3 and 
Buffer C contained 0.2M NaCl in Buffer A.
Time (min) Flow rate 
(ml/min
% Solvent 
A
% Solvent 
C
0 1 100 0
25 1 0 100
30 1 0 100
35 1 100 0
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TK activity and protein concentration.
2.4.4 SDS-Polyacrylamide Gel Electrophoresis
The four fractions collected (desalted and lyophilized) were analyzed for 
electrophoretic profile and molecular weight estimation using SDS-PAGE method. 
The buffer system and polyacrylamide concentration used varies slightly from the 
previous method described in section 22.2.2.
2.4.4.1 Sample Preparation
The sample fractions were diluted with 0.5% ammonium bicarbonate 
(elution buffer) to give a total volume of 2.5ml per fraction. The sample fraction was 
desalted on a pre-equilibrated PD-10 Sephadex G-25 column and the 
proteincomponents were eluted with 3.5ml elution buffer. The diluted fractions 
(3.5ml per fraction) were frozen on dry-ice ethanol bath for several minutes and 
lyophilized (Flexi-dry Lynphilizer Fissystem Jar) overnight. The freeze-dried 
fractions were reconstituted with SDS-PAGE sample buffer (Appendix IL9a) and 
boiled for 3 minutes.
2.4.4.2 Estimation of Molecular Weight
ETK purified fractions were subjected to SDS-PAGE for estimation 
of MW. The gel mould was prepared and set up using BioRad Protean II Cell 
Electrophoresis. The 10% acrylamide resolving gel (30ml) was prepared by mixing 
the following: 10ml polyacrylamide solution, 11.3ml 1M Tris pH 8.8, 150/d 20% 
SDS, and 8.7ml dH20  (Appendix n.9c). The solution was degassed for 10 minutes 
prior to the addition of 100/d 10% ammonium persulphate and 20/d TEMED. The 
resolving gel was poured in the gel mould, overlayed with isobutanol, as described 
in SDS-PAGE (Method 1, section 2.2.2.2), and left to polymerise for 2 hours at room
temperature. The 4% acrylamide stacking gel (20ml) was prepared by mixing:
2.66ml polyacrylamide solution, 2.5ml 1M Tris pH 6.8, 100/d 20% SDS, 100/d 10% 
ammonium persulphate and 20/d TEMED. The isobutanol was decanted, and the gel
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mould washed several times with dH20  followed by one wash with 1M Tris pH 6.8, 
and was dried prior to pouring the stacking gel. The gel comb (10 wells x 1.00cm) 
was inserted and the stacking gel was left to polymerise for one hour.
The gel comb was removed and the wells were washed and filled with 
running buffer (Appendix II.9b). 100/d of each fraction, 20/d of haemolysate (1 in 
5 dilution) pretreated with sample buffer and 20/d of pretreated BSA were loaded in 
sample well. 500ml of running buffer was poured in the upper chamber and 2.0 L 
was poured in the lower chamber of BioRad protean II cell tank. Electrophoresis was 
performed at 4°C under constant voltage of 0.4kV and a current of 350-500mA
The gel was immersed in 500ml of CBB R-250 staining solution for 
at least 6 hours to visualize bands and destained for 24 hours with several changes 
of destain solution (50% Methanol, 10% Acetic Acid). The gel was then silver 
stained with BioRad silver stain kit starting with the second fixature step.
2.5 AMINO ACID ANALYSIS
In order to characterize a protein in terms of its amino acid constituent, 
number, type and sequence and determining its primary structure, a protein must be 
obtained in a purified form. Sufficient amount of pure protein required for such 
analysis may be as little as 10 pmol (ie. 0.5-5mg for a 50kD protein), however it is 
always better to have more starting material. A rough estimate of protein 
concentration and its molecular weight are required.
The protein analyzed must be in solution or solid support that does not 
interfere with subsequent analysis and which can be obtained either by 
chromatography (HPLC) or by electrophoresis (SDS-PAGE). Direct analysis can be 
performed on proteins isolated by HPLC. However, protein analyzed on SDS-PAGE 
must be extracted by electroelution or electroblotting. The protein band must be first 
visualized with a stain dye, cut and eluted into a solution in the former or 
electroblotted, visualized, cut and directly analyzed, in the latter.
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2.5.1 Western Blotting
This technique, also referred to as Transblotting, involves the transfer 
of a protein from a gel onto the surface of a thin matrix. The protein(s) would be 
immobilized on the surface and is accessible whenever required. An advanced 
technique of transferring a protein is that performed under an electric field 
| perpendicular to the plane of the gel. This is referred to as electoblotting and was
; developed by Towbin et al. in 1979. Electroblotting apparatus may either be
i  horizontal (semi dry with graphite plate electrodes) or vertical (having large buffer
I reservoir with platinum electrodes). Transblotting conditions vary depending on the
! thickness of gel, molecular weight of protein, buffer ions and concentration, type of
i
| matrix and purpose of transfer. Proteins electroblotted for amino acid analysis must
| be seperated with electrophoretic buffers (such as Tricine in place of Glycine) that
I
do not interfere with the analysis. Electroblotting must also be performed on a
I
i  matrix that would not be damaged by reagents and solvents used in automated
analytical instruments. Such membrane used is Immobilon P supplied by Millipore
f
and manufactured from Teflon-like material polyvinylidene diflouride (PVDF) which 
possess high mechanical strength, retention and sensitivity. Gels are best blotted in
i
CAPS (3-{ Cyclohexylamino}-l- propanesulfonic acid) to reduce levels of Tris and 
Glycine contamination.
The electroblotting buffer was prepared by mixing 400ml of 10X stock 
100mm CAPS buffer (pH 11.0 with 2M NaOH, 400ml methanol and 3200ml Milli 
Q H20). The PVDF membrane (Millipore 16 x 16cm) sheet was cut to the 
dimension of the resolving gel, immersed in 100% methanol (Analytical Grade) for 
few seconds, transferred to 50% Methanol for few more seconds and placed in a 
plastic container containing blotting buffer. Two sheets of 3mm filter paper 
(dimension as resolving gel) were also soaked in blotting buffer.
Purified TK fraction (2-3//g/100ml) prepared from a normal control by 
PAGE (section 2.2) was subjected to SDS-PAGE (section 2.2.2.2). After 
electrophoresis had completed, the gel was preequilibrated with 2 changes of 400ml 
blotting buffer. A fibre pad sponge (presaturated with blotting buffer) placed on the
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cathode panel was built up with one sheet of presoaked 3mm Whatman filter paper 
followed by the gel on top (laid down carefully to avoid trapping air bubbles in 
between). The sandwich was completed by carefully laying the PVDF membrane on 
top of the gel (rubbing side to side to expel any air bubbles) and then on top of that 
was the Whatman paper, saturated sponge and anode panel. The sandwich was 
secured by closing the gel holder. This was placed in the half filled buffer reservoir 
(BioRad 170-3910 Trans-Blot-Electrophoretic Transfer Cell). The cooling plastic coil 
connected to a circulator was immersed and the reservoir was filled (to cover the 
sandwich) with blotting buffer. Electroblotting was performed under a constant 
current (Sartorius Blotting Power Supply) of 125A, 25V for 90 minutes under a cool 
temperature of circulating ice water.
The membrane was removed, rinsed with Milli-Q H20  for 5 minutes 
and dipped in 100% methanol for few seconds prior to staining. Bands were 
visualized by staining PVDF membrane in 0.1% CBB R-250 for 5 minutes and 
destaining in several changes of 50% methanol until bands were visualized and the 
background reduced. The PVDF membrane was handled with sterile forceps at all 
times and was placed in a plastic bag, sealed and stored at -20°C.
2.5.2 Amino Acid Composition
This analysis involves the cleaving of the peptide chain at random and 
identifying the nature and quantity of the amino acid residues. This is important 
prior to sequencing as it provides information on the quantitation of a protein/peptide 
which may be N-terminally blocked. It can also provide the approach to cleaving a 
protein if an internal sequence was required.
Complete analysis and quantification of amino acid analysis may be 
routinely performed in less than an hour with as little as lnmol of polypeptide chain 
using automated analyzer. This analysis provides the ratio of amino acid residues per 
polypepeptide chain. The molar ratio of each amino acid residue can be calculated 
from MW and amount of sample analyzed. This analysis can be performed, by either 
ion-exchange chromatography on a cation exchange resin or by reverse phase
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chromatography based on polarity at of an amino acid, on HPLC.
Amino acid composition analysis was performed on two TK bands 
from the PVDF membrane, by the Molecular Paleontology Laboratory in the 
Department of Geology & Applied Geology, using Applied Biosystems 420-H amino 
acid analyzer with automatic hydrolysis head. Separation of amino acids was 
performed by ion-exchange HPLC. The method used was obtained from Aitken et 
al., 1989.
2.5.2.1 Sample Preparation - Hydrolysis
Polypeptides can be broken down by either proteolytic enzymes or 
most commonly by acid hydrolysis.
Two TK bands (0.1-10/zg) were cut and collected in a precleaned (by 
heating in 6M HC1) small hard glass tubes. Hydrolysis was performed in a 
hydrolysis vessel containing 0.5-lml 6M HCL and 0.5% phenol (v/v). The vessel 
was flushed with 99.998% argon for two minutes, and closed with a teflon disc 
bonded to silicon rubber and a heat-resistant screw cap. The reaction vessel was 
heated in an oven at 165°C for one hour. Once the vessel is cool, it was placed in 
vacuo in a desiccator containing sodium hydroxide pellets to remove excess acid.
2.5.2.2 Derivatization with Phenylisothiocynate
The following procedure was carried out initially on amino acid 
standard. To the vial containing dried amino acid samples, 100/d of coupling buffer 
(0.7ml acetonitrile, 0.2ml triethylamine, 0.1ml water) was added, vortex mixed and 
removed by vacuum centrifugation. A further 100/d of coupling buffer with 5/d 
PITC (phenyisothiocynate) was added, vortex mixed and incubated at room 
temperature for 20 minutes. The sample was loaded onto the column of the Amino 
Acid Analyzer and PTC (phenylthiocarbamyl) yields were monitored at 254nm. 
Amino acid composition of TK was determined against amino acid standard and 
quantitation was analyzed by Applied Biosystem 920A Data Analysis Module, based
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on given MW. Analysis report was provided by the Molecular Paleontology 
Laboratory.
2.5.23 Statistical Analysis
In order to verify the protein bands detected and analysed for amino 
acid composition (molar ratio %) are of the same enzyme (TK), non-parametric 
statistical analysis was performed by employing Kendall’s rank correlation coefficient 
(K) and Wilcoxon signed rank test. The former allows the calculation of the 
correlation coefficient between two sets of data and does not require any assumptions 
about the data distribution. The data from the amino acid composition (% molar 
ratio) of one protein band are arranged from the lowest to the highest order, while 
- placing the corresponding values of the other protein band. Then K is calculated by
i
the following formula:
; (2.7)
i| K _ zs
/7(/7-1)
where S = P - Q where P = number of values higher than the top value of
the first protein band.
Q = number of values lower than the top value of 
the second protein band, 
n = number of values compared.
Since "K" measures the "purity" of correlation then:
k = +ve positive correlation
k = 0 no correlation
k = -ve negative correlation
The significance of "K" is determined by calculating Z, the Standardized normal 
deviate in the following formula:
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(2.8)
Z= S /18  
/[/V(AM)(2/V+5)1
where S = P - Q
N = number of values compared
Then if Z < 1.96 correlation not signficant (p > 0.05)
Z ^ 1.96 correlation signficant (p £ 0.05)
Z > 2.58 correlation highly signficant (p £ 0.01)
The Wilcoxon signed rank test is a non parametric sign test for paired 
data which measures the magnitude of differences contributing to the tested statistics. 
The null hypothesis for this test is : the distribution from two sets of observations,
which are sampled, are identical. This test was performed by using the software
SPSS/PC\
In addition, the molar ratio (%) of amino acid composition from each 
protein band were compared by plotting the values on a histogram and on a scatter 
plot.
An upward trend positive correlation
A downward trend negative correlation 
No straight line no correlation
2.5.3 Amino Acid Sequencing
The primary structure of a protein can be characterized from deriving 
sequentially the order of its amino acid residues. The amino acid sequence of a 
protein would distinguish it from other proteins. It can also characterize the chemical 
and physical properties of a protein as well as define its higher levels of structure. 
Determining the sequence of amino acid residues is performed by the sequential 
liberation and identification of one amino acid at a time from either end of the 
polypeptide chain under controlled conditions. There arc chemical and enzymatic
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methods for determining the amino acids at either the amino terminus (N) or carboxyl 
(C) terminus.
Enzymatic methods involves the use of exopeptidase which attacks 
only peptide bonds at the end of the polypeptide chain. For cleavage of the C- 
terminal, carboxypeptidases are used and for the N-terminal, aminopeptidases are 
applied. Sequencing can only be determined by close and continuous monitoring of 
the kinetics of the amino acid release as rapid digestion of the polypeptide chain can 
occur. Amino acid sequencing by chemical methods is most commonly used. This 
method involves the chemical labelling of the amino acid at either end, peptide 
hydrolysis and identification of the labelled amino acid. A chemical method for 
identification of C-terminal residues is hydrozinolysis. The chemical hydrazine reacts 
with the a-carboxyl group of each peptide bond and cleaves it. Each amino acid is 
then converted and released as a hydrazide derivative, except for the C-terminal 
residue which remains unmodified. Following chromatographic separation, the 
unmodified amino acid C-terminal residue can be identified.
The majority of protein sequences are obtained from the N-terminal. 
The first devised method was described by Sanger in 1953 who used 2,4-dinitro- 
fluorobenzene (DNFB), which reacts with the five unprotonated a-amino group, to 
form a yellow 2,4-dinitrophenyl derivates that is cleaved by acid hydrolysis. The 
amino acid residue is identified by chromatographic separation. A more sensitive 
method is the labelling of a-amino group with a fluorescent dansyl chloride and the 
derivative is detected by fluorometric methods. The most important and commonly 
used procedure is based on the Edman degradation method. It involves a three step 
cycle for the sequential identification of each amino acid residue starting at the N- 
terminal (Figure 2.4). The first step of each cycle is to couple the a-amino group by 
reacting it with phenylisothiocyanate (PITC) in an alkaline medium. This results in 
a phenylthiocarbamyl (PTC) derivative. The second step would be to cleave the 
PTC-peptide by treatment with anhydrous acid such as trifluoracetic acid (TFA). 
This yields an anilinothioxolinone ATZ-derivative and the remaining intact 
polypeptide chain. The ATZ-derivative is then converted to phenylthiohydantain 
(PTH) amino acid in the third step. This derivative can be identified by
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Figure 2.4: Chemical reaction of the Edman degradation method in an automated
sequencing instrument. In the coupling step, the PITC modifies the 
N-terminal residue of a peptide followed by the cleaving step in which 
the N-terminal residue is cleaved by TFA resulting in an unstable 
ATZ-Derivative and an intact shortened peptide with a reactive N- 
terminus to enter another cycle (cycle x + 1). These two steps are 
performed on a protein solid support (PVDF - Immobilin membrane) 
which takes place in a reaction cartridge. The next step is the 
conversion of unstable ATZ-Derivative (in a flask) to a stable PTH 
amino acid that can be identified by the elution time of a peak on 
HPLC. (After Matsudaira, 1989)
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chromatographic separation. The shortened polypeptide is then subjected to another 
cycle and so on until the last remaining amino acid residue is modified. This method 
was first automated by Edman and Begg in 1967. The development of the gas-liquid 
or pulsed-liquid chromatography improved the sensitivity, speed and the ease of 
sequencing operation. The employment of microbore columns for PTH amino acid 
detection in computerized HPLC allows longer sequencing (40-60 cycles) of peptides 
from as little as 10 pmol.
TK amino acid sequence analysis (15 cycles) was performed from 
eight bands on the PVDF membrane by the Molecular Paleontology Laboratory at 
Glasgow University. Automated sequencing of the Edman degradation method, by 
Pulse-liquid Chromatography on Applied Biosystems (477A) Protein Sequencer with 
gradient on-line (120A) HPLC, was used.
Prior to sequencing TK, four precycles of lOOpmol standard amino 
acid sequence, with 1.5mg polybrene (identify sequence by-products), was carried out 
by commencing with the coupling step. The background of PTH-amino acids must 
fall prior to loading TK bands. The eight bands excised from PVDF were loaded in 
a glass scintillation vial and inserted in the cartridge. To the cartridge, 5% (v/v) 
PITC was delivered in a volume enough to wet the filter(s). The PTC-peptide was 
washed, with 12.5% (v/v) trimethylamine and 0.001% DDT, and cleaved by the 
addition of 25% anhydrous TFA, and 0.001% DTT. Reagents were delivered 
automatically from these reservoirs via a teflon tube. The unstable ATZ-derivative 
is passed to the conversion flasks and where excess PITC, exposed to water, forms 
NjN1 diphenylthiourea (DPTU). Unreacted PITC is dissolved out to waste from the 
cartridge and conversion flasks by delivering n-heptane solvent. Excess DPTU, and 
other by-products N, N^iphenylurea (DPU), were dissolved out to waste by 
delivering a second solvent (ethyl acetate). Delivery of solvent (n-chlorobutane), 
allowed the precipitation of potentially extractable hydrophobic samples, was made 
directly into 25% TFA to initiate immediate conversion.
Once the ATZ-derivative was converted to the PTH-amino acid, the 
next cycle was initiated. The PTH-amino acid was dried and reconstituted with 20%
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(v/v) acetonitrile solvent and transferred to the HPLC. PTH-amino acids were 
identified by gradient elution on a reverse-phase column and HPLC elution profile 
at 269nm was recorded for each cycle. Amino acids Were identified by their 
characteristic retention time. The sequence was determined by the appearance of a 
PTH-amino acid in cycle 1, and the simultaneous disappearance of that amino acid 
with the appearance of the next (if different) PTH-amino acid in cycle 2. The amino 
acid detected in each cycle and the by-products elution were recorded on a 
chromatograph. The derivation of the amino acid analysis is illustrated in Figure 2.5. 
The amino acid sequence was analyzed for homologies in the Gen Bank Database.
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CRUDE ERYTHROCYTE TRANSKETOLASE
I
PAGE
I
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Reduction + Alkylation
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Figure 2.5: Summary of obtaining amino acid analysis from purified erythrocyte
transketolase. The first step is the isolation of homogenous pure 
erythrocyte transketolase from a normal individual by polyacrylamide 
gel electrophoresis (PAGE). The purified transketolase is then 
subjected to SDS-PAGE and the protein band were electroblotted on 
an Immobilon (PVDF) membrane. The bands were excised from 
PVDF; treated and subjected to amino acid analysis.
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CHAPTER 3: RESULTS
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3.1 ANALYSIS OF ERYTHROCYTE TRANSKETOLASE 
IN CRUDE SAMPLE
3.1.1 Quantitative Analysis of Erythrocyte Transketolase
3.1.1.1 Transketolase Endpoint Assay
The initial endpoint assay, developed to measure the activity of TK in 
RBC, was performed on 7 normal controls. ETK and ETKs activity were measured 
using formula 2.2 and the results are listed in Table 3.1. The mean ETK activity was 
0.51 ±0.11 IU/g Hb and the addition of TPP did not significantly (p > 0.1) increase 
the ETK activity (ETKs) which was 0.47 ± 0.12 IU/g Hb with a mean Hb 
concentration of 37.19 ± 2.52 g/dL.
The endpoint assay was modified by varying several conditions and 
measuring ETK and ETKs activity on the same samples (7 normal controls). The 
summary of these modifications and their result are listed in Table 3.2. It was 
apparent that heating the sample and precipitating Hb by the addition of TCA or 
NaOH resulted in a loss of TK activity. Other variations (boiling haemolysate and 
incubating in a shaker waterbath) resulted in negative TPPE due to the low values of 
ETKs obtained from the inhibition of TPP binding to TK.
However, reducing the Hb from 40g/dL to 20g/dL improved the assay slightly 
(Table 3.3). With this modification, TK endpoint assay was performed on 14 normal 
controls and 6 patients (results are listed in Table 3.3). Performing the Student t-test 
on mean ETK activity from normal controls (0.41 ± 0.14 IU/g Hb) and patients (0.54 
±0.16 IU/g Hb) gave a value of t = 0.679 which was not statistically signficant 
(p>0.1). The mean ETKs activity for normal controls (0.45 ± 0.18 IU/g Hb) and 
patients (0.56 ± 0.17 U/g/dL Hb) gave a t-test value of t=0.542 which was also not 
statistically significant (p>0.1) with mean Hb concentration for normal controls 20.38 
± 1.34 g/dL and patients 21.53 ± 1.36 g/dL.
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Table 3.1 Erythrocyte transketolase (ETK) activity and stimulated erythrocyte 
transketolase (ETKs) acitivity in 7 normal controls estimated by the 
developed endpoint assay. Result are averages of duplicates.
Sample Haemoglobin
g/dL
ETK 
activity 
IU/g Hb
ETKs 
activity 
IU/g Hb
TPP Effect 
(%Activation)
100180 35.7 0.46 0.30 -34.78
100181 37.5 0.45 0.32 -28.89
100182 41.9 0.63 0.46 -26.98
100183 37.2 0.68 0.57 -16.18
100184 38.2 0.36 0.47 30.56
100185 35.9 0.50 0.52 4.00
100186 33.9 0.50 0.62 24.00
MEAN 37.19 0.51 0.47 -6.89
S.D (±) 2.52 0.11 0.12 26.54
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Table 3.2 Summary of the modifications performed on the end point assay and 
their results. The mean transketolase activity with (ETKs) and without 
TPP (ETK) are listed. The result of each variation is expressed as a 
negative effect (-ve) or a positive effect (+ve). All samples applied 
were normal controls and the number of samples (n) varied.
Modification Mean ETK 
activity 
IU/g Hb
Mean ETKs 
activity 
IU/g Hb
Effect
Heating Haemolysate (n=7) 0.35(±.08) - -ve
Boiling Reaction Mix (n=6) 0.47(±.10) 0.30+05) -ve
Incubating in Shaker Bath (n=5) 0.50(±.20) 0.27(±.12) -ve
Addition of 10% TCA (n=3) 0.02(±.01) 0.005(±.002) -ve
Addition of 20% NaOH (n=5) 0.28(±.09) - -ve
Addition of DTT (n=6) 0.61(±.21) 0.59(±.22) -ve
Addition of DTT + MgCl2 (n=5) 0.65(±.ll) 0.61(±.08) -ve
Increasing Incubation At Table 3.5 Table 3.5 +ve
Reducing Hb concentration Table 3.4 Table 3.4 +ve
Addition MgCl2 (n=7) 0.50(±.12) 0.54(±.16) +ve
Addition xylulose-5-phosphate Table 3.5 Table 3.5 +ve
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3.1.1.2 Application of Transketolase Assay in Wernicke-Korsakoff 
syndrome
The modified endpoint assay (reducing Hb concentration, increasing 
incubation time, adding X-5-P and MgClJ gave a more reliable, reproducible and 
sensitive method for analysis of ETK in normal controls and patients with WKS. 
Specificity and accuracy of ETK and ETKs activity were achieved by expressing 
these values in IU/mg protein. The modified endpoint assay was performed on 20 
patients and 10 normal controls to establish any difference between ETK and ETKs 
activity with cofactor and coenzyme between the two groups. The t value (t = 0.073) 
obtained by comparing the mean and standard deviation (with the Student t-test) 
between the mean ETK activity from normal controls (0.418 ± 0.193 IU/mg protein) 
and patients (0.406 ± 0.155 I.U/mg protein) was not statistically significant (p>0.1). 
The mean ETKs activity between normal controls (0.738 ± 0.208 IU/mg protein) and 
patients (0.680 ±0.19 IU/mg protein), was also not statistically significant (t = 0.33, 
p>0.1). The mean protein concentrations in the normal controls was 18.72 ± 0.07 
mg/ml and in patients 18.43 ± 0.06mg/ml.
3.1.2 Qualitative Analysis of Erythrocyte Transketolase
3.1.2.1 Starch Gel Electrophoresis
The electrophoretic mobility of ETK was initially investigated by
starch gel electrophoresis. Samples from one normal control and one patient were 
run in duplicate after preincubation with the cofactor TPP. The gel was sliced 
horizontally and stained with specific TK stain. A faint blue band was detected 
which represents the site of ETK activity (Figure 3.1) which was cathodic to the Hb 
band. The separation of ETK from Hb was achieved using this method.
3.1.2.2 Cellogel Electrophoresis
Cellogel electrophoresis was performed from RBC of 13 normal 
controls and 7 patients with WKS. All samples were preincubated with the cofactor 
TPP prior to electrophoresis. Specific TK stain allowed the detection of two ETK
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Table 3.3a Haemoglobin concentration and erythrocyte transketolase activity with 
(ETKs) and without (ETK) coenzyme TPP (ETK) in 14 normal 
controls. Transketolase endpoint assay performed after the reduction 
of haemoglobin (Hb) concentration from 40g/dL to 20g/dL. The 
values listed are the average of duplicates.
Sample Haemoglobin
g/dL
ETK activity 
IU/g Hb
ETKs activity 
IU/g Hb
TPP Effect 
(%Activation)
100180 20.8 0.31 0.40 29.03
100181 19.6 0.62 0.72 16.12
100182 21.5 0.40 0.28 -30.00
100183 20.2 0.41 0.23 -43.90
100184 17.8 0.26 0.27 3.85
100185 17.6 0.13 0.31 138.46
100186 20.8 0.32 0.52 59.38
100187 20.8 0.50 0.58 16.00
100188 21.3 0.62 0.64 3.23
100189 20.4 0.52 0.77 48.08
100190 21.6 0.45 0.48 6.67
100191 21.8 0.46 0.24 -47.83
100192 19.5 0.32 0.38 18.75
100193 21.6 0.39 0.43 16.26
MEAN 20.38 0.41 0.45 16.29
S.D (±) 1.34 0.14 0.18 46.65
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Table 3.3b Haemoglobin (Hb) concentration and erythrocyte transketolase activity 
with (ETKs) and without (ETK) coenzyme TPP for the 6 patients with 
Weraicke-Korsakoff syndrome.
Sample Haemoglobin
g/dL
ETK 
activity 
IU/g Hb
ETKs 
activity 
IU/g Hb
TPP Effect 
(%Activation)
100100 22.8 0.48 0.54 12.5
100194 22.9 0.60 0.62 3.33
100195 19.2 0.65 0.59 -9.23
100196 21.2 0.24 0.28 16.67
100197 21.2 0.57 0.81 42.10
100198 21.9 0.68 0.53 22.06
MEAN 21.53 0.54 0.56 7.22
S.D (±) 1.36 0.16 0.17 22.26
Table 3.4: Mean erythrocyte transketolase (ETK) activity and stimulated
erythrocyte transketolase (ETKs) activity in 30 samples analyized by 
the modified endpoint assay. ETKs was obtained by the addition of 
thiamine pyrophosphate and MgCl2. The sample included 10 normal 
controls and 20 patients with Wernicke-Korsakoff syndrome.
Sample Protein
concentration
mg/ml
ETK activity 
(IU/mg protein)
ETKs activity 
(IU/mg protein)
Normal 18.72 0.418 0.738
Mean ± S.D 0.07 0.193 0.208
Patient 18.43 0.406 0.680
Mean ± S.D 0.06 0.155 0.190
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Hb
ETK activity
Figure 3.1: Illustration of Erythrocyte transketolase (ETK) activity band on starch
gel detected with specific transketolase stain. It is apparent that the 
ETK band was well separated from the haemoglobin (Hb).
SA
Hb
ETK1 activity 
ETK2 activity
Figure 3.2: Illustration of erythrocyte transketolase (ETK) activity bands on
cellogel detected with specific transketolase. Transketolase was 
resolved into two bands (ETK 1 and ETK 2) that varied in stain 
intensity and which were separated from haemoglobin (Hb). (SA = 
sample application).
A. Electrophoretic profile representing a normal control
B. Electrophoretic profile representing a patient with Wernicke- 
Korsakoff syndrome.
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bands cathodic to the Hb band for all samples (Figure 3.2). There was some 
variation in band intensity between different samples, but all showed a characteristic 
pattern of two ETK bands, one (ETK 2) which stained more densely than the other 
(ETK 1). In some gels, it was difficult to detect the second ETK 1 band due to the 
faint staining. Although the separation of ETK from Hb was improved (from the 
previous method) there was no difference observed between WKS patients and 
normal controls.
3.1.23 Polyacrylamide Gel Electrophoresis
Prior to analyzing samples from normal controls and patients with 
WKS using PAGE, the specific TK stain was modified in an attempt to reduce the 
initial heavy background staining. The first modification involved the replacement 
of NBT with MTT which resulted in better band intensity and reduced background 
staining (Figure 3.3). To confirm that the stained bands represented ETK activity one 
half of the gel ("gel 1") was stained with specific TK stain and the other half ("gel 
2") with both substrates (R-5-P and X-5-P) omitted (Figure 3.4A,B). These were 
then stained with CBB R-250 to confirm the bands detected in gel 1 and undetected 
in gel 2 do exist and are protein in nature (Figure 3.4C). Two protein bands were 
visualized in "gel 2" after staining with CBB R-250. To obtain an accurate 
localization of the ETK bands in relation to the Hb position, the gel was stained with 
silver stained (Figure 3.5D).
A total of 15 normal control samples and 11 patient samples were run 
in duplicate. All samples revealed two bands of ETK activity (varying in band 
intensity) approximately 10-15mm cathodic to the Hb band (Figure 3.5). The two 
ETK bands were qualitatively similar in both the normal control (n=15) and patient 
samples (n=ll) analyzed.
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ETK activity
A B
Figure 3.3: Illustration of the improved specific transketolase stain. The gel was
sliced in two halves after polyacrylamide gel electrophoresis.
A. The one half of the gel subjected to the unmodified specific 
transketolase stain*. Erythrocyte transketolase (ETK) activity 
is faintly visualized but well separated from haemoglobin (Hb)
B. The other half of the gel subjected to the modified specific 
transketolase stain**. The resolved ETK is clearly visualized 
and background staining reduced
* with nitroblue tetrazolium  ** with m ethyl thiazolyl tetrazolium
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BFigure 3.4: Illustration on the sensitivity of the specific transketolase (TK) stain.
A normal control (N) and a patient (P) sample with Wernicke- 
Korsakoff syndrome were run in quadreplicate on a polyacrylamide 
gel (PAG). The PAG was sliced in two halves and subjected to 
specific TK stain. The site of erythrocyte transketolase (ETK) activity 
separated from haemoglobin (Hb) was analyzed to confirm stain 
sensitivity.
A. The one half of the gel subjected to specific TK stain with the
detected ETK bands
B. The other half of the gel subjected to specific TK stain but
depleted substrates (xylulose-5-phosphate and ribose-5- 
phosphate), no bands except for Hb detected
C. Restaining of B with coomassie brilliant blue R-250, ETK
band was resolved into 2 distinct bands on both halves of the
gel
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Figure 3.5: Electrophoretic profile of erythrocyte transketolase (ETK) on
polyacrylamide gel (PAG). The samples analyzed were normal 
controls and patients with Wernicke-Korsakoff syndrome.
A. PAG subjected to specific TK stain revealing the site of ETK
activity and separation from haemoglobin (Hb)
B. Restaining of A with coomassie brilliant blue R-250 allowed
further resolution of ETK
C. PAG stained with specific TK stain
D. Restaining of C with BioRad’s silver stain allowing the
resolution of ETK into two quantitatively distinct ETK bands
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3.1.3 Analysis of Transketolase in Wernicke-Korsakoff 
syndrome
Preliminary work on the quantitative analysis of ETK by the 
development of the TK assay gave indication of difficulties that may arise from Hb 
interference and insufficient binding of cofactor to enzyme. Although these were 
overcome by several modifications negative values for TPPE and wide variation in 
values within and between samples persisted (Table 3.3). ETK and ETKs activity 
was expressed in IU/mg protein rather than IU/g Hb to obtain a more specific and 
accurate value for the analysis in WKS. Quantitative analysis of ETK and ETKs 
activity using the modified TK assay in 10 normal controls and 20 patients with 
WKS showed no systematic statistically significant differences (p>0.1) between the 
two groups (Table 3.4).
Preliminary work using electrophoretic techniques allowed the analysis of 
ETK mobility by specific TK stain and its separation from Hb on a gel matrix (starch 
gel). This was examined further by cellogel electrophoresis. Although this method 
was rapid, reliable and inexpensive the ETK bands were difficult to visualize due to 
the smearing of Hb and difficulties with specific TK stain. By employing PAGE it 
was possible to improve the sensitivity of the stain for qualitative analysis and to 
apply silver staining for quantitative analysis of ETK electrophoretic profile. 
Qualitative analysis of ETK in 15 normal controls and 11 patients with WKS 
revealed the presence of two ETK bands with varying intensities as detected by 
specific TK stain (Figures 3.5A). ETK bands were shown to vary quantitatively 
within each sample tested by the silver stain method (Figure 3.5D).
Although ETK was shown to be heterogenous by electrophoretic techniques, 
quantitative and qualitative analysis did not reveal any differences between TK in 
crude samples of normal controls and patients with WKS.
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3.2 PURIFICATION OF ERYTHROCYTE TRANS­
K E T O L A S E  BY C H R O M A T O G R A P H I C  
TECHNIQUES
3.2.1 Qualitative Analysis of Purified Erythrocyte 
Transketolase
3.2.1.1 Polyacrylamide Gel Electrophoresis
All purified and reconstituted samples were run on PAGE and protein 
detection was performed by silver staining following specific TK stain to verify any 
protein bands separated represent ETK activity*. Partially purified fractions of ETK 
from 11 normal controls and 25 patients with WKS were subjected to PAGE. Silver 
stained gels resolved two ETK bands in all samples analyzed. The electrophoretic 
profile of ETK on PAGE is illustrated in Figure 3.6.
3.2.1.2 Isoelectric Focusing
The isolated fractions from both normal control and patient samples 
were concentrated and focused on IEF gels. One gel containing fractions from one 
normal control and one patient sample was subjected to specific TK stain. Two ETK 
bands of very low intensity were detected on the IEF gel*. The gel was then 
subjected to silver staining to verify the bands detected by specific TK stain were true 
proteins and to test for the presence of contaminating proteins (ETK). Partially 
purified fractions of ETK (n=36), pi protein markers and a polyacrylamide control 
blank were subjected to IEF followed by silver staining. ETK was resolved into two 
bands with no contaminating bands present in the polyacrylamide control blank thus 
confirming the purity of the ETK fraction. All normal controls (n=ll) and patient 
samples (n=25) were resolved into two ETK bands with pi 7.35 and 6.55 (estimated 
from protein markers) as illustrated in Figure 3.7.
Due to the heavy background staining and low intensity of the bands, electrophoretic profile of ETK 
detected by specific TK stain is not illustrated
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Figure 3.6: Electrophoretic profile of purified transketolase fractions on a
polyacrylamide gel. Purified erythrocyte transketolase (ETK) from a 
normal control was resolved into two distinct bands detected by 
BioRad’s silver stain.
pi 8.15
pi 7.35 
pi 6.55
pi 5.85 
pi 5.35
ETK pi 7.35 
ETK pi 6.55
Figure 3.7: Electrophoretic profile of purified transketolase by isoelectric focusing.
The gel was stained with BioRad’s silver stain and the isoelectric 
points (pi) of the two resolved erythrocyte transketolase (ETK) bands 
in the normal sample were estimated from protein markers (pi 5.35- 
8.15).
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3.2.13 High Performance Liquid Chromatography
Fractions isolated by PAGE from one normal control and one patient 
with WKS were subjected to ion-exchange HPLC. Two peaks were recorded on the 
chromatograph in each case (Figure 3.8, 3.9). In both samples the first peak eluted 
at 19 minutes under an increasing gradient (0-35%) of 1M NaCl in 20mM Tris-HCl 
pH 7.5. The second peak eluted at 31 minutes under an increasing gradient (35- 
100%) of 1M NaCl in 20mm Tris-HCl pH 7.5. These two peaks were consistent 
with the ETK bands detected in IEF which also contained TK activity. The elution 
profile shows that the purified fractions were free from contaminating proteins since 
no other peaks were eluted. It also demonstrates the heterogeneity of TK with 
respect to ionic strength (thus retention time).
3.2.2 Analysis of Partially Purified Transketolase in Wernicke-
Korsakoff Syndrome
The extraction of TK from RBC using the PAGE purification method 
was performed on 36 samples (11 normal controls and 25 patients). The isolated 
fractions from all samples were subjected to quantitative analysis and qualitative 
analysis.
Paritally purified fractions of TK from RBC of 36 samples were 
assayed for ETK activity by the modified endpoint assay. It was found that partially 
purified ETK requires both cofactors TPP and MgCl2 for activity. The mean ETK 
activity estimated in 11 normal controls was 6.79 ± 3.61 IU/mg protein (6.41 mg/L) 
and 5.89 ± 2.02 IU/mg protein (6.60mg/L) in 25 patients with WKS. These values 
were not statistically significant (t = 1.41, p>0.1).
Although qualitative analysis of purified fractions of ETK illustrated 
its heterogeneity with respect to pi value and ionic strength no differences between 
normal controls (n=ll) and patients (n=25) with WKS were observed.
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Figure 3.8: Elution profile of purified erythrocyte transketolase (ETK) from a
normal control (100133) by high performance liquid chromatography 
(HPLC). The sample (2.5mg/100ml) was loaded on an ion-exchange 
column and eluted with 1M NaCl in 20mM Tris-HCL pH 7.6 gradient 
for 40 minutes. The first ETK peak was eluted at 19 minutes under 
an increasing gradient 0-35%; the second peak eluted at 31 minutes 
under 35-100% gradient.
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Figure 3.9: Elution profile of purified erythrocyte transketolase (ETK) from a
patient with Wernicke-Korsakoff syndrome (100100) by high 
performance liquid chromatography (HPLC). The sample 
(1.5mg/100ml) was loaded on an ion-exchange column and eluted with 
1M NaCl in 20mM Tris-HCl pH 7.6 gradient for 40 minutes. The 
first ETK peak eluted at 19 minutes under an increasing gradient of 
0-35%; the second peak eluted at 31 minutes under an increasing 
gradient of 35-100%.
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3 3 PURIFICATION OF TRANSKETOLASE FROM 
WHITE BLOOD CELLS
The crude extract of WBC (30ml) was loaded onto the Sephadex G-25 
column. The protein mixture was equilibrated and eluted with 600ml of lOmM Tris- 
HCl pH 7.8. Fractions (11ml) were collected every 3 minutes and every second 
fraction was monitored at 280nm for protein absorbance. The results were plotted 
on the graph (Figure 3.10) and peaks containing high protein absorbance (fractions 
12-20) were assayed for TK activity by a kinetic assay (section 2.3.1). TK activity 
was recovered in a total void volume of 66ml and those in fractions 12-19 were 
plotted on the same graph (Figure 3.10).
The progress of the purification was monitored by assaying protein 
concentration and TK activity at every step of the purification (Table 3.5). Enzyme 
activity after DEAE-cellulose adsorption was only 0.0102 U/mg. Following 
ammonium sulphate fractionation the final recovery declined to 0.01140 U/mg. 
Enzyme recovery became poorer as the purification steps progressed, thus no further 
purification steps were carried out.
3.4 PURIFICATION OF ERYTHOCYTE TRANS­
K E T O L A S E  BY C H R O M A T O G R A P H I C  
TECHNIQUES
3.4.1 Ion Exchange Chromatography on DEAE-Sepharose
Dialyzed haemolysate (72ml) was loaded onto the pre-equilibrated 
DEAE-Sepharose. Elution was performed with a linear gradient of equal volumes of 
1L lOmM Tris-HCl and 1L 0.1M NaCl in lOmM Tris-HCl pH 8.3. Fractions (18ml) 
were collected every 12 minutes and every second fraction was monitored at 280nm 
for protein absorbance. TK activity was assayed in every fourth fraction starting 
from the 20th fraction (last fraction collected prior to the gradient run) up to the 
100th fraction. These results were plotted on a graph alongside the protein
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Figure 3.10: Elution profile of transketolase (TK) from white blood cells (WBC) 
by gel filtration. Protein mixture (75mg/30ml) from WBC was loaded 
on a Sephadex G-25 column. TK activity was eluted in fractions 12- 
19 with lOmM Tris-HCl, pH 7.8.
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Table 3.5 Purification summary of transketolase from white blood cells (3g).
Enzyme activity was obtained from 20/d of sample and protein 
estimation was performed using Bradford’s method.
STEP Volume
(ml)
Activity
ffU/L)
Protein
(mg)
Specific
Activity
(IU/mg)
Purification
(-fold)
Crude
extract
30 9.4 75 0.00376 1
DEAE-
Sephadex
72 7.6 54 0.0103 2.7
45% Amm. 
Sulph.
80 4.9 40 0.0098 2.6
45-90% 
Amm. Sulph.
91 4.3 34 0.0114 3
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absorbance where TK activity was recovered in two peaks (Figure 3.11). Peak A was 
eluted from fractions 28-32 in a void volume of 80ml and peak B was eluted from 
fractions 53-58 in a void volume of 100ml. Fractions from Peak A were pooled and 
fractions from peak B were pooled and assayed for ETK activity (using the kinetic 
assay in section 2.3.1) and protein concentration. Hb eluted in fractions 64-100 
where very low ETK activity (1.4nmol/min/ml) was also detected in fraction 82 (peak 
C). Further analysis was not performed on peak C while peaks A and B were treated 
and analyzed separately. Conductivity was also measured in fractions 30-145 and 
plotted on the same graph (Figure 3.11).
3.4.2 Fast Protein Liquid Chromatography
After dialyzing peaks A and B, 68ml of peak A was loaded onto a 
Mono Q column and eluted with 0.2M NaCl in lOmM Tris-HCl pH 8.3 with a linear 
gradient intiated 25 minutes after the start of elution. Fractions (1.2ml) were 
collected and monitored continuously at 280nm; two peaks were resolved and assayed 
for TK activity. The results are presented in Figure 3.12. Peak A1 eluted in fraction 
48 (1.1ml) and peak A2 eluted in fraction 52 (1.1ml). Peak B (78ml) also resolved 
into two peaks (B1 and B2) after a gradient elution was initiated. Peak B1 was 
eluted in fraction 21 (1.2ml) and B2 in fraction 24 (1.2ml). The results were also 
plotted on a graph (Figure 3.13). All four fractions were dialyzed and stored at 4°C.
3.4.3 Analysis of Purified Erythrocyte Transketolase
Protein concentration and ETK activity was performed at each step of 
the purification (Table 3.6). Enzyme was recovered at all steps, however, most of 
it was lost (peak B: 30.6mg to O.lmg, peak A: 18.3mg to 0.09mg) due to either 
complete binding to the Mono Q column or its unbinding and immediate elution 
(retention time=elution time). Although sufficient material was not recovered for 
amino acid analysis this purification method allowed some characterisation of TK.
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Figure 3.11: Elution profile of erythrocyte transketolase (ETK) and haemoglobin 
(Hb) by ion-exchange chromatography. The dialyzed haemolysate 
(72ml) was loaded on DEAE-Sepharose and eluted with a linear 
gradient of equal volumes (1L lOmM Tris-HCl and 1L 0.1M NaCl in 
lOmM Tris-HCl pH 8.3). Transketolase activity was eluted in 
fractions 28-32 (Peak A) and in fractions 53-58 (Peak B). Peak C 
contained very low ETK activity.
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Figure 3.12: Elution profile of purified erythrocyte transketolase (ETK) fraction 
(peak A) by ion-exchange on fast protein liquid chromotography 
(FPLC). Peak A (68ml) was loaded onto a Mono Q column and ETK 
activity was eluted with 0.2M NaCl in lOmM Tris-HCl, pH 8.3 linear 
gradient. Peak A was resolved further into two peaks (A1 & A2). 
Peak A1 eluted in fraction 48 and peak A2 eluted in fraction 52.
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Figure 3.13: Elution profile of purified erythrocyte transketolase (ETK) fraction 
(peak B) by ion-exchange on fast protein liquid chromotography 
(FPLC). Peak B (78ml) was loaded onto a Mono Q column and ETK 
activity was eluted with 0.2M NaCl in lOmM Tris-HCl, pH 8.3 linear 
gradient. Peak B was resolved further into two peaks (B1 & B2). 
Peak B1 eluted in fraction 21 and peak B2 eluted in fraction 24.
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Table 3.6: Purification summary of erythrocyte transketolase (ETK) by
chromatographic techniques. ETK activity was estimated from 2Qwl 
of sample using kinetic TK assay and protein estimation was 
performed using Bradford’s method.
Purification Step Total
Volume
(ml)
Total
Protein
(mg)
Total
Activity
(mol/
min)
Specific
Activity
(nmol/
min/mg)
Yield
(%)
Purifi­
cation
(Fold)
60ml whole blood 
36ml Packed red 
blood cells
72 20,563 2376 0.115 100 1
DEAE-Sepharose: 
Peak (A) 
Peak (B)
80
100
18.36
30.60
156
427
8.5
13.95
6.6
18
74
121
Dialysis: 
Peak (A) 
Peak (B)
68
78
10.40
18.21
112.88
274.47
11.25
15.07
4.76
11.55
98
131
FPLC MONO Q: 
Peak (Al) 
Peak (A2)
1.2
1.1
0.0612
0.0281
5.034
3.575
82.25
127.45
0.21
0.15
715
1108
Peak (Bl) 
Peak (B2)
1.2
1.2
0.0459
0.0612
6.577
5.844
143.29
95.49
0.28
0.25
1246
830
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The heterogeneity of ETK was confirmed with regard to its ionic strength as analyzed 
by ion-exchange chromatography (Figure 3.11), FPLC (Figures 3.12 and 3.13) and 
quantitatively in relation to the proportion of ETK activity eluted in each peak. Peak 
A had ETK activity of 8.5 nmol/min/mg protein while peak B contained 
13.95nmol/min/mg protein.
Following dialysis and freeze-drying, fractions Al, A2, B1 and B2 
were analyzed for MW estimation. Protein markers (20/d), original haemolysate 
(20/d) and fractions Al, A2, B1 and B2 (100/d each) were loaded on a 10% SDS- 
PAGE. The purified TK fractions were resolved into one band (68kD) detected only 
with silver staining after CBB R-250 (Figure 3.14). Since these fractions were 
undetectable with CBB R-250, they were not suitable for amino acid sequencing.
3.5 AMINO ACID ANALYSIS OF TRANSKETOLASE
3.5.1 Isolation of Homogenous Erythrocyte Transketolase and
Western Blotting
Homogenous ETK was isolated using the PAGE purification method 
(section 3.2) since it has achieved the best enzyme recovery, high purity and 
sufficient material (3/*g/160ml) for amino acid analysis. The purification steps and 
enzyme recovery are summarized in Table 3.7. The isolated fraction (250/*g) was 
subjected to qualitiative analysis to confirm that it was TK (Figures 3.6, 3.7, 3.8).
Molecular weight estimation was determined by SDS-PAGE. Two 
species were detected with apparent MW of 51kD for the dense band and 35kD for 
the faint band as determined by the MW markers and detected by CBB R-250 and 
silver staining (Figure 3.15). Following SDS-PAGE the isolated fraction was loaded 
onto 10 wells in SDS-PAGE and transfered onto a PVDF membrane by western 
blotting. The membrane was stained with CBB R-250 and two ETK bands were 
detected (Figure 3.15). Amino acid analysis was performed on all the ETK tracks 
in PVDF.
I l l
2 2 1 1 2 3 4 5 6 7 2
67kD
A B
Figure 3.14: Electrophoretic profile of purified erythrocyte transketolase (ETK) by
chromatographic techniques. SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE method 2) was used for the molecular weight estimation 
of ETK (68kD).
A. SDS-PAG stained with coomassie brilliant blue R-250 (CBB 
R-250)
B. SDS-PAG destained from CBB R-250 and silver stained using 
BioRad’s silver stain kit
lane 1 20/d bovine serum albumin as protein marker (67kD).
lane 2 20/d starting haemolysate
lane 3 100/d Fraction Al
lane 4 100/d Fraction A2
lane 5 100/d Fraction B1
lane 6 100/d Fraction B2
lane 7 100/d track dye
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Table 3.7: Quantitative analysis of isolated erythrocyte transketolase (ETK) by
polyacrylamide gel electrophoresis. ETK was extracted from the 
haemolysate of a normal control (100133).
Variables Crude Sample Purified Sample
Total Volume (ml) 0.16 10
Total Activity (IU x 10'3) 3.248 1.45
Total Protein (mg) 3.04 0.250
Specific Enzyme Activity 
(IU/x lO3)
1.068 5.8
Purification Field 1 5.4
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ETK , !—  ETK
ETK
B
118kD
2 3
97kD
66kD
44kD
29kD
51kD ETK
35kD ETK
Figure 3.15: Electrophoretic profile of isolated homogenous erythrocyte
transketolase (ETK). ETK was purified by the polyacrylamide gel 
electrophoresis (PAGE) method. ETK migrated as two bands of 
molecular weight (MW) 51kD and 35kD as estimated by MW 
markers.
A. SDS-PAG stained with coomassie brilliant blue (CBB) R-250
B. SDS-PAG stained with BioRad’s silver stain.
C. Transblot membrane stained with CBB R-250.
lane 1: MW markers (20-215kD, Sigma)
lane 2: Haemolysate from the normal control sample (100133)
lane 3: Isolated ETK fraction
lane 4: Isolated ETK fraction
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3.5.2 Amino Acid Composition
From two tracks of the PVDF membrane the 51kD band and 35kD 
band were hydrolyzed and analyzed for amino acid content. The chromatographic 
profiles of amino acid content by height in each bands are shown in Figures 3.16 and 
3.17.
For the 51kD ETK band: 19 peaks were detected, 16 of which were 
matched to the standard amino acids (Appendix IV). Amino acid composition by 
MW and molar ratio % are listed in Table 3.8. The total weight recovered from two 
bands of 51kD ETK was 0.36 mg. As for the 35kD ETK band: 18 peaks were 
detected, 15 of which were matched to the standard amino acids. Amino acid 
composition by MW and molar ratio % are listed in Table 3.9 The total mass 
recovered from two bands of 35kD ETK was 0.18mg.
All data listed in (Tables 3.8 and 3.9) and chromatographic profiles 
(Figures 3.16 and 3.17) were obtained from the Applied Biosystems 920A Data 
Analysis report (Appendix V and VI).
To verify that the 51kD and 35kD bands are two species of the same 
protein on the basis of amino acid composition, statistical analysis was performed 
using Kendall’s test (non-parametric). This gave a highly significant (Z = 3.21, p sl) 
positive correlation (K = 0.6) between the two amino acid compositions. The 
Wilcoxon test suggests that the amino acid composition (molar ratio %) from the two 
protein bands are not significantly different (thus null hypothesis holds true and P=l, 
2-tailed). In addition, the amino acid composition (molar ratio %) from both protein 
bands were also verified to be identical by plotting the values on a scatter plot which 
also showed positive correlation by an upward trend (Figure 3.18). Moreover, the 
histogram confirmed the close resemblance between the molar ratio (%) of amino 
acids from the two TK bands (Figure 3.19). Statistical analysis thus suggests that the 
two protein bands represent similar proteins with similar functions.
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Table 3.8: Amino acid composition of 51kD transketolase (IX). Amino acid
composition was determined from 0.36mg of two IX  bands 
hydrolyzed from the transblot membrane.
(shortcode for each amino acid is shown in brackets).
Amino
Acid
No.
Amino Acid Retention
Time
(min)
Absorbance 
Unit OuAu)
Composition 
by MW
Molar
Ratio
(%)
1 Aspartic Acid (D) 2.20 31903 57.0 11.95
2 Glutamic Acid (E) 2.57 20965 35.5 7.43
3 Serine (S) 3.35 22784 56.5 11.85
4 Glycine (G) 3.79 14192 31.5 6.62
5 Histidine (H) 4.25 6869 18.5 3.90
6 Arginine (R) 4.90 5984 9.5 2.00
7 Threonine (T) 5.14 11135 25.0 5.20
8 Alanine (A) 5.54 25110 44.0 9.29
9 Proline (P) 5.82 18226 34.0 7.18
10 Tyrosine (Y) 8.49 10317 16.0 3.32
11 Valine (V) 9.49 19634 34.0 7.12
12 Methionine (M) 9.78 1975 3.5 .73
13 Isoleucine (I) 11.78 9976 21.0 4.45
14 Leucine (L) 11.99 26518 46.0 9.58
15 Phenylanine (F) 12.62 13655 19.0 3.99
16 Lysine (K) 13.65 31097 25.5 5.39
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Retention Time (min)
Figure 3.16: Chromatographic profile of the amino acid composition of the 51kD
transketolase band. 19 peaks were detected, 16 of which were 
matched to the standard amino acids. Numbers 1-16 are the amino 
acids identified and listed in Table 3.8. (Scale = 0.032 Au).
Table 3.9: Amino acid composition of 35kD transketolase (TK). Amino acid
composition was determined from 0 .18^  of two TK bands hydrolzed 
from the transblot membrane.
(Shortcode for each amino acid is shown in brackets).
Amino
Acid
No.
Amino Acid Retention
Time
(min)
Absorbance 
Unit (p.Au)
Composition 
by MW
Molar
Ratio
(%)
1 Aspartic Acid (D) 2.17 10266 24.5 7.39
2 Glutamic Acid (E) 2.56 9729 22.0 6.62
3 Serine (S) 3.33 6307 21.0 6.31
4 Glycine (G) 3.78 9879 29.5 8.85
5 Histidine (H) 4.23 4796 17.5 5.24
6 Arginine (R) 4.89 3539 7.5 2.27
7 Threonine (T) 5.13 6756 20.0 6.06
8 Alanine (A) 5.53 1977 45.5 13.56
9 Proline (P) 5.82 7589 19.0 5.75
10 Tyrosine (Y) 8.49 3512 7.0 2.17
11 Valine (V) 9.49 16635 39.0 11.60
12 Methionine (M) 9.77 1032 2.5 .73
13 Leucine (L) 11.99 20017 46.5 13.90
14 Phenylanine (F) 12.62 8857 16.5 4.98
15 Lysine (K) 13.65 13774 15.5 4.58
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Figure 3.17: Chromatographic profile of the amino acid composition of 35kD 
transketolase. 18 peaks were detected, 15 of which were matched to 
the standard amino acids. Numbers 1-15 are the amino acids 
identified and listed in Table 3.9. (Scale = 0.021Au)
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3.5.3 Amino Acid Sequencing
Eight bands from the PVDF membrane were excised to perform amino 
acid sequencing on the 51kD (yield ~ 1.5mg) and 35kD (yield ~0.75mg) bands.
Only 15 cycles of amino acid sequence were obtained from the N- 
terminal of the 35kD TK band. Data on the amino acid sequence obtained is listed 
in Table 3.10. The average and the combined repetitive yields (percent of material 
that can be sequenced after each cycle) of amino acids were 105.01% and 89.07% 
respectively. The theoretical initial yield (percent of material that can be sequenced 
from the amount of sample loaded after each cycle) was 142.82 pmol. The original 
report on the sequence data was obtained by the Applied Biosystems 477A protein 
sequencer (Appendix VII). The sequence obtained represents roughly 4% of the total 
amino acid sequence (-350 residues).
The eluted peak, representing the amino acid in each cycle, is identified by 
comparing the shift in height of one cycle from the previous and subsequent cycles. 
That is, the peak which is not present (or has a low height) in the previous cycle 
begins to appear (or increase in height) in the present cycle and then disappears (or 
declines in height) in the next cycle. Then the peak identified is matched to the 
amino acid standard by its retention time (Appendix IV). The sequence profile of the 
first 15 cycles obtained for the 35kD TK band is provided in Figure 3.20. The amino 
acid sequence was analyzed for homologies in the Gen Bank Database which verified 
its uniqueness.
As for the 51kD TK band, no amino acid sequence was obtained due to N- 
terminal blockage. Although there was sufficient material for sequencing, the initial 
theoretical yield was only 3.78 pmol.
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Table 3.10: Amino acid sequence data for the 15 cycles obtained from the 35kD
transketolase band.
Cycle
No.
Height
QiAu)
Retention 
Time (min)
Amino Acid 
Identification
Ratio
(pmol)
Nucleotide
Codon
Redundancy
1 82764 20.03 Valine (V) 195.02 4
2 28686 25.27 Leucine (L) 144.61 6
3 28212 25.25 Leucine (L) 130.86 6
4 17604 18.85 Proline (P) 73.15 4
5 20985 12.03 Alanine (A) - 4
6 12240 9.22 Glutamine (E) 47.67 2
7 19551 9.22 Glutamine (E 75.74 2
8 8388 7.95 Threonine (T) 46.91 4
9 21081 5.95 Asparagine (N) 21.97 2
10 19293 20.00 Valine (V) 40.24 4
11 8262 24.78 Lysine (K) - 2
12 4695 7.95 Threonine (T) 21.92 4
13 26907 12.03 Alanine (A) 33.20 4
14 14493 25.22 Leucine (L) 53.31 6
15 12213 8.35 Glycine (G) 7.15 4
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Figure 3.20: Chromatographic profile of the amino acid sequence for all 15 cycles 
from the 35kD transketolase band. The eluted peak in each cycle 
representing the identified amino acid is designated with a number (1- 
15). The number indicates the sequence of each amino acid residue.
+ indicates all matched amino acids with respect to retention time 
© indicates the appearance or increase in height of an identified peak 
© indicates the disappearance or decrease in height of an identified 
peak
x-axis: Retention Time (min) 
y-axis: Height (uAu)
Cycle # 1:
7(1.1
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CHAPTER 4: DISCUSSION
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4.1 QUANTITATIVE ANALYSIS OF TRANSKETOLASE
IN WERNICKE-KORSAKOFF SYNDROME
The determination of ETK and ETKs activity and the calculation of 
TPPE has been used for more than twenty years as an aid to the diagnosis of WKS 
(Sauberlich, 1984; Victor et al., 1989). However, the calculation of TPPE in a subset 
of normal controls (n=14) and patients (n=6) with WKS in the present study using 
the endpoint assay (section 2.1.4.1) were inconsistent with wide variation (mean of 
normals: 16.29% ± 46.65; patient: 7.22% ± 22.26) and negative values were also 
observed. It has been noted by others that the calculation of TPPE for clinical 
diagnosis of WKS and TD can be misleading (Sauberlich, 1967; Fennelly, 1967; 
Wood et al., 1987; Grudzinski et al., 1989; Nixon et al., 1990) and adds little to the 
single measurement of ETK activity (Nixon et al., 1990). The initial value of mean 
ETK activity and TPPE in normal samples (n=14) are listed along with other values 
reported in the literature to illustrate the wide variation of mean ETK activity and 
TPPE and their ranges (Table 4.1). It is clear that there is no uniformity in these 
values nor in the ranges quoted for ETK activity and TPPE which has also been 
observed by Bayoumi and Rosalki (1976), Gradual et al. (1985) and Anderson and 
Nicol (1986). The diversity in laboratory techniques could be a contributing factor.
In this study no signficant difference (p>0.1) was found between the 
values for ETK and ETKs activity as determined by the optimized endpoint assay 
(section 2.1.4.3) in 10 normal controls (ETK activity: 0.418 ± 0.193IU/mg protein, 
ETKs activity: 0.738 ± 0.208IU/mg protein) and in 20 patients with WKS (ETK 
activity: 0.406 ± 0.155IU/mg protein, ETKs activity: 0.680 ± 0.190IU/mg protein). 
Tate and Nixon (1987) also could not demonstrate a systematic difference between 
WKS patients and normal controls. In 1965 Leevy and colleagues reported only 50% 
of patients with WKS had an abnormally low ETK activity.
The application of the TK activation test as an aid to the diagnosis of 
WKS has been based on the following assumption: if a patient had low stores of 
thiamine in the form of TPP bound to TK then upon addition of exogenous vitamin 
there will be a large increase in activity. The patients sampled in the present study
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Table 4.1: Mean values for erythrocyte transketolase (ETK) activity and thiamine
pyrophosphate effect (TPPE) reported in literature in healthy 
individuals. (Values in brackets are ranges reported)
Report ETK (IU/g Hb) 
(mean ± SD)
TPPE (%) 
(mean ± SD)
Sample Size 
(n)
Smeets et al. (1971) 0.77
(0.59-1.06)
11 ± 4.5 10
Williams et al., (1976) 0.82 ± 0.40 (0-25) 20
Bayoumi & Rosalki (1976) - 23 ± 12 15
Buttery et al. (1980) 0.93
(0.53-1.21)
12
(2-25)
30
Thomson et al. (1980) 0.897 ± 0.015 - -
Duffy et al. (1981) - 6.3 ± 3.0 120
Waring et al. (1982) 0.615 ± 0.059 11
(2-19)
360
Gradual et al. (1985) (0.718-1.98) (5-23) 21
Puxty et al. (1985) 0.711 9.9 11
Anderson & Nicol (1986) 0.698 ± 0.065 10.3
(2.7-15.3%)
200
Jeyasingham et al. (1987) 0.503 ± 0.221 - 40
Melgaard et al. (1989) 0.67 ± 0.42 
(0.11-0.96)
12.9 ± 11 
(0-34)
15
Present study 0.41 ± 0.14 
(0.13-0.62)
16.29 ± 46.5 14
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were hospitalized and receiving thiamine supplementation. They would be expected 
to have adequate stores of thiamine thus might not show signficant increase in ETK 
activity upon addition of TPP in vitro. This is in agreement with Gradual et al.
(1985) who evaluated ETKs activity and TPPE as indices of nutritional status based 
on a study of alcoholic (AL, n=23) and non-alcoholic (NAL, n=21) groups. They 
found normal ETK activity after oral thimaine adminstration (lOOmg). Another study 
illustrating restoration of ETK activity and TPPE to normal after treatment with 
thiamine in WKS was reported by Leigh et al. (1981). However most other reports 
on the evaluation of ETK and ETKs activity in patients with WKS have only been 
determined prior to treatment with thiamine (Sauberlich, 1984; Bayoumi & Rosalki, 
1976; Gradual et al., 1985; Kerr et al., 1986; Jeyasingham et al, 1987; Melgaard et 
al., 1989; Hill & Truswell, 1990) and therefore showed elevated values of ETK 
activity. It would appear that the apoenzyme (ApoTK) must be measured prior to 
thiamine supplementation in patients to assess the true value of ETK activity and TD.
It has been assumed that variation of ETK and ETKs activity and 
TPPE results from the dissociation of part of the enzyme into apoform (Jeyasingham 
et al., 1987) or from an abnormality in the binding affinity of coenzyme to ApoTK 
(Kjosen, 1977, Gradual et al., 1985; Kerr et al., 1986; Takeuchi et al., 1988). Such 
abnormalities would be expected to be prominent in WKS (Blass & Gibson, 1977; 
Greenwood et al., 1989; Pratt et al, 1985; Kerr et al., 1986; Jeyasingham et al., 1987). 
The properties, kinetics and reactivation of ApoTK have been described (Greenwood 
et al., 1984; Pratt et al., 1985; Tate & Nixon, 1987; Jung et al., 1988). Upon acidic 
treatment (e.g. ammonium sulphate, pH < 4.0) human TK can be seperated into its 
apoenzyme (ApoTK) and coenzyme (TPP) (Wamock & Prudhomme, 1982; 
Greenwood et al., 1984; Tate & Nixon, 1984; Jung et al., 1988). The resolved 
ApoTK, prepared from native or purified holoenzyme, has been shown to be stable 
at 0°C with optimum pH 7.6 and temperature 37°C and requires TPP or MgCl2 for 
reactivation (Wamock & Prudhomme, 1982; Greenwood et al., 1984; Pratt et al., 
1985; Jeyasingham et al., 1986; Tate & Nixon, 1987; Jung et al., 1988).
In order to establish the existence of ApoTK variants in the binding 
affinity for TPP, as first suggested by Blass and Gibson (1977), kinetic analysis (ie.
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determination of Michaelis-Menten constant) on TPP and its binding to ApoTK had 
been performed by several workers (Greenwood et al., 1984; Pratt et al., 1985; Tate 
& Nixon, 1987; Jeyansingham et al., 1987). Jung et al. (1988) have found that TPP 
bound to enzyme has a direct influence on catalytic activity and that it was 
characterized by a single active site. A more recent report (Nixon et al., 1990) 
suggested that the finding of variation in ApoTK level reflects changes in the 
concentration of total IX  protein (e.g. synthesis or catabolism) and are dependent 
upon coenzyme concentration. Although ApoTK can be estimated from the 
difference between ETK and ETKs activity (Nixon et al., 1990) a more reliable 
measurement of TK protein would be achieved by immunoassay (Takeuchi et al., 
1988; Paoletti et al., 1989) or by qualitative analysis of ETK (Greenwood et al., 
1984, Nixon et al., 1984; Pratt et al., 1985). This would also allow the 
characterization of variant ApoTK (Nixon et al., 1990) whether arising from low 
affinity for TK (Blass & Gibson, 1977; Mukherjee et al., 1987), altered turnover or 
by decreased stablity of ApoTK (Mukheijee et al., 1987; Jeyasingham & Pratt, 1988).
4.2 QUALITATIVE ANALYSIS OF TRANS-
KETOLASE IN WERNICKE-KORSAKOFF  
SYNDROME
The reported findings of isoenzyme variants (Kaczmarek & Nixon, 
1983; Nixon et al., 1984; Kaufmann et al., 1987) associated with ETK in WKS was 
investigated by electrophoretic methods using crude haemolysates and partially 
purified ETK from normal contols and patients with WKS.
Qualitative analysis by electrophoresis allowed the resolution and 
separation of TK variants, as well as the elimination of Hb interference. This was 
only achieved after improving the specific enzyme stain which had caused 
background staining and detection of false bands as also observed by Kaufmann et 
al. (1987). The application of PAGE yielded the best electrophoretic profile and 
allowed the detection of two TK bands in all normal controls and patients with WKS. 
These findings are in agreement with those of Paoletti et al. (1989) who performed 
IEF techniques and western blotting of TK from leukocytes and detected TK by
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specific antibodies. The results obtained in the present study with regard to the 
electrophoretic profile of TK from crude haemolysates do not support the original 
reports of Kaczmarek and Nixon (1983) and Nixon et al. (1984). The former 
described the detection of 8 individual species of TK with pi ranging from 6.6  to 9.2 
on IEF gels following partial purification of TK from stored human erythrocytes by 
ion-exchange chromatography and gel filtration (Kaczmarek & Nixon, 1983). Nixon 
and associates (1984) reported a variation in the distribution of TK isoenzymes 
between normal controls, alcoholic controls and patients with WKS using the method 
of Kaczmarek and Nixon (1983). This technique was re-examined by Kaufmann and 
associates (1987) who despite detecting 7 TK bands with pi values from 7.4-8.4 
concluded that methodological influences may induce artifacts which is evident from 
the four additional marginal bands that were not always reproducible.
In an attempt to resolve this discrepency as well as to further 
investigate TK qualitatively in normal controls and patients with WKS, partial 
purification of TK was performed by PAGE. The TK preparations were subjected 
to various qualitiative analysis using PAGE, IEF and HPLC. All analyses supported 
the presence of two TK bands in all samples tested differing in MW, pi and ionic 
strength. Similar results have been reported by others (Greenwood et al., 1984; Pratt 
et al., 1985; Jeyasingham, 1987; Thomson et al, 1987; Sheu et al., 1988; Jeyasingham 
& Pratt, 1988) (Table 4.2). It has been suggested (Puxty et al., 1985; Kaufmann et 
al., 1987; Jeyasingham & Pratt, 1988) that prolonged storage of haemolysates can 
give rise to altered TK thus inducing artifacts. In this study, samples analyzed 
qualitatively from stored haemolysates in glycerol citrate buffer (at -20°C) revealed 
no variation in TK in all normal controls and in patients with WKS. Several reports 
have suggested that any variation in TK which may occur can arise from haemolysate 
preparation methods rather than any storage effect (Anderson & Nicol, 1986).
Smeets et al. (1971) suggested that haemolysates could be stored at 
20°C for four weeks without any loss of activity. This was contradicted by Bayoumi 
and Rosalki (1976) and Leunis et al. (1982) who observed a 10% loss in activity after 
1-2 weeks of storage. Puxty et al. (1985) also reported a signficant decline (p<0.05) 
in ETK activity after prolonged storage which allowed misleading interpretation of
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results as observed by Kaufmann et al. (1987). Although such an effect may exist 
it was not observed in this study suggesting that it is the method of storage (i.e. 
storage in detergent) that gives altered ffoms of TK rather than prolonged storage. 
The storage of samples in this study were intact cells in buffer citrate glycerol thus 
preserving ETK activity. This is in agreement with Anderson and Nicol (1986) and 
Mount et al. (1987). Moreover, the detection of various isoenzymes (Kaczmarek & 
Nixon, 1985; Nixon et al., 1984; Kuafmann et al., 1987) may have arisen from 
formation of complexes between TK, TA and G-3-P as a result of storage of samples 
(Takeuchi et al., 1986).
Although qualitative analysis on TK from haemolysates of normal 
controls and patients with WKS strongly support TK heterogeneity, both quantitative 
and qualitative analysis revealed no systematic differences between the samples 
tested. This prevented the investigation of possible genetic factors by enzymatic 
analysis. However, quantitative analysis of TK electrophoretic profile (i.e. PAGE, 
IEF, HPLC) by silver staining hinted on the existence of variation between the two 
bands with regard to the proportion of each band present. These findings had also 
been reported by Greenwood et al. (1984), Pratt et al. (1985), Jeyasingham and Pratt 
(1988), and Takeuchi et al. (1988) who performed detailed studies on the kinetics and 
reactivation of TK from partially purified preparations and provided a tentative 
explanation on the role of TK in WKS.
Kinetic studies on TK variants were performed by Greenwood et al. 
(1984) using the Michaelis-Menten constant (Km) which is defined as the coenzyme 
or substrate concentration at which the initial reaction is half the maximal; that is the 
affinity of apoenzyme for TPP has a concentration at which 50% of TK is activated. 
Thus a high affinity apoenzyme would have a low Km for TPP. The two fractions 
of TK obtained by ion-exchange chromatography were separated from Hb and were 
each shown to contain two further variants of TK differing in their affinity for TPP 
(Km) (Greenwood et al., 1989). Further work on binding affinities for TPP was 
performed in five different groups of patients. A variant with reduced affinity for TPP 
(high Km) was found in the demented and alcoholic patients. Increased concentration 
of TPP (beyond 3/^M) was shown to exhibit an inhibition effect on the high affinity
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Table 4.2: Qualititave analysis of partially purified transketolase (TK) variants
reported in literature. These include variants with regard to pi value, 
electrophoretic and chromatographic profile
Report Analysis Finding Characteristic
Kaczmarek & Nixon 
(1983)
IEF on 25 
normals 
DEC & GFC
8 species of TK 
isoenzymes 
2 peaks
pi range: 6.6  - 9.2
Nixon et al. (1984) IEF on 42 
WKS and 36 
normals
different 
distribution of 
isoenzyme pattern
-
Greenwood et al. (1984) IEC at least 2 variants differ in binding 
affinity to TPP 
concentration
Pratt et al. (1985) GFC on
normal
controls
at least 2 variants 
varying in size 
and binding 
affinity
larger molecule had 
bound TPP; smaller 
component inactive 
without TPP
Thomson et al. (1987) GFC on 
patients with 
WKS
2 variants 
differing in 
molecular weight
patients with WKS 
had high proportion 
of low molecular 
weight TK
Kaufmann et al. (1987) IEF 7 TK bands and 4 
marginal artifacts
pi range: 7.4-8.4
Paoletti et al. (1988) IEF from 
leukocytes
at least 2 variants pi 7.3 & 8.6
Mocali & Paoletti (1989) EEF of 
isolated TK 
from 
leuckocytes
6-8 bands pi range: 6.5-8.5
Present Study PAGE at least 2 variants differ in molecular 
weight
IEF 2 variants pi: 6.55 & 7.35
HPLC 2 peaks as eluted 
by ionic strength
vary in proportion 
same as PAGE & 
IEF
I EC - ion-exchange chromatography GFC - gel filtration chromatography
HPLC - high performance liquid chromatography IEF - isoelectric focusing
PAGE • polyacrylamide gel electrophoresis
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ApoTK while a low TPP concentration (under 0.3/zM) would mask the low affinity 
ApoTK (Jeyasingham et al., 1987). Takeuchi et al. (1988) described the analysis of 
TK concentration and activity in human haemolysates and suggested that a heavy 
drinker would have a low concentration of TK thus confirming the findings of 
Greenwood et al. (1984).
Although RBC haemolysates provide a convenient access to enzymatic 
changes, it is the brain enzyme which is particularly relevant to the gene of ApoTK 
(Jeyasingham et al., 1986). A study on rat brain ApoTK was performed by 
Jeyasingham and Pratt in 1988 demonstrating existence of ApoTK in more than one 
form differing in binding affinities with TPP. Kinetic studies performed on rat brain 
ApoTK and its activation by in vitro addition of TPP suggested that one part of the 
apoenzyme reacts rapidly with TPP while the other appears to react slowly. Their 
findings also suggested that HoloTK may be converted to a third form as a result of 
storage changes and conditions. These findings indicate that dissociation of rat brain 
TK can give rise to three forms of ApoTK. The first apoenzyme (ApoTKl) can be 
reactivated by rapid combination with TPP and can be measured directly in the 
presence of MgCl2 (Greenwood et al., 1984; Pratt et al., 1985). The second 
(ApoTK2) can be reactivated by prolonged incubation with TPP (Waring et al., 1982) 
and measured directly in the presence of MgCl2 (Greenwood et al., 1984; Pratt et al., 
1985; Jeyasingham et al., 1987). The last (ApoTK3) cannot be reactivated but can 
be estimated indirectly by firstly measuring HoloTK activity (ApoTKl + ApoTK2) 
and then subtracting it from total TK activity (Jeyasingham & Pratt, 1988). The 
breakdown of HoloTK and formation of Apol, Apo2 and Apo3 is illustrated in 
Figure 4.4.
The likely occurrence of such changes in vivo during thiamine 
deficiency producing TK variants (apoenzymes) also supports the possible role of TK 
in the etiology of WKS (Jeyasingham & Pratt, 1988).
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HoloTK
AP°TK1 ....................................................... -► ApoTK2
*
ApoTK3
(inactive)
HoloTK -* ApoTKl (rapidly binds with thiamine pyrophosphate (TPP) in presence of MgGj) -* HoloTK 
HoloTK -* ApoTKl (slowly binds with TPP in presence of MgCIj) -* low HoloTK 
HoloTK -* ApoTKl (pH dependent and storage duration) -* ApoTK2 -+ ApoTK3
Figure 4.1: Dissociation of holotransketolase (HoloTK) to apotransketolase
(ApoTK) as a result of damage in system secondary to chronic 
alcoholic abuse and thiamine deficiency.
HoloTK:
ApoTKl
ApoTK2
ApoTK3
Stimulated erythrocyte transketolase (ETKs) activity 
- erythrocyte transketolase (ETK) activity 
ETK (low concentration of TPP)
ETKs (high concentration of TPP)
HoloTK - (ApoTKl + ApoTK2)
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4 3 ISOLATION AND CHARACTERIZATION 
OF TRANSKETOLASE
Despite the finding of TK variants and their possible role in WKS it 
remains to be resolved whether such variants are genetically determined (Blass & 
Gibson, 1977; 1979; Nixon et al., 1989; Victor et al., 1989) or are products of a 
damaged system (e.g. post-translational modification) (Pratt et all, 1985; Jeyasingham 
and Pratt, 1988; Lishman, 1990).
There are several clinical and epidemiological observations which 
support a genetic aetiology for WKS. Only a small majority of alcoholics (both TD 
and non TD) and other chronically malnourished persons develop WKS (Victor et al., 
t" 1971; Blass & Gibson, 1979), it occurs more frequently in Europeans than non-
i  Europeans on a similar thimaine deficient diet whereas Asians develop "wet” cardiac
beri beri (Sauberlich, 1967) and some WKS patients have failure of restoration of 
ETK activity despite addition of TPP in vitro (Sauberlich, 1967; Blass & Gibson, 
1979).
In an attempt to investigate the presence of a genetic component, 
homogenous TK from a normal control was isolated and characterized with regard 
to pi value, MW and amino acid composition. Three purification methods were 
tested prior to the final isolation of TK.
The purification of TK from WBC was attempted using the method of 
Mocali & Paoletti (1989). They described three conventional steps employing 
desalting by gel filtration, ammonium sulphate fractionation (45-90%) and affinity 
chromatography. Their sample was prepared from fresh leukocytes obtained from 
two healthy blood donors. In this study packed leukocytes were prepared as 
described by Mocali and Paoletti (1989) and desalted by gel filtration. By plotting 
the protein absorbance against elution time, only one peak containing TK activity was 
eluted. This was subjected to protein fractionation after which TK activity became 
insufficient for further purification. The outcome of this purification method was not 
as successful as described by Mocali and Paoletti possibly due to any or all of the
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following reasons. The starting material in this study was one third the volume of 
the described method (Molcali & Paoletti, 1989) and the isolation of IX  was not 
obtained from fresh leukocyte preparation. The packed leukocytes were subjected to 
several freeze/thaw cycles which could have also resulted in loss of activity. 
Moreover, the ammonium sulphate fractionation may have resulted in further loss of 
TK activity. This method was also shown to be expensive, time-consuming, and to 
require a source of TK (leukocytes) which is inconvenient to obtain in large 
quantities. The results in the present study employing this method was compared to 
the findings of Mocali & Paoletti (1989) in Table 4.3.
Since erythrocytes are conveniently available in the required quantities 
(i.e. 50ml), the isolation of TK was attempted employing ion-exchange 
chromatography and advanced chromatographic methods (FPLC) as described by 
Takeuchi et al. (1986). In the present study, several of the steps described (Takeuchi 
et al., 1986) were modified. Different column materials were used but similar elution 
profiles of ETK activity and similar yields were obtained from the first ion-exchange 
step. Takeuchi and associates employed DEAE-Sephadex for the first purification 
step; however, in the present study fast flow DEAE-Sepharose (Pharmacia) was used 
because it had a higher tolerance for strong ionic buffers and better resolution for 
proteins than DEAE-Sephadex. In the present study two well-resolved ETK activity 
peaks were eluted with a trace of a third ETK activity peak whereas Takeuchi et al. 
(1986) reported the elution of a well resolved third ETK activity peak. This 
discrepancy could result from their use of outdated RBC or from the reaction of 
oxyhaemoglobin present in the third peak with NADH and R-5-P in TK assay 
(Grudzinski et al., 1989). The latter would be a more likely explanation for the 
production of an artifact since Hb was also eluted in that third peak. The third peak 
was not resolved in this study possibly because fresh RBCs were used but more 
likely because a more specific enzymatic assay was used for estimating ETK activity 
whereas a colormetric method was used by Takeuchi et al. (1986) Takeuchi et al.
(1986) reported further resolution from the fraction in peak B into three ETK peaks 
on Mono P which they claimed to represent the same elution profile. In the present
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Table 4.3: Comparison of results obtained by the purification of transketolase
from leuckocytes using the method of Mocali and Paoletti (1989) 
(M & P). In the present study (PS) the dry weight of leukocytes was 
3.0g and in Mocali & Paoletti 10-12g.
STEP Total Volume 
(ml)
Total Protein 
(mg)
Specific Activity 
(TU/mg)
PS M & P PS M & P PS M & P
Crude extract 30 105 75 665 0.0037 0.031
DEAE Column 72 212 54 155.6 0.0103 0.154
Ammonium Sulphate 
Fractionation (45-90%)
91 15 34 67.9 0.014 0.249
Table 4.4: Comparison of results obtained by the purification of transketolase
from packed red blood cells (RBC’s) using the method by Takeuchi 
et al. (1986). This table summarizes the four purification steps 
performed in this study and compares them to those in the Takeuchi 
et al. (1986) report. In the second purification step, desalting was 
performed with dialysis tubing whereas in Takeuchi’s method 
desalting was performed on a gel Alteration column. These results are 
those obtained from peak B only. 36ml of packed RBC was used 
whereas Takeuchi et al. (1986) used 100ml RBC.
STEP Total Protein (mg) Total Activity 
(nmol/min)
Yield (%)
Present
Study
Takeuchi 
et a l 
(1986)
Present
Study
Takeuchi 
et a l  
(1986)
Present
Study
Takeuchi 
et aL 
(1986)
Haemolysate 20,563 83,000 2376 142,000 100% 100%
IEC 30.6 500 427 26,700 18% 18.8%
Desalting 18.2 5.6 274.47 9,560 11.55% 6.7%
FPLC 
(sum of all 
peaks eluted)
0.11 2.2 238.78 5,970 0.54% 4.2%
IEC - Ion Exchange Chromatography FPLC - Fast Protein Liquid Chromatography
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study, following dialysis, the fractions from peaks A and B were subjected to FPLC 
on Mono Q instead of Mono P and the gel filtration step was omitted. Both fractions 
in peaks A and B were resolved into two further peaks by FPLC on Mono Q. This 
resulted in appreciable loss of TK allowing only sufficient material for SDS-PAGE 
analysis. This loss of TK may have resulted from the retention of TK on Mono Q. 
The comparison of findings between the present study and to those of Takeuchi et 
al. (1986) are summarized in Table 4.4. A sample from fraction B was analyzed on 
SDS-PAGE to estimate the MW of TK TK migrated as a single band with MW 
about 68kD as reported by Takeuchi et al. (1986). Despite achieving high purity of 
TK using this method it was too laborious, time-consuming and expensive and 
resulted in only 4.2% yield.
Therefore a third purification method for the isolation of TK from 
erythrocytes was attempted employing electrophoretic techniques (Jamieson, 1983) 
used previously for the partial purification of ETK from normal controls and patients 
with WKS. This is the first method described for the purification of TK that employs 
rapid, cheap and convenient electrophoretic methods. It also provides sufficient (i.e. 
250mg) protein for the qualitiative analysis (i.e. MW, IEF, HPLC) and amino acid 
analysis of TK. The isolation of TK from fresh haemolysate of a normal control was 
achieved in four steps involving PAGE, dialysis, SDS-PAGE and western blotting.
The isolated TK was shown to separate into two bands both in SDS- 
PAGE and IEF with estimated MW of 51 and 35kD and pi value of 7.35 and 6.55 
and into two peaks eluted by ion exchange HPLC varying in ionic strength. Similar 
MW estimations were reported by Warnock and Prudhomme (1982) and similar pi 
values were also reported by Kaczmarek and Nixon (1983), Kaufmann et al. (1987) 
and Paoletti et al. (1988) (Table 4.2). Others have reported different MW estimation 
for TK by various purification method (Table 4.5). In 1971 Henrich and Wiss 
reported the MW of whole TK molecule to be 136kD. There is a lack of agreement 
on the exact MW of TK. However, all reports on the purification of TK (with the 
exception of Takeuchi et al., 1986) have described TK to be heterogenous comprising 
of at least two variants (Wamock & Prudhomme, 1982; Greenwood et al., 1984; Pratt 
et al., 1985; Jeyasingham & Pratt, 1988; Sheu et al., 1988; Mocali & Paloetti, 1989).
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Table 4.5: Summary of the various purification methods reported. Results from
the purification method by electrophoretic techniques in this study 
were compared to the reports given.
Report Purification
Techniques
Source Purification
(-FOLD)
Method of 
MW 
estimation
MW of 
TK(kD)
Wamocke & 
Prudhomme 
(1982)
IEC RBC 400 SDS-PAGE 3 variants: 
50-60, 26- 
30 & 33
Takeuchi et al. 
(1986)
IEC & FPLC RBC 16,000 GFC
SDS-PAGE
104 
2 subunits 
(70)
Himmo et al. 
(1988)
Affinity
Adsorption
RBC 6,200 PAGE 140
Sheu et al. 
(1988)
Immunoaffinity brain - SDS-PAGE 2 variants: 
72 & 70
Mocali & 
Paoletti (1989)
GFC & 
Affinity 
Adsorption
WBC 327 SDS-PAGE
GFC
2 subunits 
(66) 
135 ± 4
Present Study PAGE & 
western 
blotting
RBC 5.4 SDS-PAGE 2 variants: 
51 & 35
IEC & FPLC RBC 2076 SDS-PAGE 68
MW - molecular weight in kiloDaltons 
IEC - Ion exchange chromatography 
RBC - Red blood cells 
SDS-PAGE - SDS-polyacrylamide gel electrophoresis
FPLC - Fast performance liquid chromatography 
GFC - Gel filteration chromatography 
WBC - white blood cells
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The findings in the present study have also confirmed this heterogeneity. The 
disagreement on the heterogeniety of TK by Takeuchi et al (1986) may have arisen 
from racial differences. This may be evident because different susceptibility to WKS 
exists between the Caucasian and Asian races.
The discrepancy in the MW of TK among the various reports can 
result from changes caused by the different purification methods applied. Acylation 
and glycosylation of a protein can change its MW and so can other chemical and 
enzymatic events such as proteolysis. This was evident in this study since the 
purification of TK by chromatographic techniques (Takeuchi et al., 1986) showed the 
MW of ETK to be 68kD while by electrophoretic techniques the MW of ETK was 
estimated to be 51 and 35kD. This difference in TK migration on SDS-PAGE may 
have also arisen from the different buffer systems used (i.e. a continuous buffer was 
used in the former and a discontinuous buffer in the latter).
The amino acid composition of both TK bands was analysed using the 
material isolated from fresh erythrocytes of a normal control using electrophoretic 
technqiues. There has been only one report on the amino acid composition of TK 
(Takeuchi et al., 1986). These findings were compared to the findings in this study 
(Table 4.6). Statistical analysis employing Kendall's test showed the reported amino 
acid composition (Takeuchi et al., 1986) to have a highly significant (Z = 2.97, 
prsO.Ol) positive correlation with the 51kD TK and a signficant (Z = 2.57, p^O.05) 
with the 35kD TK in the present study. Other reports on the amino acid composition 
of TK included that of Kuimov et al. (1988) who described chemical modification 
methods which allowed the detection of specific groups essential for the activation 
of TK. These comprise carboxyl group, tryptophan, histidine and arginine residues 
which have also been detected in the study (Tables 3.8 and 3.9). Kuimov et al. 
(1988) also suggested that HoloTK was inhibited more slowly than ApoTK due to 
the presence of a tyrosine residue in the enzyme's active site. Moreover, the 
dependence of TK inhibition rate on the concentration of H+ ions suggests the 
inhibition of a tyrosine residue.
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Table 4.6: Amino acid composition (molar ratio %) of the isolated erythrocyte
transketolase (TK) in the present study and in the Takeuchi et al. 
(1986) study. Takeuchi et al. performed amino acid composition on 
the TK peaks eluted from Mono P by fast performance liquid 
chromatography.
Amino Acid Takeuchi et aL 
(1986) 
composition (%)
Present Study 
composition (%)
Occurrence 
in Proteins
(%)*
Peak I Peak II 51kD 35kD
Aspartic Acid (D) 9.7 9.9 11.95 7.39 5.5
Glutamic Acid (E) 10.9 11.2 7.43 6.62 6.2
Serine (S) 7.1 6.9 11.85 6.31 7.1
Glycine (G) 8.0 7.9 6.62 8.85 7.5
Histidine (H) 3.0 3.0 3.90 5.24 2.1
Arginine (R) 4.8 4.8 2.00 2.27 4.7
Threonine (T) 5.5 5.6 5.20 6.06 6.0
Alonine (A) 10.8 11.2 9.29 13.56 9.0
Proline (P) 2.5 2.4 7.18 5.75 4.6
Tyrosine (Y) 2.7 2.5 3.32 2.17 3.5
Valine (V) 6.2 6.4 7.12 11.60 6.9
Methionine (M) nc nc 0.73 0.73 1.7
Isoleucine (I) 7.7 7.5 4.45 - 4.6
Leucine (L) 7.8 8.2 9.58 13.90 7.5
Phemylamine (F) 5.3 5.1 3.98 4.98 3.5
Lysine (K) 7.6 7.5 5.39 4.58 7.0
nc = not counted although had been detected
* Frequency of occurrence of each amino acid residue in the primary structures of 207 unrelated proteins of 
known sequence values were obtained from M.H. EQapper, Biochemistry Biophysics Research Communications, 
78: 1018-1024, 1977 (Creighton, 1983).
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In the present study, amino acid sequence of 15 residues was obtained 
for the 35kD peptide. This sequence was compared in the Gen Bank Database for 
exisiting homologies which had verified the obtained sequence to be unique. The 
sequence of the smaller TK peptide indicates the N-terminal of TK to be 
hydrophobic. No sequence was obtained for the 51kD TK peptide due to N-terminal 
blockage which can occur from the chemical modifications of the N-terminus by 
either the buffers used in SDS-PAGE and western blotting or by post-translational 
modification. The buffers used in this study were not the cause of the blockage since 
all precautions were taken to avoid such an event, and since one peptide (35kD) was 
sequenced from the same SDS-PAGE - PVDF membrane. Therefore it would appear 
that the blockage may have arisen by post-translational modification. It has been 
suggested that greater than 75% of all intracellular proteins of eukaryotic cells have 
blocked N-termini and are resistant to the Edman degradation method as a result of 
post-translational modifications (i.e. enzymatic processes following the biosynthesis 
of proteins). Such modifications may occur due to the clipping off of amino acids 
at the N or C termini by peptidases, acylation of the amino terminus, glycosylation, 
phosphorylation or sulphation of certain amino acids. The report by Kuimov et al. 
(1988) has illustrated the inhibition of TK during acetylation by N-acetylimidazole 
rendering TK susceptible to acetylation (Baines & Davies, 1988; Lishman, 1990). 
This may also imply that the N-terminus of the 51kD peptide is the active site of TK 
(binding region with coenzyme TPP) since kinetic data (Kuimov et al., 1988) has 
shown the acetylation of at least one amino acid residue (tyrosine) would be 
sufficient for TK inactivation (Kuimov et al., 1988). There have been no reported 
TK sequences except that of Hawkins et al. (1989) who described a common 
structural motif in TPP binding enzymes such as transketolase formaldehyde in E.coli.
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4.4 CONCLUSION AND FUTURE PROSPECTS
Preliminary work on the quantitative and qualitative analysis of TK has 
not resolved the role of this enzyme in the WKS as postulated by others (Sauberlich, 
1984; Victor et al., 1989). Qualitative analysis and the successful isolation and 
characterization (in particular, amino acid composition) of TK in this study has 
confirmed the heterogeneity of TK (Kaczmarek & Nixon, 1983; Pratt et al, 1985; 
Kaufmann et al., 1987; Paoletti et al., 1989) and the existence of at least two variants 
differing in MW, pi value, ionic strength and amino acid composition. The role of 
these variants in WKS remains to be resolved. On close examination, the 
electrophoretic profile of silver stained TK showed the two variants may be present 
in different quantities. It had been suggested (Blass & Gibson, 1977; Greenwood et 
al., 1989; Pratt et al., 1985; Thomson et al., 1987; Jeyasingham et al., 1987) that the 
smaller molecule of TK represented the ApoTK which would be present in larger 
quantities in patients with WKS and that the larger molecule (HoloTK) would be in 
larger quantities in normal individuals.
Results obtained from MW estimation and amino acid analysis of TK 
have confirmed its susceptibility to post-translational modifications. This had also 
been observed by others (Pratt et al., 1985; Takeuchi et al., 1986; Mocali & Paoletti, 
1989). To establish whether such modifications are genetically determined (Blass & 
Gibson, 1977; Kaczmarek & Nixon, 1983; Nixon, 1984; Paoletti et al., 1989; Victor 
et al., 1990) or are products of a damaged system induced by thiamine depletion and 
ethanol intoxication (Freund, 1973; Pratt et al., 1985; Jeyasingham & Pratt, 1988; 
Lishman et al., 1990) molecular genetic techniques must be employed for the cloning 
and characterization of the TK gene. This would also allow the study of the 
interaction between the environment and heredity in the pathogenesis of WKS and 
its mode of inheritance. It would also provide means for population screening of 
those who are susceptible to TD and/or WKS, thus assisting in the reduction of 
incidence of such disorders.
In 1990 Singleton et al. reported the cloning and characterizations of the 
human TK gene. They described the isolation of two cDNA clones specific to TK
150
as detected by TK polyclonal antibodies. The nucleotide and amino acid sequence 
of 60% of the gene had been predicted (Singleton et al., 1990) although this was not 
published. The amino acid sequence described in the present study may be used as 
a template for the synthesis of oligonucleotides and for the cloning of the 35kD gene. 
However, due to the number of degenerate codons in the 15 amino acid residues 
sequenced (Table 3.10) it would be essential to obtain more sequence data for the 
35kD protein and to sequence the 51kD protein which is N-terminally blocked. As 
an alternative approach, the peptide can be fragmented into smaller peptides by 
cleaving agents specific for amino acid pairs. The number of fragments obtained 
must be controlled by employing site-specific proteases or chemicals for digestion of 
specific residues when molar ratios are known. These ratios can be obtained from 
amino acid composition analysis. For example, in this study, methionine was 
estimated to have a molar ratio of 0.73%, therefore cynanogen bromide (CNBr) can 
be used for cleavage at methionine-serine and methionine-threonine bonds 
(Matsudaira, 1989). These would result in the cleavage of the 51kD TK peptide into 
a few smaller peptides in which internal sequences can be obtained thus avoiding N- 
terminal blockage in such circumstances.
To synthesize a highly specific TK clone it would be best to obtain 
oligonucleotides that are low in degenerate codons and from various points on the 
peptide sequence. Another approach would be the synthesis of monoclonal antibodies 
using purified TK prepared by the PAGE purification method described in this study. 
This would then enable the cloning of a cDNA library specific to TK. Finally, the 
gene for TK can be determined by localizing and sequencing the nucleotides of the 
TPP binding site from the common motif in gene clones of PDH and aKGDH and 
then screening for the TK gene in erythrocytes (since TK is the only enzyme in RBC 
which utilizes TPP) by the elimination of the known PDH and aKGDH genes.
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APPENDIX Is List of Samples from Normal Controls
Red blood samples collected from normal controls at different times and 
stored at -20°C in buffered citrate glycerol.
Collection & 
Storage Date
Label No. Sex Age
25/4/1989 100180 M 40
25/4/1989 100181 F 38
25/4/1989 100182 M 34
25/4/1989 100183 F 37
25/4/1989 100184 F 22
25/4/1989 100185 M 27
25/4/1989 100186 M 29
6/7/1989 100187 M 22
6/7/1989 100188 M 26
6/7/1989 100189 M 25
6/7/1989 100190 F 22
6/7/1989 100191 F 21
22/6/1989 100192 M 30
20/7/1989 100193 M 30
25/4/1989 100123 F 37
25/4/1989 100124 M 31
25/4/1989 100125 F 22
6/7/1989 100126 M 25
6/7/1989 100127 M 26
30/10/1989 100128 F 30
30/10/1989 100129 F 21
20/12/1989 100130 F 22
20/12/1989 100131 M 31
20/12/1989 100132 F 39
20/12/1989 100133 M 41
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APPENDIX II: Materials and Reagent Concentrations 
(All reagents were purchased from Sigma and Merck unless stated otherwise)
II.1 Drabkin's Solution for Haemoglobin Estimation 
(stable for several months at 4°C in dark bottle)
200mg K Fe3 CN6 Potassium Ferricyanide
50mg KCN Potassium cyanide
140mg KH2P04 Potassium dihydrogen orthophosphate
0.2 Reagents Used in Transketalase Assay 
II.2a Materials for section 2.1.4.1 and 2.1.4.2
1% Titron X-100
0.1 M Tris-HCl pH7.6 - stable for 1 month at 4°C. 
14mM Ribose-5-phosphate in 0.1M tris-HCl pH 7.6 
4.16% GDH + 6.25% TPI + 89.58% Tris HC1 pH 7.6 
lOmM NADH in 0.1M Tris-HCl pH 7.6 
lOmM TPP in 0.1M Tris-HCl pH 7.6
n.2b Materials for section 2.1.4.3
same materials as above (II. 2a)
1.2mM MgCl2
7.0mM Xylulose-5-Phosphate
113 Reagents for Starch Gel and Cellogel Electrophoresis
(All buffers are stable for several weeks at 4°C)
10 X Anode Buffer, pH 9.2:
2.52% (w/v) Trizma-Base 
0.25% (w/v) EDTA 
0.9% (w/v) Boric Acid
10 X Cathode Buffer, pH 8 .6 :
0.515% (w/v) Sodium Barbitone 
0.092% (w/v) Barbitone
Gel Buffer:
50% Cathode Buffer 
50% Anode Buffer
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n.4 Reagents for Polyacrylamide gel electrophoresis 
(Section 2.1.53 ,  2.2.1)
(All solutions stored at 4°C unless stated otherwise) 
Glycerol
Bromophenol Blue 
0.1% Triton
Tank Buffer:
Tris-Glycine Buffer pH 8.2 (x 10)
0.6% Trizma Base 
2.9% Glycine
Gel Solution (stable for 1 week):
29.1% Acrylamide + 0.9% DHEBA
0.14% Ammonium Persulphate 
0.28% TEMED (made up fresh)
D.5 Reagents for Transketolase Staining Method
n.5a Starch Gels and Cellogel Stain
0.1m Tris-HCl pH 7.6 (store at 4°C, stable 1 month)
5.2mM Ribose-5-phosphate
l.lm M  Xylulose-5-phosphate
l.OmM NAD
500U GDH
0.05mM Phenazine Methasulphate 
0.5mM NitroBlue Tetrazolium 
0.5mM MgCl2 
2.0mM Sodium Arsenate
n.5b Polyacrylamide Gel Stain
0.1m Tris-HCl pH 7.6 (store at 4°C, stable 1 month)
5.2mM Ribose-5-phosphate
l.lm M  Xylulose-5-phosphate
l.OmM NAD
500U GDH
0.05mM Phenazine Methasulphate 
0.5mM Methyl Thiazolyl Tetrazolium 
0.5mM MgCl2 
2.0mM Sodium Arsenate
n.6 Reagents for Coomassie Brilliant Blue R-250 Stain
45% (w/v) Methanol 
10% (w/v) Acetic Acid
0.1% (w/v) Coomassie Brilliant Blue R-250 (SIGMA)
0 .7  Reagents for Silver Stain
(Bio Rad’s Silver Stain Kit)
10% Oxidising Reagent (Potassium dichromate and Nitric Acid)
(made up fresh)
10% Silver Concentrate Reagent (Silver Nitrate) - made up fresh
3.2% Developer (Sodium Carbonate and Foraformaldehyde) - can be stored
for one month at room temperature
n.8 Reagents for Isoelectric Focusing
Gel solution:
29.1% Acrylamide - stored at 4°C 
0.9% Bis-Acrylamide - stored at 4°C
1% Ammonium Persulphate 
87% Glycerol - stored at 4°C
Electrode Buffer:
IM Sodium Hydroxide 
1M Ortho-phosphoric Acid
Ampholines (PI 3-10 PHARMACIA -LKB) 
pi markers (3.5-10 PHARMACIA -LKB)
n.9 Reagents for SDS-Polyacrylamide Gel Electrophoresis
n.9a Sample Buffer for SDS-PAGE
6% 1M Tris pH 6.8 
10% of 20% SDS
20% Glycerol - Store at 4°C 1 week 
10% P-Mercaptoethanol 
53% DHjO
1% of 0.1% (w/v) Bromophenol Blue
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n.9b Reagents for SDS-PAGE in section 2.2.2.2, 2.5.1
Anode Buffer: 0.2M Tris-Buffer, pH 8.9 
Cathode Buffer, pH 8.25 (Adjust with Tricine):
0.1M Tris-Buffer 
0.1M Tricine 
0.1% SDS
Gel Buffer, pH 8.45 (Store at 4°C 1 week):
3M Tris Buffer 
0.3% SDS 
Polyacrylamide gel solution:
48% acrylamide 
1.5% Bis-acrylamide
SDS-PAGE molecular weight marker 20-215kD
H.9c Reagents used for SDS-PAGE in section 2.4.4.2
20% SDS (store at room temperature for 1 week)
1M Tris pH 6.8  (store at room temperature for 1 week) 
1M Tris pH 8.8  (store at room temperature for 1 week) 
10% Ammonium Persulphate (make up fresh)
TEMED
Polyacrylamide gel solution (store at 4°C for 1 week): 
30% Acrylamide 
0.8% Bis-Acrylamide 
Iso Butanol
Running Buffer, pH 8.3 (store 4°C for 1 week):
0.3% (w/v) Trizma-Base 
1.44% (w/v) Glycine 
0.5% (w/v) of 20% SDS
Bovine Albumin Serum (MW marker 67kD)
n.10 Reagents for Kinetic Assay of TK (section 23.1)
0.1M Tris-HCl pH 7.6
15mM Ribose-5-phosphate
70mM Xylulose-5-phosphate
lOmM NADH in 0.1M Tris-HCl pH 7.6
40ml GDH/TPI in 0 .1M Tris-HCl pH 7.6
lOmM MgCl2 in 0.1M Tris-HCl pH 7.6
lOmM TPP in 0.1M Tris-HCl pH 7.6
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APPENDIX HI: Endpoint Assay Raw Data
Table m .l: Optimizing the endpoint assay. All samples tested were normal
controls (Appendix I). Results were summarized in Table 3.2 and are 
averages of duplicates and replicates.
Table m .la: Various modifications of erythrocyte transketolase (ETK) assay to 
obtain full activation and reduce haemoglobin interference.
Sample Hb conc. 
(g/dL)
Boiling
m
Sample
sHb)
Incubation in Shaker 
Bath (IU/gHb)
ETK ETKs
activity
ETK ETKs
activity
100180 39.3 0.51 0.27 0.70 0.35
100181 35.9 0.56 0.29 0.24 0.10
100182 30.7 0.54 0.28 0.67 0.37
100183 32.0 - - 0.35 0.18
100184 35.1 0.32 0.30 0.56 0.35
100185 34.5 0.52 0.27 - -
100186 35.1 0.39 0.40 - -
Table HI.lb: Various modifications of ETK activity assay.
Sample Hb conc. 
(g/dL)
Heating Sample 
(IU/gHb)
Addition of 
20% NaOH 
(IU/gHb
100180 42.8 0.48 0.25
100181 40.1 0.35 0.27
100182 40.7 0.20 0.33
100183 39.4 0.24 0.26
100184 110.1 0.40 0.15
100185 39.1 0.34 0.41
100186 37.3 0.35 -
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Table m.lc: Various modications of ETK activity assay and its activation (ETKs) 
to enhance the binding of apoenzyme to coenzyme.
Sample Hb conc. 
(gm/dL)
+ MgCl2 
(IU/gmHb)
+ DTT 
(IU/gmHb)
+ MgClj + DTT 
(IU/gmHb)
ETK ETKs ETK ETKs ETK ETKs
100180 35.7 0.53 0.74 - - - -
100181 37.5 0.47 0.45 0.56 0.63 0.72 0.67
100182 41.9 0.63 0.61 0.92 0.54 0.66 0.61
100183 37.2 0.66 0.55 0.52 0.46 0.70 0.65
100184 38.2 0.31 0.73 0.60 0.41 - -
100185 35.9 0.43 0.39 0.76 1.01 0.73 0.63
100186 35.9 0.52 0.34 0.20 - 0.46 0.47
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Table HI.2: Application of erythrocyte transketolase (ETK) activity assay and its
stimulation (ETKs) expressed in IU /L of haemolysate and IU /mg of 
protein on 20 patients and 10 normal controls. All data shown are 
averages of duplicates and were summarized in Table 3.4.
Sample Total
Protein
(mg)
aOD
(Au)
Time
(min)
ETK 
(aOD / 
min)
aOD
(Au)
Time
(min)
ETKs
(aOD
/min)
ETK
activity
(IU)
(/L) (/mg)
ETKs activity
(IU)
C/L) (/mg)
TPPE
%
100100 1.11 - - - - - - * - - * -
100101 1.09 0.05 70 0.0007 0.086 70 0.0017 5.68 0.310 1035 0.578 86.45
100102 1.05 0.67 70 0.0010 0.119 70 0.0017 8.12 0.464 13.80 0.789 70.04
100103 1.12 0.033 70 0.0005 0.076 70 0.0011 4.06 0.220 8.93 0.476 116.36
100104 1.16 0.021 70 0.0003 0.061 70 0.0009 2.44 0.126 7.31 0.377 199.21
100105 1.06 0.049 70 0.0007 0.078 70 0.0011 5.68 0.320 8.93 0.503 57.19
100106 1.12 0.070 70 0.0010 0.090 70 0.0013 8.12 0.433 10.55 0.563 30.02
100107 1.11 0.052 70 0.0007 0.078 70 0.0011 5.68 0.307 8.93 0.483 57.33
100108 1.18 - - * - - - - - - - •
100109 1.17 0.075 70 0.0011 0.092 70 0.0013 8.93 0.458 10.55 0.541 18.12
100110 1.18 0.063 65 0.0011 0.154 65 0.0024 8.93 0.452 19.99 0.987 118.36
100111 1.17 0.071 65 0.0011 0.103 65 0.0016 8.93 0.458 12.99 0.666 45.41
100112 1.18 0.032 65 0.0004 0.088 65 0.0014 3.25 0.165 11.37 0.576 249.09
100113 1.15 0.041 65 0.0006 0.100 65 0.0015 4.87 0.253 12.18 0.633 150.20
100114 1.12 0.060 65 0.0009 0.089 65 0.0014 7.31 0.390 11.37 0.606 55.38
100115 1.03 0.099 65 0.0015 0.151 65 0.0023 12.18 0.706 18.67 1.08 52.97
100116 1.01 0.090 65 0.0014 0.122 65 0.0019 11.37 0.679 15.43 0.921 35.64
100117 1.11 0.061 65 0.0009 0.097 65 0.0015 7.31 0.395 12.18 0.658 66.58
100118 1.16 0.100 65 0.0015 0.144 65 0.0022 12.18 0.633 17.86 0.928 46.60
100119 1.04 0.059 65 0.0009 0.129 65 0.0020 7.31 0.424 16.24 0.941 121.93
100120 1.00 - - - - - * - - - - -
100121 1.13 0.051 65 0.0008 0.088 65 0.0014 6.50 0.347 11.37 0.606 74.64
100122 1.01 0.076 65 0.0012 0.093 65 0.0014 9.74 0.581 11.37 0.679 16.87
100123 1.16 0.020 65 0.0003 0.078 65 0.0012 2.44 0.127 9.74 0.506 298.43
100124 1.05 0.048 65 0.0007 0.064 65 0.0010 5.68 0.325 8.12 0.464 42.77
100125 1.13 - • - - - - * - - - -
100126 1.10 0.045 65 0.0007 0.087 65 0.0013 5.68 0.311 1035 0.578 85.85
100127 0.99 0.042 65 0.0006 0.071 65 0.0011 4.87 0.295 8.93 0.541 83.39
100128 1.16 0.021 65 0.0003 0.090 65 0.0015 2.44 0.127 12.18 0.633 398.9
100129 1.07 0.083 65 0.0013 0.144 65 0.0022 10.55 0.594 17.86 1.006 6936
100130 1.20 0.104 65 0.0016 0.144 65 0.0022 12.99 0.650 17.86 0.893 3738
100131 1.20 0.097 65 0.0015 0.127 65 0.0020 12.18 0.609 16.24 0.812 3333
100132 1.17 0.096 65 0.0014 0.135 65 0.0021 1137 0.583 17.05 0.874 49.91
100133 1.14 0.082 65 0.0013 0.164 65 0.0025 10.55 0.555 2030 1.068 92.43
100134 1.02 - - - 0.104 65 0.0016 - - 12.99 0.764 -
100135 1.17 - - - 0.111 65 0.0017 - - 13.80 0.708 -
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APPENDIX IV: Elution Profile of the Standard Amino Acids
-  A p p l i e d  D i o s v a l e o a  177 fl P r o t e i n  S e q u e n c e r  C h r o n a t o a r a n  R e p o r t
SAMPLE . 150 1 92SAB.L0
( I n i t i a t e d  15 Jan  1994 9:33am J
CYCLE SUMMARY :
R e a c t i o n  c y c l e  : BEGIN 
C o n v e r s i o n  c y c l e  : BEGIN
G r a d i e n t NORMAL
D at a  c o l l e c t  t i n e
0 a t a  * n ( « r v » l
I n j e c t  v o lu n e
0 . 0  t o  :
1 . A V>r 
50 o f
CALIBRATION ft 
Baseline Cor-scled Data
I 15 Jan  1992 10:38am  ] 0
5.3 10.0 tS.fl 2D.I
R e t e n t i o n  Time: Minu t e s  
PEAK TA'ULATIC’N : < 100X I n j e c t i o n  ) C a l i b r a t i o n  :
Pe a t R. r i me C. T i ne H e ig h t Pnol Peak R . T i n e C .T in e H e i g h t
111 (•' . in) ( min) ( uAU) 10 ( n i n ) ( n i n ) ( uAU)
,'1=N G 0“ S.  00 23985 79 .94 PRO 18 .93 18.75 13371
SEP 7 10 7 . 0 2 10470 68.27 MET 19 .68 19.52 16932
GIN 7 45 7 . 3 5 13815 64 .29 UAL 2 0 .0 7 19.90 16551
TrIR G 08 7 . 9 8 8772 62.41 OPT 2 1 . 6 5 2 1 . 5 0 17466
GLY 8.  4? s . z e 1 1793 64 .44 22 .4 2 363
GLU 9 37 9 .2 5 1 6680 50.73 22 .5 2 363
OMP 9 77 9 . 5 7 6765 75 . 54 TRP 2 2 .9 0 22 .7 3 20775
ALA 12.18 12 .02 13680 69.08 PHE 2 3 .7 8 23 .6 3 14910
12 37 14652 ILE 2 4 .4 3 24 .2 7 13521
13 38 2100 LYS 2 4 . 8 0 2 4 .6 5 17955
14 32 531 LEU 2 5 .2 7 25 .12 13530
TYF. 15 80 15 .40 15705 63.56
IS 25 573
IS.  75 6414
ARG 17 .37 17 .13 237 2 .43
T a b u l a t  i o n t h r e s h o l d : 300 uAU
2 9 . 0  n i n  
150 uL 
. 0 1 0 0  AU
140192
Pnol
5 8 .0 3  
S 3 . G3 
6 1 .4 0  
6 4 .4 5
5 8 .9 9  
5 7 .G6 
5 9 .2 9  
5 9 .5 5  
5 7 .4 7
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APPENDIX V: Amino Acid Compostion of the 51kD Transketolase Band
flBI ~ 92QR Data Roalvsis Module
Sanple ID: 35301004 RRU ORTH scale : 0.03Z RU
U.O
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Pnol By Height Report
S a n p l e  10:  35301004 ( i n i t i a t e d  12/19/51 1:39pm) BASELINE CORRECTED
T u r n t a b l e  P o s i t i o n  
O a t a  S t a r t  
D a t a  D u r a t i o n  
Peak Ht T h r e s h o l d
2 A 
4 . 0 0  n in  
16 . 00  min 
999 uAU
Sampl ing  I n t e r v a l  
Samples  I n  Run 
O p e r a to r  10 
I n t .  S t d .  Ant
0 . 5  s ec
19
DEREK 
0 pmol
C a l i b r a t i o n  F i l e  
R e f e r e n c e  Time 
R e f e r e n c e  O f f s e t  I 
R e f e r e n c e  O f f s e t  Z
35201HYD 
0 . 0 0  n i n  
0 . 0 0  n i n  
0 . 0 0  n i n
( i n i t i a t e d  12/15 /91  3 :01pm) 
( No ISTD Peak S p e c i f i e d  )
I n t e g r a t i o n  I n t e r v a l :  0 . 0  t o  15.0 n in
PEAK RET. CAL.
10 TIME TIME
min min
A s p a r t i c  Acid 2 . 2 0 2 .1 7
G lu t a m ic  Acid 2 . 5 7 2 .5 4
S e r i n e 3 . 3 5 3 .3 2
S i y c i n e 3 . 7 9 3 .7 5
H i s t i d i n e 4 .2 5 4.21
A r g i n i n e 4.  90 4 .86
T h r e o n in e 5 . 1 4 5 .1 0
A l a n i n e 5 . 5 4 5 .4 9
P r o l i n e 5 . 8 2 5 .7 8
6 . 2 2 -------
T y r o s i n e 8 . 4 9 3 .4 5
V a l i n e 9 .4 9 9 . 45
M e t h io n i n e 9 .7 8 9 .73
I s o l e u c i n e 1 1 . 78 11 .75
Leuc i n e 1 1 . 99 11 . 97
P h e n y l a l a n i n e 12 .52 12.60
13 .15 -------
L y s in e 13 .5 5 13.53
14 .19 —— —• —
Minimum Peak T h r e s h o l d : 999 i
PEAK PMOL PMOL
HEIGHT BY c o r r e c .
uAU HEIGHT I NT STO
31903 401 . 70  0 . 0 0
20555 249 .56  0 . 0 0
22784 3 98 .3 5  0 . 0 0
14192 22 2 .2 8  0 . 0 0
6859 131.17 0 . 0 0
5984 67 .1 6  0 . 0 0
11135 174.74 0 . 0 0
25110 312 .05  0 . 0 0
18226 241 . 29  0 . 0 0
10317 111 .45  0 . 0 0
19634 239 . 39  0 . 0 0
1975 2 4 .4 9  0 . 0 0
9976 149 .39 0 . 0 0
2S518 322.01 0 . 0 0
13655 134.21 0 . 0 0
1033--------- ------------------ ------------------
31097 130.96 0 . 0 0
3796 -----------------  ------------------
( 29 peaks  below t h r e s h o l d  )
( 19 peaks found >
( 16 peaks  matched  )
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Mol Percent Report
S a n p l e  ID: 55501004 ( i n i t i a t e d  12 /13 /51  1:59pm) BASELINE CORRECTED
T u r n t a b l e  P o s i t i o n  
D a t a  S t a r t  
D a t a  D u r a t i o n  
Peak Ht T h r e s h o l d
2 A 
4 .0 0  min 
15.00 min 
999 uAU
Samp l ing  I n t e r v a l :  0 . 5  s ec
S a n p l e s  I n  Run : 19
O p e r a t o r  ID : DEREK
I n t .  S td .  Ant : 0 pno l
C a l i b r a t i o n  F i l e  
R e f e r e n c e  T ine  
R e f e r e n c e  O f f s e t  I 
R e f e r e n c e  O f f s e t  2
35201HYD 
0 .0 0  n in  
0 .0 0  n in  
0 .0 0  min
( i n i t i a t e d  12 /13 /91  3 :0 i pm)  
( No ISTD Peak S p e c i f i e d  )
I n t e g r a t i o n  I n t e r v a l :  0 . 0  t o  15.0 min
PEAK RET. PMOL PMOL
ID TIME BY c o r r e c . MOL
n i n HEIGHT INT STD Z
A s p a r t i c  Acid 2 .20 401 .70 0 .0 0 11 .95
G lu t am ic  Acid 2 .57 249.55 0 . 00 7 .43
S e r i n e 5 .55 398 .35 0 .0 0 1 1 .85
G ly c in e 5 .79 222 .23 0 . 0 0 5 .52
Hi s t i d i n e 4 .25 131.17 0 .0 0 3 .9 0
A r g i n i n e 4 .90 57.  1 5 0 . 0 0 2 .0 0
T h r e o n in e 5 .14 174.74 0 . 0 0 5 .2 0
A l a n i n e 5 .5 4 512 .05 0 . 00 9 .29
P r o l i n e 5 .82 24 1 .29 0 .0 0 7 .1 8
T y r o s i n e S . 49 11 ! . 4 5 0 . 00 3 .32
Va1 in e 9 .49 23S.33 0 . 00 7 . 12
M e t h io n i n e 3.78 24 .49 0 . 0 0 0 . 7 3
I s c l e u c i n e 11 .78 149.33 0 . 00 4 .4 5
L e u c in e 11 .99 322.01 0 . 00 9 .58
P h e n y l a l a n i n e 12.52 134.21 0 . 00 3 .9 9
Lys i n e 15.55 180.95 0 . 0 0 5 .3 9
TOTAL PMOLS RECOVERED 3350 .19
Minimum Peak T h r e s h o l d :  993 uAU ( 2S peak s  be low t h r e s h o l d  >
( 19 peaks  found  >
( 15 peaks  ma tched  >
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Composition Report
S a n p l e  ID: 35331004 ( i n i t i a l e d  12 /19 /91  1:39pm) BASELINE CORRECTED
T u r n t a b l e  P o s i t i o n  
D a t a  S t a r t  
D a t a  D u r a t i o n  
Peak Ht T h r e s h o l d
2 A 
4 . 0 0  min 
I E . 00 min 
999 uAU
Sam pl ing  I n t e r v a l  
S a n p l e s  I n  Run 
O p e r a t o r  ID 
I n t .  S td .  Ant
0 . 5  s ec  
19
DEREK 
0 pmol
C a l i b r a t i o n  F i l e  
R e f e r e n c e  T ine  
R e f e r e n c e  O f f s e t  1 
R e f e r e n c e  O f f s e t  2
35201HYD 
0.00 min 
0 . 0 0  m:n 
0 . 0 0  mm
( i n i t i a t e d  12 /19 /91  3:01pm)  
< No ISTD Peak S p e c i f i e d  ) 
Based  on Mol Ut : 51 0 00 .0 0
I n t e g r a t i o n  I n t e r v a l :  0 . 0  t o  1S.0 min
PEAK RET. PMOL PMOL COMP
ID TIME BY c o r r e c . APPLIED BY
n in HEI6HT INT STD ngns MU
A s o e r t i c  Acid 2 .2 0 401 .70 0 . 00 45 .2 4 57 . 0 5 8
G lu t a m ic  Acid 2 . 5 ? 249 .55 0 .0 0 32 .2 2 3 5 . 4 48
S e r i n e 5 . 55 39 8 .3 5 0 . 0 0 3 4 . 7 0 55 .5 82
G l y c i n e 3 .7 9 222 .28 0 . 00 12 .59 31 .572
Hi s t i d i n e 4 .25 131.17 0 .  00 18 .00 18.531
A r g i n i n e 4 .9 0 57 .15 0 . 00 10 .49 9 .5 39
T h r e o n in e 5 .1 4 174.74 0 . 0 0 17 .57 24 . 8 2 0
A l a n i n e 5 .5 4 312 .05 0.  00 2 2 .1 9 44 .3 24
P r o l i n e 5 . 52 241 .29 0 . 00 2 3 .4 3 34 . 2 7 3
T y r o s i n e 3 . 49 111.45 0 . 00 13 .13 15 .830
V e l i n e 5 .49 239 . 39 0 .0 0 23 .7 2 3 4 . C03
M e t h io n i n e 9 .73 24 .4 9 0.  00 3.21 3 .4 7 9
I s o l e u c i n e 11 . 73 149 .39 0 .0 0 15.91 2 1 . 2 19
Leuc i n e 11 . 99 322.01 0 . 0 0 3 5 .4 5 45 . 733
P h e n y l a l a n i n e 12.52 134.21 0 .0 0 1 9 .7 5 19 .053
L y s i n e 13.55 180.55 0.  00 2 3 .2 0 25 .7 04
TOTAL HASS RECOVERED 0. 35 ugns
CALCULATED MU OF SAMPLE 510 18 .00
Minimum Peak T h r e s h o l d : 999 uAU ( 29 peeks  below t h r e s h o l d  )
( 19 pea ks  found )
( 15 peek s  ma tched  )
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APPENDIX Vis Amino Acid Composition of the 35kD Transketolase Band
RBI ~ 920R Data Analysis nodule
Sanple 10: 3S301005 RRU ORTH scale : 0.021 RU
U.0
176
S a n p l e  ID: 35301005 ( i n i t i a t e d  12/19 /31  2 :28pm) BASELINE CORRECTED
T u r n t a b l e  P o s i t i o n 2 5 S am pl ing  I n t e r v a l :  0 . 5  s ec
D a ta  S t a r t 4 . 0 0  min S a n p l e s  I n  Run : 1 9
D a ta  D u r a t i o n 1B.00 min O p e r a t o r  ID : DEREK
Peak Ht T h r e s h o l d 959 uAU I n t .  S t d .  Ant : 0 pmol
C a l i b r a t l o n  F i l e 35201HYD ( i n i t i a t e d  12/19 /91  3:03pm)
R e f e r e n c e  T ine  
R e f e r e n c e  O f f s e t  1 
R e f e r e n c e  O f f s e t  2
8 .8 8  mm 
0 . 0 0  min 
0 .0 0  m;n
( No ISTD Peak S p e c i f i e d  )
I n t e g r a t i o n  I n t e r v a l :  0 . 8  t o 15.8  min
PEAK RET. CAL. PEAK PMOL PMOL
ID TIME TIME HEI6HT BY c o r r e c .
n i n n i n uAU HEIGHT INT STD
A s p a r t i c  Acid 2 . 17 2 .1 7 10266 129.25 0 . 0 0
51u t a m ic  Acid 2 .55 2 .5 4 9729 115.61 0 . 0 0
S e r i n e 3 .3 3 3 .32 6307 110.27 0 . 0 0
51yc i ne 3 .7 8 3 . 7 5 9879 154.73 0 . 0 0
H i s t  i d i n e 4 .2 3 4.21 4795 91 .53 0 . 0 0
A r g i n i n e 4 .8 9 4.es 3539 39 .72 0 . 0 0
T h re o n in e 5 .1 3 5 . 1 0 5756 185.02 0 . 0 0
A la n in e 5 . 53 5 .4 9 19077 237 .08 0 . 0 0
Pro  1 ine 5 .82 5 .7 8 7559 100.47 0 . 0 0
5.21 ------- 10108 -------------- ------------------
I y r o s  ine 3 .4 9 S . 45 3512 37 .94 0 . 00
Y e l i n e 9 .4 3 9 .45 15535 202 .83 0 . 0 8
M et h io n i ne 9 .77 9 .7 3 1032 12.30 0 . 00
l e u c  i ne 1 1 . 99 1 1 . 97 20017 243 .07 0 . 0 0
P h e n y l a l a n i n e 12.62 12 .50 8857 87 .05 0 . 0 0
13.15 ------- 1058 -------------- --------------
L y s in e 13.55 13 .63 13774 80.16 0 . 0 0
14.18 — — — — — 4358
Minimum Peak T h r e s h o l d : 999 uAU ( 27 peak s be low  t h r e s h o l d )
( 18 p eak s  found  )
( 15 p ea k s  ma t ched  )
Mol Porcent Report
S a n p l e  ID: 35301005 ( i n i t i a t e d  12 /19/91 2 : 2 8 p n )  BASELINE CORRECTED
T u r n t a b l e  P o s i t i o n  
Da t a  S t a r t  
Da t a  D u r a t i o n  
Peak Ht T h r e s h o l d
4.00 min 
1B.00 min 
999 uAU
Sampl ing  I n t e r v a l :  0 . 5  s ec
Samples  I n  Run : 19
O p e r a to r  ID : DEREK
I n t .  S td .  Amt : 0 pmol
C a l i b r a t i o n  F i l e  
R e f e r e n c e  Time 
R e f e r e n c e  O f f s e t  1 
R e f e r e n c e  O f f s e t  1
25201HYD 
0 . 0 0  min 
0 . 0 0  n i n  
0 . 0 0  min
( i n i t i a t e d  12/19 /91  3:03pm) 
< No ISTD Peak S p e c i f i e d  )
I n t e g r a t i o n  I n t e r v a l :  0 . 0  t o  1S.0 min
PEAK RET. PMOL PMOL
ID TIME BY c o r r e c . MOL
min HEIGHT I NT STD Z
A s p a r t i c  Acid 2 . 17 129.25 0 .0 0 7 . 3 9
c l u i a m i c  Acid 2 .5 5 115.81 0 .0 0 5 .6 2
Sen m e 3 .3 3 110.27 0 .00 5 .31
S l y c i n e 3 . 78 154.73 0 .0 0 8 .8 5
H i s t i d i n e 4 .2 3 91 . 58 0 .0 0 5 .2 4
Argi  r,i ne 4 . 6 9 39 .72 0 .0 0 2 .2 7
T h r e o n i n e 5 .1 3 106.02 0 .0 0 6 .0 6
A l a n i n e 5 .5 3 237 .08 0 . 00 13 .55
r r c 1in e 5 .8 2 100.47 0 . 00 5 .7 5
T y r o s i n e 8 .4 9 37 .9 4 0 . 00 2 .1 7
Ve 1 m e 9 .4 9 202 .63 0 . 00 11 .50
M e t h io n i n e 9 .77 12.60 0.  00 0 .7 3
L eu c in e 11 . 99 243 .07 0 .0 0 13 .90
P h e n y l a l a n i n e 12.52 67 .05 0.  00 4 .9 8
L i s i ne 13.55 80 .15 0 . 00 4 .5 8
TOTAL PMOLS RECOVERED 1743.77
Minimum Peak T h r e s h o l d :  999 uAU ( 27 peaks  be low t h r e s h o l d  )
( 18 peaks  found  >
( 15 peaks  ma tched  )
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S a n p l e  ID: 35301005 ( i n i t i a t e d  12/19/91 2:28pm) BASELINE CORRECTED
Turn - t ab l e  P o s i t i o n 2 B Sampl ing  I n t e r v a l :  0 . 5  s ec
O a t a  S t a r t 4 . 0 0  n i n S an p l e s  I n  Run : 19
D a t a  D u r a t i o n 1 E .00 min O p e r a to r  ID : DEREK
Peek Ht T h r e s h o l d 95S uAU I n t .  S td .  Ant : 0 pmol
C a l i b r a t i o n  F i l e 35201HYO ( i n i t i a t e d  1 2 / 1 S / S 1 3:03pm)
R e f e r e n c e  T ine 8 . 8 0  min ( No ISTD r e a k  S p e c i f i e d  )
R e f e r e n c e  O f f s e t  1 0 . 0 0  min Based on Hoi Ut : 3500 0 .0 0
R e f e r e n c e  O f f s e t  2 0 .0 0  n i n
I n t e g r a t i o n  I n t e r v a l :  0 . 0  t o 1 S . 0 mm
PEAK RET. PMOL PMOL COMP
ID TIME 8Y c o r r e c . APPLIED BY
n i n HEI6HT INT STD ngms MU
A s p a r t i c  Acid 2 . 1 7 129.25 0 . 00 1 4 .8 3 24 . 730
S l u t a m i c  Acid 2 .5S 115.51 0 .  00 14.55 2 2 . 15B
S e r i n e 3 .3 3 1 10.27 0 .  00 S . 80 21 .035
G ly c in e 3 .7 3 154.73 0 . 00 8 . 83 29.802
H i s t  i d i n e 4 .2 3 91 . 53 0 .  00 12 .57 17.521
A r g i n i n e 4 . 89 35 .72 0 . 00 S . 20 7 .5 99
T h re o n in e 5 .1 3 105 .02 0 .0 0 10.72 20 .283
A l a n i n e 5 .5 3 237 . 08 0 . 00 15.55 45.355
F r o l i n e 5 . 8 2 100.47 0 . 00 9 .75 19.221
T y r o s i n e 3 .4 9 37 .5 4 0 . 00 5 .1 5 7 . 2 5 3
V a l i n e 9 .4 9 202 .8 3 0 . 00 20.  10 38 . 804
M e t h io n i n e 9 .7 7 12.50 0 .0 0 1.53 2 .4 48
L eu c in e 11 .59 243 .0 7 0 . 00 27 . 52 45 .502
P h e n y l a l a n i n e 12.52 97 . 05 0 .0 0 12.51 <o .554
L y s i n e 13 .55 50 .15 0 .0 0 10 .28 15.335
TOTAL MASS RECOVERED 0. 18 ugms
CALCULATED MU OF SAMPLE 350 18 . 00
Mininun  Peak T h r e s h o l d : 995 uAU ( 27 peaks  below t h r e s h o l d  )
( 18 peaks  found )
( 15 peaks  match* d )
APPENDIX VII: Amino Acid Sequence of the 35kD Transketolase Band
-  R e p l i e d  B i o s u s t e n s  177R  P r o t e i n  S e q u e n c e r  C I » r o r > a t o q r a n  R e p o r t  -
SAMPLE : 150192SA5.LO
i i n i t i a t e d  15 Jen  '552
CYCLE SUMMARY : 
R e a c t i o n  c y c l e  
C o n v e r s i o n  c y c l e  
G r a d i e n t
Da t a  c o l l e c t  t i n e  
Dat a  i n t e r v a l  
I n j e c t  v o l u n e
0 . 0  t o  2 S . 0  n i n
1 . 0  s ec
50 of 150 uL
B L A N K
Besshne Corrected Deia
I 15 Jen 1522 S :* 5 e n  ] C .0100  AU
S.C 1C.0 15.0 20.0
r e t e n t i o n  T ine :  Minu tes  
PEAK TABULATION : ( 1002 i n j e c t i o n  ) C a l i b r a t i o n
Peak R .T in e  C .T in e  
ID <nin> <nin>
He igh t  
< uAU)
Pnol
7 .7 3  
7 .S7  
8 .0 3  
8 .1 7  
9.<2 
8.  £5 
8 .7 5  
S . 00 
2 .07  
5.20 
: s . 5 3
:=. se
iit-
Zi-Z 
21 5
«5S
3£7-C 3
OC i 
C C'
T a b u l a t i o n  t h r e s h o l d  : 300 uAU
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-  A p p l i e d  B l o s t i a t e n s  ^ 7 7 H  P r o t e i n  S e q u e n c e r  C h r o w a t o o r a n  R e p o r t
SAMPLE : 1 50 1 92S.AS. LO
t I n i t i a t e d  15 Jan 15:2 9 : 23an ]
CYCLE SUMMARY :
R e a c t i o n  c y c l e  s ELOTT 
C o n v e r s i o n  c y c l e  : NORMAL
G r a d i e n t NORMAL
Da ta  c o l l e c t  t i n e  
Da t a  i n t e r v a l  
I n j e c t  v o lu n e
0 . 0  t o  0 5 . 0  n i n
1 .0  s e c  
50 o f  150 uL
AMINO ACID #  1
Baashne Corrected Qeta
[ 15 J an  1552 1 1 :24am J 0 . 0 1 0 0  AU
5.0 10.0 15.0 20.0 25.0
R e t e n t i o n  T in s :  Minut es
PEAK TABULATION : ( 100Z i n j e c t i o n  ) C a l i b r a t i o n  : 1401£2
Peak R. T i n e C.T i n e He ig h t Pnol  1 Peak R . T i n e C . T i n e H e i g h t Pnol
ID ( n i n ) ( n i n ) ( uAU) : ID ( n m ) ( n i n ) (uAU)
5 . 5 7 533? 1 FRO 18.83 18 .75 1812 7 . 55
ASN 5 . 9 0 6 . 0 0 7544 25 .44 1 MET 19 .65 19.52 452 1 .74
SEA E .9 5 7 .0 2 17385 113.26 1 UAL 2 0 . 0 5 19.90 82754 307 .03
GLV 8 . 3 7 8 .3 8 20757 113.43 I DPT 21 .6 2 2 1 . 5 0 169962 6 2 7 .1 7
GLU 9 .2 3 9 . 2 5 1550 S . 01 5 TRF 22 . 58 22 . 73 8670 24 .92
DMP 9.7Z 9 .S 7 3638 4 0 .6 0  ! 2 3 .2 0 U S 7
M . 1 2 7S5 ; PHE 23 .7 7 23 .53 1035 4 .0 0
ALA 12 .0 3 12 .02 5484 27 .59  1 ILE 24 .4 3 24 .2 7 960 4 . 2 !
HIS 12 .85 12 .7 5 1 *7 “J* 1.05 I LYS 24 . 52 24 . 65 432 1 .43
13 .90 1-43 : LEU 2 5 .2 7 25 .12 1794 7 .52
TYP 15 .50 15.  40 2274 9 . 20  i
15 .17 1 55 ’
IS.  53 “ 477
17 .87 573
18.42 785
T a b u l a t i o n  t h r e s h o l d  : 300 uAU
181
— f f l p o l i e d  B i o s u s t e w s  ^ 7 7 H  P r o t e i n  S e q u e n c e r  C h r o f i a t o o f ' a n  R e p o r t  -
SAMJIPLE : 150132SAE.LO
C I n i t i a t e d  15 Jan  1932 9 :33am ]
CYCtLE SUMMARY : 
R i e a c t i o n  c y c l e  
C co nve r s i on  c y c l e  
G i r a d i e n t
AMIfNO ACID # 2
Easelnne Corrected Data
3L0TT Da ta  c o l l e c t  t i n e
NORMAL Da ta  i n t e r v a l
NORMAL I n j e c t  v o lu n e
l 15 Jan 1992 12: 1 (5pm 3
0 . 0  t o  2 S . 0  n i n
1.0 s e c  
50 o f  153 uL
0 . 0 1 0 0  AU
A/v\
/ UvAJ X .. . . . . . .
10 .0 1:.0
R e t e n t i o n  Time: Minut es
20.0 210
PEAK TABULATION : ( 100X i n j e c t i o n  ) C a l i b r a t i o n  : 140192
Peakk R.Time C. T ine He igh t Pnol Peak R.T ime C.T ime He igh t Pmol
ID ( min) ( min) ( uAU) ID ( m i n ) ( min) ( uAU)
5 .5S 5585 MET 19 .59 19.52 357 1 . 34
ASN 5 .92 5 . 0 0 8373 27 .87 UAL 2 0 . 0 5 IS.  SC- 6093 2 2 .5 0
SER S . 92 7 .0 2 1 1445 74.  £3 2 0 .3 3 8208
THR 8 . 0 3 7 . 9 8 1541 1 1 .57 DPT 21 .6 2 2 1 . 50 390213 1439 .92
£LY 8 .3 7 3 . 33 21050 1 1 5 . es 2 2 .1 7 5783
SLU 9 .2 3 S . 25 1555 5 .70 TRP 2 2 .8 8 *5 ~!T 7038 ' i 9 . 9 9
DMP 9 . 7 3 9 . 6 7 2736 30 .55 PHE 23 .7 8 23 .53 1 983 7 . 5 7
1 1 .03 345 ILE 24 . 45 24 .2 7 1083 4 .75
11.15 313 LYS 2 4 .3 7 24 .55 159 0 . 5 3
ala 12.02 12 .02 13085 55.05 LEU 2 5 .2 7 25.1 2 29585 121 .84
mIS 12.82 12 .73 292 1 . E7
TYR 15.52 15 .40 34 41 13.33
15.52 2070
17.85 £09
PRO 18.90 18 .75 3141 13.53
Tabiul  a t  i on t h r e s h o l d : 500 uAU
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- -  A p p l i e d  B i o s v s t e n a  1 7 7 R  P r o t e i n  S e q u e n c e r  C h r o n a t o q r a n  R e p o r t  -
S6AMPLE : 150192SAB.LO
C I n i t i a t e d  15 J an  1952 9 :33an  I
CYYCLE SUMMARY :
R e a c t i o n  c y c l e  : BLOTT Da ta  c o l l e c t  t i n e  : 0 . 0  t o  2 9 . 0  m n
C o n v e r s i o n  c y c l e  : NORMAL Oata  i n t e r v a l  : 1 . 0  s e c
G r a d i e n t  : NORMAL I n j e c t  v o lu n e  : 50 of  150 uL
AMMINO ACID # 3  [ 15 Jan  1992 !2 :5 S p n  ] 0 . 0 1 0 0  AU
Bexseline Corrected Data
fII
's .0 .0  10.0  1S.0 20.0  1 5 .0
R e t e n t i o n  T ine :  Minutes  
PBEAK TABULATION : ( 100X i n j e c t i o n  ) C a l i b r a t i o n  : 140152
R.Time C .T i n e  H e ig h t  Pno l
( n i n )  ( n i n )  (uAU)
17 .15 17 .13 51 0 .S 3
17.32 552
18.87 18 .75 3429 14 .83
19.57 19.52 330 1 . 2 4
20 .02  19 .90  3530 14.59
20 .3 7  5300
2 1 . 6 0  2 1 . 5 0  383931 1415.72
22 .6 7  2 2 .7 3  S7S6 15 .2 7
23 .7 5  2 3 . 5 3  2391 3 . 2 5
24 .4 3  2 4 . 2 7  575 2 .9 5
24 .78  24 .5 5  251 0 . 8 7
25 .25  25 .1 2  2 e 2 l 2  119 .83
PeJeak R.T i n e C. T i n e He igh t Pnol Peak
IID < n i n ) ( n i n ) ( uAU) ID
5 . 5 3 4092 AR6
ASSN 5 .9 0 5 . 0 0 6312 21 .01
S . 20 3240 PRO
SEER E. 93 7 . 0 2 12135 79 .13 MET
7KHR 7. 38 7 . 9 e 1026 7 .3 0 UAL
GLiLY 8 .33 8 .3 8 17214 94.07
GLL'J 9 .22 9 . 25 1759 5 . 4 0 DPT
DMMP 9 . 7 0 9 . 6 7 2820 31 .49 TRP
1 1 . 07 518 PHE
ALLA 12.02 12 .02 5531 32 .98 ILE
H11S 12.95 12 .73 96 0 .5 7 LYS
13.38 804 LEU
TYYR 15.48 15 .40 2258 9.15
16.13 1248
16.52 2988
T a ab u l a t  i on t h r e s h o l d : 300 uAU
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-  A p p l i e d  B i o s u a t e n a  1 7 7 f l  P r o t e i n  S e q u e n c e r  C h r o n a t o q r a n  R e p o r t  —
SAMPLE : 1S0192SAS.LO
C I n i t i a t e d  15 Jen 1 S92 i : 33an  ]
CYCLE SUMMARY :
R e a c t i o n  c y c l e  : 3LGTT 
C o n v e r s i o n  c y c l e  : NOF.MAl 
Gr a d i e n t  : NORMAL
Da ta  c o l l e c t  t i n e  
□ a t a  i n t e r v a l  
I n j e c t  vo lun e
0 . 0  t o  2 9 . 0  n i n
1 .0  s e c  
50 o f  150 uL
AMINO ACID #  
Baseline Corrected Data
t 15 J an  i 252 1 : 41 pm ] £ . 0 1 0 0  AU
5.0 10.0 15.0 20.0 25.0
R e t e n t i o n  T in e :  Mi n u t e a
PEAK TABULATION : ( 100X i n j e c t i o n  ) C a l i b r a t i o n  : 140192
Peak R.T i n e C .T i n e H e ig h t Pnol Peak R . T i n e C.T i ne H e i g h t Pnol
ID ( n i n ) ( n i n ) ( uAU) ID ( n i n ) ( n in ) ( uAU)
5 . 5 7 3905 17.13 555
ASN 5 . 9 3 6 . 0 0 5983 C3 ft?. 5 17 .22 17.13 420 4 . 4 0
SER S. 9S 7 .0 2 8513 55 .15 17 .83 1689
SLN 7 . 2 2 7 .2 5 5315 24.74 FRO 18.85 1 5 .75 17504 7 5 .4  1
THR 7 . 9 5 7 . 98 5790 69 .55 MET 1 5 . 5 2 • 3.52 23 0.11
GLY S. 37 8 .3S 1 2555 70 .4! UAL 20 .0 2 13.90 4033 15.15
GLU 9 . 2 2 9 .2 5 1 323 4 .82 2 0 .3 5 2522
DMP 9 . 7 0 9.G7 2712 30.28 OPT 21 . 58 21 .5 0 308829 1139.59
11 . 08 35 5 TP.P 2 2 .8 7 22 .73 5091 14 .4  =
ALA 12 .0 3 12.02 4S2S 24. 42 FHE 2 3 . 7 5 22 .53 1 524 7 . 0 5
HIS 12 .32 12 .73 204 1.21 ILE 2 4 .3 8 24 .27 453 1 .99
1 2 .5 7 305 LYS 24 .80 2 4 . E5 C ~ 1 . 30
TYR 15 .5 0 15.40 1S33 7 .42 LEU 25 .23 25 .12 5096 2 5 .8 9
15 .12 459
15 .5 0 1535
T a b u l a t i o n  t h r e s h o l d  : J00  uAU
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-  A p p l i e d  B i o a v s t e n s  1 7 7 f l  P r o t e i n  S e q u e n c e r  C h r o n a t o q r a n  R e p o r t  -
SAMPLE : l50192SAe.LG
[ I n i t i a t e d  15 J an  19SI 5 : Z3em 1
CYCLE SUMMARY :
R e a c t i o n  c y c l e  : BLOTT 
C o n v e r s i o n  c y c l e  : NORMAL
G r a d i e n t NORMAL
D at a  c o l l e c t  t i n e  
Da ta  i n t e r v a l  
I n j e c t  volume
0 . 0  t o  2 5 . 0  n i n
1.0 s e c
50 of  150 uL
AMINO ACIO U  5 I IS Jan 1952 2 :27pm 2 0 . 0 1 0 0  AU
Baseline Corrected Data
1 0 . 0 2 0 .0
R e t e n t i o n  T ine :  Minu te s
PEAK TABULATION : ( 100Z i n j e c t i o n  ) C a l i b r a t i o n  : 140152
Peak R .T i ne C.T i n e H e i g h t Pnol Peak R.T i n e C.Time He ig h t Pn o l
ID ( n i n ) ( n i n ) ( uAU) ID ( n i n ) ( n i n ) (uAU)
5 .5 5 2475 PRO 18 .8 7 18.75 205S2 8 9 .7 7
ASN 5 . 52 5 . 0 0 5763 15.18 MET 19 .55 19 .52 351 1 .32
5ER S . 55 7 . 0 2 7555 52.  13 UAL 2 0 . 0 3 15 .90 5613 20 .6 2
GLN T . 35 5442 25 .33 2 0 . 3 5 3818
▼ up 7 .5 5 7 . 5 3 1847 1 1 .72 DPT 2 1 . 6 0 2 1 . 5 0 461283 1702 .15
GLY 6 .35 8 . 3 8 1 1460 = 2 .62 TRP 2 2 . 8 7 2 2 . 7 3 824! 23.4C
GLU 5.22 5 . 2 5 2334 5 .50 PHE 2 3 .7 5 23.  S * 274= 10.61
DMP 9 . 58 9 .G7 3060 34. 17 ILE 2 4 . 4 3 2 4 . 2 7 4 4 4 1 .55
ALA 12.03 12 . 02 20585 105.98 LYS 2 4 . 7 5 24 .6 5 375 1 .24
HI5 12.50 12 .73 155 0.  52 LEU 2 5 . 2 5 25 .12 381 0 15.13
TYR 15.52 15 . 40 2SS7 10.79
15.02 381
15.52 1560
nP.G 17.15 17 .13 560 6 . 22
17.83 515
T a b u l a t i o n  t h r e s h o l d  : 300 uAU
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-  A p p l i e d  B l o s v s t e n s  - 1 7 7 R  P r o t e i n  S e q u e n c e r  C h r o n a t o q r a n  R e p o r t  -
SAMPLE : 150192SAB.LO
C I n i t i a t e d  IS Jan 1952 9:33am 3
CYCLE SUMMARY :
R e a c t i o n  c y c l e  : E'LQTT 
C o n v e r s i o n  c y c l e  : NORMAL 
G r a d i e n t  : NQPMAL
Oat a  c o l l e c t  t i n e  
Da t a  i n t e r v a l  
I n j e c t  volume
<3.0 t o  2 9 . 0  n i n  
l . 0 s e c  
50 of  150 uL
AMINO ACID U  S 
Bewiine lorrested Data
t 15 Jen  1992 3 : 13pm ] 0 .0 1 0 0  AU
10.0
R e t e n t i o n  Time: Minu te s
PEAK TABULATION : ( 1001 i n j e c t i o n  ) C a l i b r a t i o n  : 140192
Peak R . T i n e C.T i n e H e ig h t Pnol Peak R . T i n e C.T i n e He igh t P n o l
ID ( n i n ) ( n i n ) ( uAU) ID < n i n ) ( n i n ) (uAU)
ASN S . 83 6 . 0 0 1 4585 48 .88 MET 19.65 19 .52 390 1 . 47
SEP. 6 .  97 7 .0 2 7630 50 .08 UAL 20 .0 2 19 .90 4397 18 .13
SLN 7 . 2 3 7 . 3 5 5658 26 .33 2 0 .3 3 2629
'HR 7 . 9 5 7 .9 8 1 305 9 .28 OPT 21 . 6 0 2 1 . 5 0 366618 1352 .83
GLY 9 . 3 5 8 . 3 8 1 01 43 55 .43 TRP 2 2 .9 7 22 .7 3 5351 19 .12
GLL' 9. 22 5 .25 1 2240 4 4 . S7 5HE 23 .7 5 23 .5 3 3141 12 .15
DMP 9 . 7 0 9 . 6 7 Z358 26 .3 3 I l E 24 .42 24 .27 429 1 .89
ALA 12 . 03 12.02 8253 4 1.67 LYS 24 .7 6 2 4 . 6 5 330 1 .09
HIS 12 .7 3 12 .73 160 1 .05 LEU 2 5 . 2 3 25 .12 3639 15 .45
TYn 15.  *3 15 .40 2160 8.74 26 .7 2 4 39
16 .52 1419
17 .0 9 309
ARE 17. IS 17 .13 7Ji 2.96
17 .82 509
PRO 18 .8 5 16 .75 10227 44 .39
T a b u l a t  i on t h r e s h o l d : 300 uAU
186
-  A p p l i e d  B i o s v s t e n a  1 7 7 R  P r o t e i n  S e q u e n c e r  C h r o n a t o q r a n  R e p o r t  —
SAMPLE : 150152SAB.LQ
[ I n i t i a t e d  15 J en  1552 5:Z2an 3
CYCLE SUMMARY :
R e a c t i o n  c y c l e  : 3L07T 
C o n v e r s i o n  c y c l e  : NORMAL 
G r a d i e n t  : NORMAL
AMINO ACID 8 7
Eesekne Corrected Deis
D a t a  c o l l e c t  t i n e  
D a t a  i n t e r v a l  
I n j e c t  v o l u n e
[ 15 Jan 19S2 3 : S£pm 3
0 . 0  t o  2 5 . 0  n i n
1 .0  s e c
50 of  150 uL
0 .0 1 00  AU
i Af
i n
i..........
iin
L A i A J .  U U . . V . !
5.0 10.0 i u 20.0 2E.0
Ret e r . t i on  T ine:  Min u t e s
PEAK TABULATION : ( 100X i n j e c t i o n  ) C a l i b r a t i o n  : 1401=2
Peak R .Tine C . T in e He igh t Pnol Peak R. T i n e C .T i n e H e ig h t Pno l
ID ( n i n ) ( n i n ) ( uAU) ID ( n i n ) ( n i n ) ( uAU)
ASN 5 .8 3 5 .0 0 12559 42 .17 UAL 2 0 .0 2 19 .90 5184 1 9 . 23
SER £ .57 7 . 02 E837 44 .53 2 0 . 3 2 3033
GLN 7 . 23 7 . 3 5 5220 24 .25 DPT 2 1 . 5 8 2 1 . 5 0 313536 1156.96
7 HR 7 .55 7 .5 6 1251 8 . 90 TRP 2 2 . 8 7 2 2 .7 3 5934 15 .55
SLY 8 . 37 S . 35 5510 51.97 PHE 2 3 . 7 3 2 3 . E3 3675 14.21
GLU c _ 2 2 5 .25 15551 71 .15 ILE 2 4 . 4 3 2 4 .2 7 390 1 .71
DMP 9 . 68 9 . 6 7 2409 2 6 . 9 0 LYS 2 4 .7 7 2 4 .6 5 S372 31 . 08
ALA 12.C3 12.02 5852 34 .75 LEU 2 5 .2 2 2 5 .1 2 5073 21 .5 5
HIS 1 2 .8 8 12 .73 1 52 0 .55 2 6 . 5 3 3B3
TYR ’5 .52 15. 40 2154 8.72
I E . 50 147E
ARS 17.10 17.13 1 1 1 1.15
17.77 i 128
PRO 18.85 18 .75 E4S2 28 .13
met 15 .5“ 15.52 51E 1.54
T a b u l a t i o n t h r e s h o l d : 500 u flu
187
-  R p p l i e d  B i o s v s t c n s  1 7 7 R  P r o t e i n  S e q u e n c e r  C h r p n a t o a r e n  R e p o r t  -
SAMPLE : 150192SAB.LO
[ I n i t i a t e d  15 J e n  1992
CYCLE SUMMARY :
R e a c t i o n  c y c l e  : BLOTT 
C o n v e r s i o n  c y c l e  : NORMAL 
G r a d i e n t  : NORMAL
Da ta  c o l l e c t  t i n e  
Dat a  i n t e r v a l  
I n j e c t  v o l u n e
0 . 0  t o  2 9 . 0  n i n
1 .0  s e c  
50 of  150 uL
AMINO ACID *  
Baseline Corrected OeU
[ 15 Jen  1 9 S2 4 :4 4 p n  3 0 . 0 1 0 0  AU
£.0 10.0 li.o 20.0 25.0
R e t e n t i o n  T ine :  Minut es
PEAK TABULATION : ( 1002  i n j e c t i o n  ) C a l i b r a t i o n  : 140192
Peak R.T i n e C .T i n e H e ig h t Pnol Peak R .T ine C.T i n e H e ig h t Pno l
ID ( n i n ) ( n i n ) ( uAU) ID ( n i n ) ( n i n ) ( uAU)
ASN 5 . 8 3 6 . 0 0 9570 31.55 PRO 18.85 18.75 5064 21 .98
SER E.S3 7 .0 2 5886 38.38 MET 19.52 19.52 483 1 .81
SLN 7 . 2 5 7 . 3 5 4281 19.92 UAL 20 . 02 19 .90 5640 20 .9 2
Trin 7 . 9 5 7 . 9 8 8393 5 3 . e s 20 .32 2466
5LY 8 . 3 5 8 . 3 9 9207 50.31 DPT 21 .5 8 2 1 . 5 0 262452 9 6 8 . 4 6
6LU 9 .2 2 9 . 25 > 2359 45.04 TRP 22 .9 5 2 2 .7 3 5024 14 .29
DMP 9 . 6 8 9 . 6 7 2295 25 .63 PHE 23 .73 2 3 . 6 3 3726 14.41
11 . 47 387 ILE 24 . 35 2 4 .2 7 288 1 .26
ALA 12 .03 12 .02 6585 33 .25 LYS 24 .75 2 4 . 5 5 10311 3 4 .2 0
r  I S 12 .75 12 .73 1 05 0.62 LEU 25 .22 2 5 .1 2 5430 23 .0 6
7YR 15 .50 15 .40 2517 10.19 25 .50 312
18 .03 354 26 .9 7 3ES
16 .57 1 454
AR£ 17 . 23 17 .13 99 1 .04
17 .8 0 1809
T a b u l a t  i o n t h r e s h o l d : 300 uAU
188
-  R o p l i e d  B i o s v s t e n s  1 7 7 f l  P r o t e i n  S e q u e n c e r  C h r o n a t o q r a n  R e p o r t  -
SAMPLE : 150192SA9.LG
I I n i t i a l e d  15 J en  l 992 9 : 33sm 3
CYCLE SUMMARY :
R e a c t i o n  c y c l e  : BLOTT 
C o n v e r s i o n  c y c l e  : NGRMAL
G r a d i e n t NORMAL
Da ta  c o l l e c t  t i n e  
Da ta  i n t e r v a l  
I n j e c t  volume
0 . 0  t o  2 9 . 0  n i n
1 .0  s e c  
50 of  150 uL
AMINO ACID # 9
Baseline Corrected Dale
5.0 10.0
. v .
15.0 20.0 25.0
R e t e n t i o n  T n e : Mm u t e s
PEAK TABULATION : ( 100X i n j e c t i o n  ) C a l i b r a t i o n  : 140192
Peak R. T i n e C .T i n e HeiQht Pnol Peak R.Time C .T i n e HeiQht P n o l
ID ( n i n ) ( n i n ) ( uAU) ID ( n i n ) ( n i n ) ( uAU)
5 .5 2 2037 15 .55 1=41
ASN 5 . 95 5 . 0 0 21081 70 .18 ARG 17 .17 17 .13 57 0 . 5 0
S . 43 2898 17 .82 1 104
S . 50 2973 PRO 18 .85 18 .75 4555 1 9 . 8 2
SER 5 . 95 7 . 0 2 7191 46 . 89 met 19 .60 1 9.  =2 553 2 . 4 S
SLN 7 . 23 7 . 3 5 4157 19.39 UAL 20 .0 2 15 .90 5517 2 0 . 4 7
T HR 7 .9 5 7 . 9 8 4175 29.71 2 0 .3 0 1893
SLY 9 .3 5 8 . 3 8 S4S3 45.41 DPT 2 1 .5 8 2 1 . 5 0 202656 7 47 .8 1
SL'J 9 .20 9 .2 5 7536 27 .4 4 22 .5 8 735
DMP 9 . 7 0 9 .B7 1728 19.29 TRP 2 2 .5 7 2 2 .7 3 3959 1 1 . 2 7
ALA 12.03 12 .02 6275 31 . 59 PHE 2 3 . 7 3 2 3 .5 3 4107 15 . 88
13. SS 390 1LE 2 4 . 4 0 2 4 .2 7 324 1 .42
TYR 15.48 15 .40 2552 10.73 LYS 2 4 .7 5 2 4 .6 5 4520 15 .32
15.08 4 95 LEU 25 .2 2 25 .1 2 5543 2 3 . 9 7
15.15 492
T a b u l a t i o n  t h r e s h o l d  : 500 uAU
t 15 J an  1952 5 : o 0 p n  3 0 . 0 1 0 0  AU
n
189
-  A p p l i e d  B i o s v s t e n s  i 7 7 f l  P r o t e i n  S e q u e n c e r  C h r o n a t o a r a n  R e p o r t  -
SAMPLE : 1501925AS.LO
t I n i t i a t e d  15 J a n  1982 9 :3 3 e n  I
CYCLE SUMMARY : 
R e a c t i o n  c y c l e  
C o n v e r s i o n  c y c l e  
G r a d i e n t
AMINO ACID tt 10 
East!ine Corrected Data
3L0TT Da ta  c o l l e c t  t i n e
NORMAL Da ta  i n t e r v a l
NORMAL I n j e c t  volume
[ 15 Jen 1892 S:l6pm 1
3 . 0  t o  2 9 . 0  n i n
1 .0  s e c
50 of  150 uL
0 . 0 1 0 0  AU
R e t e n t i o n  T i n e :  Minu te s  
PEAK TABULATION : < 1002 i n j e c t i o n  ) C a l i b r a t i o n
Peak R .T i n e  C . T i n e  H e ig h t
ID ( n i n )  ( n i n )  (uAU)
ASN
SER
GLN
THR
SLY
SLU
DMP
ALA
HIS
TYR
AR6
5. 
c,
6. 
7. 
7. c ( 
e, 
9.
1 2 .
12.
15.
IE.
IS.
17.
17.
52
95
57 
25 
55 
35 
20 
E8 
03 
77 
50 
07
58 
15 
82
S. 00 
7 .0 2  
7 . 3 5  
7 . 9 9  
8 . 3 9  
9 . 2 5  
9 . 5 7  
12.02 
12 .73 
15.40
i 7 .  i:
1539
10974
5502
3741
1990
8094
4E44
1713
14481
150
2484
4S5
1541
54
793
Pnol
oa
17
14 
44
15 
19
77
0
10
,53
,88
,41
,05
,23
,91 ■
.13
, 12
.89
.05
0 .5 7
Peak R .T in e  C .T i ne  H e i g h t
ID ( n i n )  ( n i n )  (uAU)
PRO
MET
UAL
7RP
PHE
1LE
LYS
18 .85  
19.S3 
20 .0 0
DPT 2 1 .5 8
LEU 25 .22  
2 5 . e s
18.
IS.
19,
2 1 .
2 2 .8 7  22
2 3 .7 3  23
24 .4 5  24
24 .7 7  24
, -'a 
,52 
,50 
50
,E3
,27
,55
, 12
4C77
579
19253
173850
3335
3501
150
2205
5269
303
140192
Pno l
17 .70  
2 . 1 8  
71 . 57  
541 .51Q
14,
,47 
,70 
0 . 5 6  
7 .31  
2 2 .4 6
T a b u l a t i o n  t h r e s h o l d  : 300 uAU
190
-  A p p l i e d  B i o s v s t e w s  5 7 7 H  P r o t e i n  S e q u e n c e r  C h r o n a t o q r a n  R e p o r t  —
SAMPLE : 150192SAB.LO
[ I n i t i a t e d  15 J an  1S92 9:33am 3
CYCLE SUMMARY :
R e a c t i o n  c y c l e  : BLOTT 
Conv e r s io n  c y c l e  : NORMAL 
G r a d i e n t  : NORMAL
Data  c o l l e c t  t i n e  
Da t a  i n t e r v a l  
I n j e c t  volume
0 . 0  t o  2 9 . 0  n i n
1 .0  s e c  
50 o f  150 uL
AMINO ACIO »  11
Baseline Corrected Oats
C 15 Jan 1992 7:01pm ] 0 .0 1 0 0  AU
2C.fi
R e t e n t i o n  Time: Minu te s
PEAK TABULATION : ( 100X i n j e c t i o n  ) C a l i b r a t i o n  : 140132
Peak R. Tine C.T i n e H e ig h t Pnol Peak R. T in e C .Tine H e ig h t P no l
ID ( n in ) ( n i n ) (uAU) ID ( min) ( n i n ) ( uAU)
5 .58 4494 PRO 18 .87 18.75 4071 17.67
ASN 5 .93 6 . 0 0 1 1880 39.55 MET 19 .63 19.52 717 2 .6 9
SER S . 97 7 . 0 2 8576 56 .57 UAL 20 .0 2 19.50 21057 78 .  12
SLN 7 .25 7 . 3 5 6345 29 .53 DPT 2 1 . 6 0 21 .50 317979 117 3 .3 5
THR 7 .95 7 .9 9 1587 11 .29 TRF 2 2 .6 7 22 .73 5271 14 .97
GLY 8 .37 8 .3 5 8052 44 .00 PHE 2 3 . 7 5 23 .53 4122 15.94
GL'J 9 .22 9 . 25 3927 14.30 ILE 24 .4 2 24 .27 360 1 .59
DMP 9 .7 0 9 . 6 7 3771 42.11 LYS 2 4 .7 8 24 .65 8262 2 7 .4 0
ALA 12.03 12.02 1 1523 55 .19 LE'J 25 .2 3 2£.  1.2 6306 26 .78
HIS 12.82 12 .73 1 14 0 .6 7
TYR 15.50 15 .40 2667 10.79
18.13 402
15.55 1881
17.78 921
17 . e5 861
T a b u l a t i o n t h r e s h o l d : 300 uAU
191
-  A p p l i e d  B i o s v s t e n g  ^ 7 7 f l  P r o t e i n  S e q u e n c e r  C h r o n a t o q r a n  R e p o r t  —
SAMPLE : 150192SAB.LO
[ I n i t i a t e d  15 Jan 1952 9:33am I
CYCLE SUMMARY :
R e a c t i o n  c y c l e  : BLOTT 
Conv e r s io n  c y c l e  : NORMAL 
G r a d i e n t  : NORMAL
AMINO ACID # 12
Baseline Corrected Date
D a t a  c o l l e c t  t i n e  
Da t a  i n t e r v a l  
I n j e c t  volume
[ 15 Jan 1592 7:47pm I
0 . 0  t o  2 9 . 0  n i n
1 .0  s e c
50 of  150 uL
0 . 0 1 0 0  AU
V + J U
+
Ai
- M L .
'5.8 10.0 150 20.0 25.0
Ret e n t i o n  Time:  Mm u t e s
PEAK TABULATION : ( 100Z i n j e c t i o n  ) C a l i b r a t i o n  : 140192
Peak R.Tine C.Time Heigh t Pno l Peak R.T i ne C .Tine He igh t Pno l
10 ( n in ) ( n i n ) ( uAU) ID ( n i n ) ( n i n ) ( uAU)
5 .55 1479 MET 19.55 19.52 837 3 . 1 5
ASN 5 .95 6 . 0 0 10182 33 .89 UAL 20 .02 19.90 13434 4 9 .8 4
SER 5.98 7 .S 2 4971 32.41 DPT 2 1 . 6 0 21 .50 233520 8 6 1 . 7 0
GLN 7 .23 7 . 3 5 3747 17.44 TRP 22 .98 22 .73 4542 12 . 90
TnR 7 .95 7 . 9 3 4S95 33 .40 FHE 23 . 73 23 .83 4050 15 .55
GLY 8.37 £ . 3 8 7746 42 .33 ILE 24 . 38 24 .27 204 0 . 8 9
GL'J 9.22 9 . 2 5 3231 1 1 .75 LYS 24.76 24.55 2913 9 . 55
DMP 9 .73 9 .G7 1785 19.93 LEU 25 .23 25 .12 5420 2 7 . 2 7
ALA 12.05 12 .02 18732 54 .59 25 .62 397
HIS 13.00 12 .73 59 0 . 59 27 .0 0 506
TYR 15.50 15 .40 2508 10.15
15.13 387
IE .58 1485
1 7 . e s 1074
PRO 18.37 18 .75 4266 18.52
T a b u l a t i o n t h r e s h o l d : 300 uAU
192
— R p o l l e d  B i o s t f s t e w s  5 7 7 R  P r o t e i n  S e q u e n c e r  C h r o n a t o q r a n  R e p o r t .  —
SAMPLE : 1S0192SAS.LO
[ I n i t i a t e d  15 J an  1952 S:33en 3
CYCLE SUMMARY :
R e a c t i o n  c y c l e  : BLOTT 
C o n v e r s i o n  c y c l e  : NORMAL 
G r a d i e n t  s NORMAL
O at a  c o l l e c t  t i n e  
Da t a  i n t e r v a l  
I n j e c t  volume
0 . 0  t o  2 9 . 0  n i n
1.0 s e c  
50 o f  150 uL
AMINO ACID ft 13 
Baseline Corrected Bate
[ 15 Jan 1932 £ :33pm 3 0 . 0 1 0 0  AU
20.0 25.0
PEAK TABULATION
R e te n t i o n  l i n e :  Minut es  
( 100X i n j e c t i o n  ) C a l i b r a t i o n
Peak R .T in e  C .T in e  HeiQht
ID ( n i n )  ( n i n )  (uAU)
ASN
SER
GLN
THR
GLY
GLU
DMP
ALA
HIS
TYR
ARG
5. 55  
5 .9 5  
E.52 
E. 97 
7 . 25  
7 .9 3  
S . 35 
9. 22  
9 . 72  
12.03 
12.77 
15.50
15.12 
1S.E3
17.13
?.e:
7 .3 5
7 .9S
e . 3 £
9 .2 5
9 . 6 7
1 2 . 0 2
12.73
15 .40
17 .13
1 464 
8406 
2382 
44G7 
3537 
3129 
7284 
2892 
1908 
25907 
189 
2379 
453 
1341 
135
Pnol
27.58
29.13 
15.45 
-o n z
33.80
10.53
21 .30
135.87
1 . 1 2
9.63
1 .42
Peak R .T i n e  C . T i n e  
ID ( n i n )  ( n i n )
FRO
MET
UAL
DPT
TRP
PHE
ILE
LYS
LEU
17.82
18.87
19 .83 
20 .02  
2 1 .6 0
22.88 
2 3 . 7E 
24 .37  
24 .78  
25 . 23
8 . 7 5  
9 . 52  
9 .9 0  
1 .5 0  
2 . 7 3  
3 . 6 3  
4 . 2 7  
4 . 6 5  
5 . 1 2
H e ig h t  
( uAU)
816
4179
819
9651
157296
3162
3924
234
1655
6648
140192
P no l
18 . 14  
3 . 0 8  
3 5 . 9 0  
5 8 0 . 4 3  
8 . 9 8  
15 . 17  
1 . 03  
5 . 5 0  
2 8 . 2 4
T a b u l a t i o n  t h r e s h o l d  : 300 uAU
-  f l p p l i g d  B i o s u s t e n s  i 7 7 f l  P r o t e i n  S e q u e n c e r  C h r o n a t o a r a n  R e p o r t  -
SAMPLE : 150192SAB.LO
[ I n i t i a t e d  IS J en  1 992
CYCLE SUMMARY : 
R e a c t i o n  c y c l e  
C o n v e r s i o n  c y c l e  
G r a d i e n t
AMINO ACID *  14
baseline Corrected Hteie
BLOTT Da t a  c o l l e c t  t i n e
NORMAL Da ta  i n t e r v a l
NORMAL I n j e c t  volume
t 15 Jan 19S2 S:16pm 1
0 . 0  t o  2 9 . 0  n i n  
1 . 0 s e c  
50 o f  150 uL
0 .0 1 0 0  AU
y 1L0 15.0 20. C 25.0
R e t e n t i o n  Time: Mi nu t e s
PEAK TABULATION : ( 100X i n j e c t i o n  ) C a l i b r a t i o n  : 140192
Peak R .T i ne C . T i n e He igh t Pnol Peak R.T i n e C.T i n e HeiQht Pno l
ID ( n i n ) < n i n ) ( uAU) ID ( n i n ) (  n i n ) ( uAU)
5 .5 5 1491 PRO 18.62 16 .75 4*10 19 .14
ASN 5 .9 0 6 . 0 0 9021 30 .03 MET 19 .5 0 19 .52 640 3 .1 6
SER G.S2 7 .0 2 4428 28 .87 UAL 19.58 19 . 90 6532 3 1 . 6 5
GLN 7 .2 3 7 . 3 5 3570 16.61 DPT 2 1 . 5 7 2 1 . 5 0 153876 567 .81
7 HR 7 .9 0 7 .SS 1600 12.61 TRP 2 2 . 8 3 2 2 .7 3 3995 11 . 35
GLY 8 .32 6 .3 8 7338 40.  10 PHE 23 .7 2 2 3 . 5 3 4 140 15.01
GLU 9 .1 5 9 . 2 5 2805 10.21 ILE 2 4 . 4 0 2 4 . 2 7 245 1 .0 8
DMP S . 63 9 . 6 7 1860 20.77 LY5 2 4 . 7 8 2 4 . E5 1502 5.31
11 .10 LEU 25 .2 2 2 5 .1 2 144 53 El .56
i t  £ 11.98 12 .02 15662 80.20 2E .S7 375
HIS 12 .90 12 .73 166 0 .99 2 7 . 0 0 432
TYR 15 .45 15 .40 2379 9 .63
l G. 07 372
16 .58 1515
17 .67 795
T a b u l a t i o n t h r e s h o l d : 300 uAU
194
-  R p p l i e d  B i o s w s t e n s  i 7 ? H  P r o t e i n  S e q u e n c e r  C h r o n n t o a r a w  R e p o r t  —
SAMPLE : 150192SAB.LO
L I n i t i a t e d  15 Jan  19S2 9 :3 3 a n  3
CYCLE SUMMARY :
R e a c t i o n  c y c l e  : BLOTT Da ta  c o l l e c t  t i n e  : 0 . 0  t o  2 S . 0  n i n
C o n v e r s i o n  c y c l e  : NORMAL Da ta  i n t e r v a l  : 1 . 0  s e c
G r a d i e n t  : NORMAL I n j e c t  v o lu n e  : 50 o f  150 uL
AMINO ACID # 1 5  t 15 J e n  1392 10:04pr :  3 0 . 0 1 0 0  AU
Baseline Corrected Date
5.0 1C.0 16.0 20.0 25.0
R e t e n t i o n  T in e :  Min u t e s
PEAK TABULATION : ( 1002 i n j e c t i o n  ) C a l i b r a t i o n  : 140192
Peak R .T i ne C .T i n e HeiQht Pno l Peak R . T i n e C .T in e HeiQht P n o l
ID < n i n ) ( n i n ) ( uAU) ID ( n i n ) ( n i n ) ( uAU)
5 .5 3 1245 MET 19 .62 18.52 732 2 . 7 5
ASN 5 .9 2 6 . 0 0 7101 23 .6 4 UAL 2 0 . 0 0 19 .90 7170 2 6 . E0
8 .4 0 2315 DPT 2 1 . 5 8 2 1 . 5 0 128439 4 7 3 . 9 4
SER 6 .9 5 7 . 0 2 4419 28.61 2 2 . 4 5 804
GLN 7 . 25 7 . 3 5 3411 15 .87 TRP 2 2 . 8 7 2 2 . 7 3 3171 9 . 0 0
THR 7 .9 3 7 . 9 8 . 1266 9,01 PHE 2 3 . 7 2 2 3 . 5 3 3450 13 . 34
GLY 6 .3 5 8 . 3 8 12213 66 .7 4 ILE 2 4 . 4 0 24 .2 7 306 1 . 34
GLU 9 .22 9 . 2 5 2295 8 . 55 LYS 2 4 . 7 3 2 4 . 6 5 1272 4 . 2 2
DMP 9 . 7 0 9 . 6 7 17Z8 19.29 LEU 2 5 . 2 0 25 .12 10380 44 . 09
ALA 12.02 12.02 8769 4 4 . 2 8
HIS 12 .78 12 . 73 156 0 .9 2
TYR 15 .50 15 . 40 2028 8.21
16.53 1272
17 .90 630
PRO 18.85 18 .75 4071 17 .67
T a b u l a t i o n  t h r e s h o l d  : 500 uAU
-  R m o T i e d  B i o s v s t e n s  1 7 7 f l  P r o t e i n  S e q u e n c e  R e p o r t  —
SAMPPLE : 150192SA3.LO
C i n i t i a t e d  IS J an  19S2 9:33am ]
Sanp o l e  Amount :  100 pno l
AAciid AAcid R . T i n e C .T ine Pnol P no l Pno l Pnol AAcid
n ID ( n i n ) ( n i n ) ( r a u ) ( - b k g d ) ( + l a g ) R a t i o ID
11 V 2 0 . 0 3 19.90 307.03 2 9 4 . 3 8 303 . 12 195 .02 VAL
"in L 2 5 . 2 7 25 .12 121.84 112.29 118 .99 144.61 LEU
33 L 2 5 . 2 5 25 .12 119.83 108.31 107.67 130.86 LEU
44 P
A
18 .8 5 18.75 7S.41 6 2 . 1 5 6 6 .8 9 7 3 . 1 5 PRO
55 ft 1S^-W— i C -. . .
So E 9 .2 2 9 .25 44 .57 34.31 4 0 .0 7 47 .5 7 6LU
77 E 9 .2 2 9 .25 71 .19 5 9 . 7 5 63 .6 6 75 .74 GLU
33 T 7 . 9 5 7 .98 59.58 4 7 .5 7 5 9 .8 7 46.91 THR
39 N 5 . 9 5 G .00 70 .18 3 8 . 6 0 4 4 .6 0 21 .9 7 ASN
100 V 2 0 . 0 0 19 .90 71 .57 48 .2 2 6 2 . 5 5 40 .2 4 VAL
ALA
ITT . 0m r  » r-t« 1 1 f t < U . 1 4- ^  J  • J  J
122 T 7 . 9 5 7 .9 8 33 .40 2 0 .9 4 27 .9 8 21 .92 THR
133 A 12 . 03 12.02 135.87 9 5 .0 4 105 .83 33 .2 0 ALA
144 L 2 5 . 2 2 25 .12 51 .56 31 .3 8 43 .8 6 53.31 LEU
1SS 6 8 . 3 5 8 .38 66 .74 1 9 .4 8 7 . 1 5 GLY
REPEETITIVE YIELD ANALYSIS:
R e p . Y i e l d V a r i a n c e
V: U , 10 . 11 8 3 . 3 2  X 0 . 9 8 0 : VAL
L: 2 ,  3 . 1 4 8 9 . 6 8  X 0 . 9 9 7 :LEU
P: 4 . 5 119 .49  X 1 . 000 : PRO
E: S .  7 174 . 15  X 1 . 000 : 6LU
T: 8 . 1 2 8 1 .4 6  X 1 . 000 : THR
A ve r r a g e  AA R e p e t i t i v e  Y ie ld : 103.01 X
Conbbimed AA R e p e t i t i v e  Y ie ld : 8 9 . 0 7  X 0 .5 44
T h eco r< e t i c a l  I n i t i a l  Y i e l d :  142.82 pnol  1 1 4 2 .3Z X  )
196
